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Abstract 
Active, sodium-dependent nucleoside transport systems have been kinetically 
described in a number of different mammalian tissues. The recent cloning of several 
active, mammalian nucleoside transporters belonging to a novel gene family has 
provided an opportunity to examine both the structure/function relationships and the 
tissue distributions of these proteins in detail, and thus to elucidate their 
physiological roles. The first of these transporters to be cloned was rCNTI, a protein 
from rat jejunal epithelium which exhibits pyrimidine-selective, cit-type transport 
activity. The present study involved a bi-directional approach to the investigation of 
this protein by the analysis of its distribution in rat tissues at both the cellular and 
subcellular levels,, in addition to structural investigation of rCNTI by protein 
chemistry and gene manipulation techniques. 
A model originally proposed for the topology of this protein, based largely 
upon hydropathy analysis of its sequence, suggested that the N- and C-terminal 
hydrophilic regions of this protein were cytoplasmic. However the present study has 
shown, from the effect of endoglycosidase F treatment of the protein expressed in 
I,, - Axnopus oocytes, that the C-terminal hydrophilic domain of the protein is N- 
glycosylated and so must in fact be extracellular. Furthermore, mutagenesis of 
rCNTI cDNA allowed for the production of an aglyco-rCNTI mutant into which 
novel glycosylation sites were introduced as a means of probing topology. Evidence 
from this mutagenesis has indicated that the N-terminus of rCNTI is cytoplasmic, 
therefore suggesting that rCNTI exists in the lipid bilayer with thirteen putative 
transmembrane domains and not fourteen as originally proposed. Analysis of the 
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protein sequence using predictive algorithms suggests that the originally-predicted 
transmembrane helix 6 is in fact extramembranous. 
Analysis of the distribution of rCNTI in rat tissues by immunoblotting has 
revealed that this active transporter is more widespread than originally suggested by 
the results of Northern blotting experiments. Moreover, it has been possible by 
immunocytochernical analysis not only to identify the cell types in which rCNTI is 
expressed but also to show that its distribution is restricted to certain domains of the 
plasma membrane. rCNTI in the jejunum and kidney has been localized at the 
intestinal and renal brush-borders respectively. While in the liver it is abundant in the 
bile canalicular membranes. This location is consistent with roles for the 
concentrative transporter in the absorption of nucleosides from the diet or their 
salvage from the extracellular breakdown of nucleotides. Unexpectedly, rCNTI also 
appears to be abundant in the hippocampus, and in the actively dividing seminiferous 
epithelium of the testis. Furthermore, its presence has also been suggested in cardiac 
muscle, skeletal muscle and the spleen, although these observations await further 
confirmation. 
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1.1 Membrane Proteins: An Introduction 
The basic unit of life, the cell, has to produce an internal milieu contrasting from its 
surrounding environment in order to survive. To achieve this it must possess an 
impermeable barrier to enclose its components. One of the earliest proposals 
concerning the state of this barrier was put forward by Gorter and Grendel in 1925 
who suggested that this barrier was in the form of a bimolecular leaflet, or lipid 
bilayer [I]. This was further elaborated in the paucimolecular model of Davson and 
Danielli (1935) who proposed that on either side of the bilayer resided a protein 
monolayer and it was these protein layers that were responsible for the enzymatic 
properties exhibited by membranes [2]. This proposal remained relatively unchanged 
for the following thirty years until experimentation using freeze fracture electron 
microscopy showed that there were apparently globular proteins embedded in the 
membrane [3]. Spectroscopic evidence indicating the presence of an appreciable 
amount of a-helix likewise supported the presence of globular proteins rather than a 
monolayer of extended polypeptide chain [4,5]. Finally, appreciation of the non-polar 
characteristics of membrane proteins [6] and of the fluid nature of the lipid bilayer 
[7] culminated in the development of the fluid mosaic model by Singer and Nicolson 
in 1972 [8]. 
The globular proteins found in membranes showed great diversity in their ftinction, 
being enzymes, receptors, pores, transporters etc., but the insoluble characteristics of 
these proteins and of the hydrophobic peptides derived from them made primary 
structure determination difficult. However, investigation of the sialoglycoprotein 
glycophorin, found in the erythrocyte membrane, indicated the presence of a short 
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stretch of 23 nonpolar amino acids near the middle of the molecule [9]. Topological 
and other studies indicated that glycophorin extended completely through the 
membrane and that this stretch was oc-helical [10]. This discovery led to the concept 
of membrane spanning cc-helical domains in membrane proteins. Many membrane 
proteins in fact are predicted to contain multiple membrane-spanning cc-helices. For 
example, electron microscopy image reconstruction studies of bacteriorhodopsin, the 
predominant protein found in the purple membrane of Halobacterium halobium, the 
presence of seven (x-helical segments traversing the bilayer [I I]. 
While the hydrophobic nature of membrane proteins rendered their sequencing by 
conventional means difficult, deduction of these protein sequences could be obtained 
from cDNA and gene sequence data. Thus leading to an explosion in the amount of 
inforination available on transporter sequences. An example of which is the major 
facilitator superfamily, with the first member to be sequenced being the lac 
permease, but comprises greater than fifty other transporters including the bacterial 
proteins GaIP, AraE and XylE in addition to the mammalian erythrocyte glucose 
transport protein GLUTI [12,13]. Subjecting the amino acid sequences of members 
of this superfamily to hydropathic analysis produced profiles that identified typically 
that its members contained hydrophobic regions of approximately 21 amino acid 
residues in length which are predicted to traverse the membrane in the form of (x- 
helices. In addition, application of secondary structure algorithms and the positive 
inside rule led to the prediction that the N- and C- termini are cytoplasmic with the 
fore-mentioned 12 hydrophobic regions traversing the membrane between them. Of 
course, such a predicted topology must be backed by experimentation before it can 
be confirmed that the model is a true reflection of the protein structure [14]. In the 
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case of GLUTI there is much evidence to support the model described above, based 
on circular dichroism [ 15,16]; Fourier Transform Infra-red (FTIR) spectroscopy [ 17]; 
proteolytic digestion [18]; site-specific antibodies [19,20]; biotinylation [21]; and 
glycosylation scanning mutagenesis [22]. Thus suggesting that the predicted 
secondary structure for the major facilitator superfamily as a whole is correct. 
However, while the topology and secondary structure of the major facilitator 
superfamily members is now well established, this is not the case for many other 
unrelated transport protein families that have emerged from genome sequencing and 
other approaches over the past few years. An example is provided by the rat active 
nucleoside transport protein rCNTI, which forms the subject of this thesis and which 
will be discussed in more detail later in this chapter. 
1.2 Nucleoside Transport 
1.2.1 Physiological and synthetic substrates 
Nucleosides perform a wide variety of specialized roles in different cells and tissues. 
For example, adenosine is involved in regulation of platelet and neutrophil functions, 
of blood flow in the heart, kidneys and other tissues, and functions as a local 
honnone in the regulation of lipolysis, as well as acting as a neuromodulator [23], 
whilst inosine acts as an in vivo energy supply for adult pig erythrocytes, cells which 
cannot transport and hence metabolize glucose [24]. Similarly, both inosine and 
guanosine are also energy sources for embryonic and adult chicken erythrocytes [25]. 
Moreover, not all cells can synthesize these molecules de novo. Cells lacking de novo 
biosynthetic pathways include enterocytes, erythrocytes, leukocytes, certain brain 
cells and bone marrow cells [26,27]. Such cells rely upon dietary nucleosides or upon 
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the production by other cells of an excess of nucleosides which can then be 
transported via the circulation to sites where they are needed. Such is one of the 
specialized functions of the liver parenchymal cells. 
Due to the importance of nucleosides many synthetic analogues have been made over 
the years with the aim of developing useful clinical drugs. Indeed some of these 
compounds have proven useful in the treatment of viral diseases and haematologic 
cancers including the use of azidothymidine (AZT) and dideoxycytidine (ddC) as 
anti-viral nucleosides, with the former being used in the treatment of acquired 
immuno-deficiency syndrome (AIDS) [28,29]. The majority of these drugs act 
intracellularly by interfering with DNA synthesis following chemical modification, 
namely phosphorylation. More recently interest has expanded to the development of 
agonists and antagonists which act on the adenosine receptors as a means of 
preventing reperfusion injury after ischaemia and in the treatment of hypertension, 
epilepsy and renal failure [30]. 
In relation to the efficiency of such drugs, the presence of nucleoside transporters can 
greatly affect this. For instance, in experimental systems using cultured cells, which 
have been genetically modified to eliminate nucleoside transport, resistance to a 
variety of nucleoside analogs with anticancer activity has been shown [31,32]. This 
therefore demonstrates that the absence or presence of these transporters plays a key 
role in the pharmacokinetics, disposition and in vivo biological activity of nucleoside 
analogues. The specificity and activity of these transporters in different cell types 
varies greatly, but there are certain features that are common to several of them 
which allows for their allocation into distinct groups or subclasses, see section 1.2.4. 
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1.2.2 Nucleoside transport and metabolism 
Uptake of nucleosides by cells is followed by modification of these substrates in the 
majority of cases, although cells such as enterocytes and hepatocytes are capable of 
releasing unmodified nucleosides into the circulation for use by other cells within the 
organism. The reason for this modification is to prevent the loss of the acquired 
substrate while altering its chemical properties to make it more readily metabolized. 
This modification may be either anabolic, as in the phosphorylation by nucleoside 
kinases,, or catabolic, as in phosphorolytic cleavage or deamination by nucleoside 
phosphorylases or nucleoside dearninases respectively. Thus when considering the 
rate limiting step for uptake, not only is the rate of translocation important but also 
the relative activity of the metabolizing enzyme. 
For the purposes of exemplification a few cases of nucleoside fate following 
transport will be discussed but for more in-depth coverage see the review by Boss 
and Seegmiller [33]. One case where post-translocational modification of the 
nucleosides is essential is in cell types that are unable to synthesize their own 
nucleotides de novo, such as is the case with erythrocytes and hematopoietic bone 
marrow cells. Therefore they rely on other cells, namely hepatocytes, for a supply of 
nucleosides which they generally modify in one of two ways. Pyrimidine nucleosides 
are generally phosphorylated by nucleoside kinases whereas purines are modified by 
the sequential action of a phosphorylase followed by a phosphoribosyltransferase. 
Both of these salvage processes are simpler and much less energetically costly than 
de novo nucleotide synthesis. 
Another area of interest concerning metabolism of translocated nucleosides is that 
regarding therapeutic analogues. In the majority of cases these only become active 
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when modified in situ. One such case is that of arabinosylcytidine which is 
phosphorylated by deoxycytidine kinase so producing the clinically active anti- 
cancer analogue [34]. Another such case is that of AZT used in the treatment of 
AIDS. This molecule is translocated prior to being phosphorylated by thymidine 
kinase which allows subsequent phosphorylation to the tri-phosphate form which is 
the active compound. This acts by two mechanisms, firstly it competes with 
endogenous nucleotides while secondarily acting as a chain ten-ninator in the 
generation of proviral DNA [35]. 
1.2.3 Nucleoside transport and regulation 
Understanding of the regulation of nucleoside transport is beginning to develop. 
Evidence now exists that factors including hormones, steroids, adenine nucleotides 
and key intracellular signaling pathways, including the protein kinase A and C 
systems, are important in the regulation of both facilitative and active nucleoside 
transport protein expression at the plasma membrane. In addition, cell growth and 
differentiation have also been shown to cause changes in the expression of these 
proteins, even showing the replacement of one transporter by another. Considering 
the effects of hormones first , it 
is understandable that such molecules should regulate 
more than one specific function depending on the physiological condition of the 
organism. This is exemplified by the transient and stable increase in sodium- 
dependent uridine uptake in liver parenchymal cells, caused by glucagon and insulin 
respectively [36]. The former of these phenomena involves the hyperpolarization of 
the cell membrane while the latter involves the synthesis and insertion of new 
transporters into the plasma membrane. Similar to this insulin effect thyroid hormone 
has been demonstrated to increase the number of es-type transporters present in the 
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cell membrane of cultured chromaffin cells by the synthesis and insertion of new 
transport protein molecules [37], (see subsequent section for classification of 
nucleoside transporter types). Interestingly this effect is antagonized by steroids and 
retinoic acid suggesting that these may act to return nucleoside transport to steady 
state levels. The nucleoticle adenosine triphosphate (ATP) has also been established 
to increase es-type transport, thus indicating that ATP and possibly other nucleotides 
are capable of possessing regulatory roles in relation to nucleoside transport [38]. 
The role of intracellular signaling pathways in the regulation of nucleoside transport 
has recently been investigated, although the results obtained at present are only 
preliminary and require much more in-depth investigation. In chromaffin cells 
transport has been demonstrated to be under the control of protein kinase A or C 
whereas in bovine adrenomedullary endothelial cells transport was shown to be 
independent of such signaling mechanisms [39,40]. In the former of these activation 
of the kinases resulted in inhibition of transport which coincides with the observation 
that a cAMP-dependent protein kinase is involved in the reduction of es-type 
transport by phosphorylation of the transporter molecule or of a protein that interacts 
with it in cultured pig kidney cells [41]. 
Another factor effecting the regulation of the transporters is the stage of the cell 
within the cell cycle. Work carried out on quiescent SI macrophages indicated that 
the majority of nucleoside transport is via the ei system but on the addition of 
colony-stimulating factor I (CSF-1) a 3-fold increase in activity was shown to be 
produced by es-type transport as the cells synchronously entered the S phase of the 
cell cycle [42]. Likewise es-type activity in haernopoietic cells and sodium- 
dependent nucleoside transport in the liver have been shown to increase in response 
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to rapid cell division [43-451. In addition, differentiation of cells can also result in 
changes in levels of nucleoside transport observed while the actual type of transport 
itself varies. For example, in human HL60 leukemic cells induced to differentiate 
using dimethyl sulfoxide exposure to N-formyl-Met-Leu-Phe (FLMP) resulted in an 
increase in the Vmax of cib-type nucleoside transport pr-eteios present while 
parallel reductions in ei- and es-type transport were observed [46,47]. The fate of 
these transporters that disappear may be direct molecular modification of the 
transporters or translocation between the plasma membrane and a microsomal pool. 
The latter of these possibilities has been demonstrated using chrornaffin cells, where 
es-type transporters were demonstrated to internalize with 50 to 60 percent being 
destroyed [48]. However the remaining transporters were later recycled but were 
once again internalized. The presence of cycloheximide, a protein synthesis inhibitor, 
resulted in a faster rate of internalization, suggesting that although originally 
internalization was occurring and a high percentage were being destroyed 
concomitantly synthesis of new transport proteins was occurring, thus 
preventing the total loss of this transporter from the cell. 
1.2.4 Classification of nucleoside transporters 
Until recently classification of nucleoside transport proteins was based solely on their 
functional and phannacological characteristics with no indication of structural 
similarities. Based on these characteristics two obvious nucleoside transport classes 
have been observed, those which are equilibrative or concentrative. Each of these can 
be further subdivided into a number of more defined subclasses. The characteristics 
used to distinguish these nucleoside transport processes are, the ability to transport a 
non-metabolized nucleoside against its concentration gradient utilizing sodium 
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gradients; sensitivity to inhibition by the nucleoside analogue nitrobenzylthi oino sine 
(NBMPR); and the preference for purine and/ or pyrimidine nucleosides as 
permeants [49]. Generally, the facilitative transporters exhibit the aspects of any 
other equilibrative transport system in that transport appears to be bi-directional 
depending on which way the concentration gradient of the substrate is orientated. In 
contrast the concentrative transport systems use sodium ions as the driving force to 
allow the movement of the substrate from areas of low to higher concentrationt These 
differences in transport properties may explain why the equilibrative transporters are 
more widely dispersed than their concentrative counter-parts. 
Equilibrative nucleoside transport falls into two subclasses based solely on the 
sensitivity to the nucleoside analogue NBMPR. Those transporters that are 
equilibrative and sensitive to :! ý I nM concentrations of this compound are designated 
es (equilibrative and sensitive) while transporters which are equilibrative and 
insensitive to NBMPR, only being inhibited by > 10 ýM concentrations, are 
designated ei (equilibrative and insensitive). Both of these subclasses have similar 
substrate specificities, transporting all of the natural nucleosides in addition to many 
analogues which have been modified both at the base and/ or sugar moiety 
levels. 
Each of these subclasses is widely distributed throughout different cells and tissues. 
By kinetic analyses they have been shown either independently or collectively to 
be 
present in erythrocytes, enterocytes, choroid plexus and cardiocytes to name 
but a 
few in addition to many cell lines [50-55]. More recently Griffiths et al. cloned the 
first of these transporters from a human placental cDNA 
library [56]. The cDNA 
obtained encoded a 456-residue glycoprotein with 
functional characteristics of an es- 
type transporter. Algorithmic analysis predicted this protein to have II membrane 
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spanning regions and to show significant homology to a number of yeast, nematode, 
plant and mammalian proteins of unknown function. This cloning opened up the 
gateway for further facilitative proteins to be cloned including that of the first ei-type 
transporter from the rat jejunum [57]. Although comparison of the sequences of the 
cloned ei- and es-type transporters indicated that they were approximately 50 percent 
identical it was clear that they were different proteins and not the same protein that 
existed in two differing conformations, a possibility suggested by Plagemann and 
Wohlhueter to explain the existence of es and ei transporters [58]. 
Concentrative nucleoside transport at present has been divided into five subclasses 
depending on the substrates transported. However, two differing nomenclatures for 
these subclasses have been employed. The first and most common system of 
nomenclature is based on the fact that these proteins are concentrative and substrate 
selective whereas the second system is numeric and based on the order of discovery. 
For the purposes of the current description the former system will be used with only 
a comparative summary of the numerical classification being included at the end. The 
first two subclasses characterised were the cif- and cit-type nucleoside transport 
proteins. The former of these showed preference for purine nucleosides transporting 
the analogue formycin-B as its model substrate (! ýoncentrative insensitive to 
inhibition by NBMPR capable of transporting _fon-nycin-B) 
[5 9-61 ] while the latter 
preferred pyrimidine nucleosides transporting thymidine as its model substrate 
(concentrative insensitive to inhibition by NBMPR capable of transporting 
ýhyrnidine) [62-64]. However these subclasses showed overlapping specificity with 
each transporting adenosine and uridine. The third subclass showed broad substrate 
specificity, transporting both purine and pyrimidine nucleosIdes, thus being 
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designated cib (concentrative insensitive to inhibition by NBMPR and possessing 
broad permeant selectivity for both purine and pyrimidine nucleosides) [65,66]. The 
fourth type is a form of cit-type nucleoside transport with the difference that it also 
transports guanosine [67,68]. Within this fonn of classification no unique title has 
been given to this subclass so for the purpose of description it shall be termed citg 
(concentrative insensitive to inhibition by NBMPR capable of transporting thymidine 
and guanosine). The final and most recently identified subclass has the unique feature 
that it is a concentrative system inhibited by NBMPR and thus has been designated 
cs (concentrative and sensitive to NBMPR) [69,70]. The second method of 
classifying is solely concerned with active transport and has been designated NI to 
N5 corresponding to cif, cit, cib, citg and cs respectively. A summary of the 
functional properties of both equilibrative and concentrative nucleoside transport 
processes can be seen in Table I. I. 
Of the concentrative nucleoside transporters those of the cif- and cit-type have been 
most extensively investigated. Vijayalakshmi and Belt in 1988 made the momentous 
step of identifying that there were at least two types of concentrative nucleoside 
transport subclass [62]. Using freshly isolated mouse intestinal epithelial cells they 
demonstrated that two populations of transporters were present, one group with 
characteristics of the cif-type subclass while the other showed features of the cit-type 
subclass. Since then each of these subclasses have been demonstrated in a number of 
different species in a variety of tissues. cif-type transport has been established in 
mouse enterocytes, splenocytes and activated peritoneal macrophages [60,62,71 
]; in 
rat kidney brush border membrane vesicles (BBMVs), hepatocytes, and macrophages 
[72,73]; in rabbit small intestinal BBMVs and renal BBMVs [64,74]. In comparison 
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cit-type transport has been observed in mouse intestinal enterocytes and activated 
peritonea macrophages [60,62]; in rat renal BBMVs [75]; in bovine renal BBMVs 
[76]; in rabbit choroid plexus, small intestine BBMVs and renal BBMVs [52,64,77]; 
and in guinea pig enterocytes [78]. 
The distribution of the three remaining subclasses has proved more restricted. Jarvis 
in 1989 was the first to demonstrate cib-type transport activity while working with 
rabbit intestinal BBMVs [77]. Here purine and pyrimidine nucleosides were shown 
to be transported while obeying Michael is-Menten kinetics corresponding to a single 
transport mechanism. Such a mechanism was later shown again by Huang et al. by 
Aenopus expression of rat intestinal mRNA isolates and Gutierrez et al. in human 
kidney BBMVs [79,80]. Reports describing the properties of the citg-type transport 
have been restricted to research carried out by the Gutierrez group working with 
human renal BBMVs and this type of transport has yet to be observed by other 
researchers [67,68]. Finally, cs-type nucleoside transport has only been exhibited in 
leukemic cells [69,70]. In addition to these tissues nucleoside transport has been 
observed in a number of cultured cell lines, for a more information see the review by 
Cass [49]. 
1.3 A novel gene family 
1.3.1 Establishment of homologues 
For many years active nucleoside transport had been studied using functional 
techniques. Although this did provide evidence for the existence of a number of 
different nucleoside transport subclasses it was 
transport 
impossible to confirm whether a 
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activity observed in one tissue was due to the same protein as that observed in 
another tissue, or indeed if that observed in one organism was identical to that 
observed in another. Therefore when the first active sodium/ pyrimidine nucleoside 
transporter, rCNTI, was cloned by Huang et al. in 1994 this allowed for a better 
understanding of these proteins [81 ]. Database analysis indicated that there were a 
number of proteins that showed significant homology. Of these the closest were a 
number of E coli proteins including the recently cloned proton/ pyrimidine 
nucleoside transporter NupC [82] and two proteins of unknown function, YeiM and 
YeiJ. These proteins showed between 27 and 34 percent identity to the amino acid 
sequence of rCNTI. This finding showed that rCNTI was a member of a new gene 
family, which has been verified by the further cloning of several more proteins 
including its human homologue from the human kidney, hCNTI [83]; the rat liver 
sodium/ purine nucleoside transporter, formerly designated SPNT I for sodium purine 
selective nucleoside transporter type-] but which has now been renamed rCNT2 to 
standardize nomenclature [84]; the human kidney transporter hCNT2 with similar 
characteristics to the rat liver homologue [85]; and more recently the pig kidney 
transporter pCNTI which has similar characteristics to the two sodium/ pyrimidine 
transporters mentioned earlier. To date this is the total number of mammalian 
homologues detected although there are a number of homologous proteins in other 
organisms including the hagfish, hfCNT3. The importance of the latter discovery is 
that the hagfish is one of the evolutionally oldest vertebrates on the planet and thus 
indicates that members of this gene family have existed for millions of years. 
Moreover,, this protein appears to be cib-type and has thus been designated as the first 
CNT3-type transporter to be cloned. Of the remaining homologues so far identified 
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two very similar Caenorhabditis elegans proteins bear close homology to the active 
mammalian nucleoside transporters while the remaining homologues, from bacteria, 
are relatively shorter, appearing to lack at least 130 amino acid residues from the N- 
terminus as indicated in appendix 2. Additionally a partial EST from Drosophila has 
demonstrated significant homology but has been omitted from this discussion due to 
the lack of complete sequence. A summary of the phylogenetic relationships between 
all known prokaryotic and eukaryotic concentrative nucleoside transport proteins can 
be seen in Figure 1.1. 
1.3.2 Cloning of thefirst active nucleoside transporter: rCNTI 
As mentioned above rCNTI was the first active nucleoside transport protein to be 
cloned [81], thus confirming its identity and allowing more in-depth investigation 
into its structure and function. Cloning of this protein involved expressional 
screening in Xenopus oocytes to isolate a 2.4 kb cDNA clone encoding properties of 
a cit-type sodium dependent nucleoside transporter. That iý it transported primarily 
the pyrimidine nucleosides thymidine, cytidine and uridine in addition to the purine 
nucleoside adenosine. Uptake was saturable having an apparent K, of 37 ýtM for 
uridine and aVmax of 21 pmol/ oocyte min-'. Of pharmacological importance was the 
observation that the therapeutic nucleoside analogues AZT and ddC were also 
transported. In accordance with this being active transport rCNTI was shown to 
couple sodium ion transport to nucleoside transport in a ratio of 1 to I as expected for 
cit-type transport. 
The cDNA sequence predicted rCNTI to be 648 amino acid residues in length giving 
it an unmodified molecular mass 71 kDa [8 1 ]. Further analysis indicated that there 
were three potential N-linked glYcosylation sites at positions 543,605 and 643; three 
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potential O-linked glycosylation sites, as predicted by the World Wide Web available 
application NetOglyc (web site of which is http: //www. cbs. dtu. dk/), which compares 
the protein sequence of interest against a database which currently contains 
approximately 160 0-glycosylated proteins [86]; four potential protein kinase C- 
dependent phosphorylation sites at residues 5,203,421 and 527; a -S-S-S-S- motif 
at residues 609 to 612; and that the protein possessed a relatively high cysteine 
content of 3.1 percent. Fourteen potential transmembrane domains (TMDs) were 
identified using physiochemical (Goldman, Engelman, Steitz) and statistical (von 
Heijne) hydropathy scales [14,87], which in addition to the lack of an N-terminal 
signal sequence suggested that the N-terminus was cytoplasmic and assuming that all 
fourteen putative TMI)s resided in the membrane this also placed the C-terminus on 
the cytoplasmic side of the membrane. However, using alternative algorithms 
allowed the number of TMDs to vary between 10 and 14 indicating that this may not 
be the true representation of the 2-dimensional model of this protein, which can only 
truly be determined by experimentation. The majority of this information has been 
represented in Figure 1.2. 
In vivo expression of rCNTI as indicated by Huang et al. was restricted to the rat 
jejunum, from where it was isolated, and the kidney as indicated by Northern blotting 
[8 1 ]. However, more recently mRNA for this transporter has been demonstrated to be 
widely distributed in the rat brain, being observed in superior colliculus, choroid 
plexus, striaturn, hypothalamus, cerebellum, cortex and hippocampus. In this latter 
region, due to the low presence of ei- and es-type activity, it is predicted that rCNT I 
and the co-expressed rCNT2 play major roles in nucleoside regulation [88]. 
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Furthermore, Felipe et al. have also demonstrated the presence of rCNTI in the rat 
liver [89]. 
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Table 1.1 Functional properties of nucleoside transporter subclasses 
Equilibrative Concentrative 
Descriptive es ei C if Cit cib citg CS 
abbreviation 
Numerical NI N2 N3 N4 N5 
abbreviation 
Na'-dependent +++++ 
Na: '/ nucleoside 1: 1 1: 1 2: 1 1: 1 nd' 
stoichiometry 
Inhibited by: 
NBMPR + + 
Dipyridamole + + + 
Dilazep + + + 
Permeants: 
Adenosine + + +++ + + 
Uridine + + +++ + nd 
Guanosine + + ++ + nd 
Inosine + + ++ nd 
Fon-nycin B + + ++ + 
Tubercidin + + + nd nd 
Thymidine + + + + nd 
a 
ndý not determined. 
Table adapted from review by Cass [49] 
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Figure 1.1 Phylogenetic analysis of rCNT1 gene family 
rCNTI 
hCNT1 
pCNTI 
rCNT2 
hCNT2 
hfCNT3 
F27ell-l 
-F27ell-2 
Nupe-Strep 
Yeim-Haein 
Nupc_Helpy 
- Yeij_Ecoli 
Yeim-Ecoli 
- Nupc-Bacsu 
- Nupc_Ecoli 
Yxja_Bacsu 
Phylogenetic analysis of the rCNTI gene family members was performed to provide 
a multiple sequence alignment file using the software program ECLUSTALW which 
was subsequently analyzed to obtain evolutionary distance inforination in the GCG 
DISTANCES program, based upon the method of Kimura [90]. This information was 
subsequently interpreted by the GCG program GROWTREE, based the original 
method of Saitou and Nei [91], to produce the graphical representation observed 
above, where the horizontal axis represents sequence differences and thus 
evolutionary distances. Accession numbers for each member are provided in 
appendix 1. The original alignment output obtained was further modified to include 
further observations and analyses, and is represented in appendix 2. 
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Figure 1.2 Putative model of rCNT1 secondary structure in the 
lipid bilayer 
Image on opposite page 
Putative topological model of rCNTI in the lipid bilayer, illustrating the presence of 
fourteen potential TMDs as predicted by the physio-chemical Goldman, Engelman 
and Steitz analysis and von Heijne statistical hydropathy scales [14,871. The lack of 
an N-terminal signal sequence suggested that the N-terminus was cytoplasmic and 
assuming that all fourteen putative TMI)s resided in the membrane, this also placed 
the C-terminus on the cytoplasmic side of the membrane. The amino acid residues in 
the model have been colour coded based on the classification used by SOMAP [92]; 
general non-polar residues are A, M, 1, L&V (grey); general polar residues are S, T, 
N&Q (green); positive residues are H, K&R (blue); negative residues are D&E 
(red); aromatic residues are F, W&Y (purple); structure breaking residues are G& 
P (brown); and cysteine residues (yellow). Also shown in the model are the three 
potential N-linked glycosylation sites at positions 543,605 and 643 although the 
fonner of these is located within predicted helix thirteen (residues with orange 
borders); the three potential 0-linked glycosylation sites at S13, T320 and T607 
(residues with purple borders); the four potential protein kinase C-dependent 
phosphorylation sites at T5, S203, S421 and S527 (indicated by #); and the four 
serine motif (indicated by *** *). 
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1.3.3 A comparative study of rCNTI and the mammalian homologues 
The cloning of rCNTI and the subsequent isolation of a cDNA encoding rCNT2 
allowed additional nucleoside transport proteins within these two subclasses, cit and 
cif respectively, to be obtained with greater ease with the aid of degenerate primers 
and the polymerase chain reaction (PCR). As a result the cDNA sequences of 
hCNTI, hCNT2, pCNTI and hfCNT3 have been isolated in addition to some of the 
other proteins mentioned in section 1.3.1. However little is known about the majority 
of these proteins with the exception of rCNTI, hCNTI, rCNT2 and hCNT2. 
Therefore discussion about rCNTI and its homologues in the earlier part of this 
section is to be restricted to these four proteins with any exceptions specifically 
mentioned while later comparison of sequences will involve all the fore-mentioned 
homologues. 
Since rCNTI has already been discussed in the previous section rCNT2 will be 
considered firstly. This protein was cloned by functional expression in Xenopus 
oocytes of mRNA isolated from the rat liver. Like rCNTI it exhibited sodium- 
dependent nucleoside transport but unlike rCNTI it showed preference for purine 
nucleosides while additionally transporting uridine. The apparent K.. for adenosine 
was 6 ýtM with a V., a,, of 
457 fmol/ oocyte min-' in this expression system. The size 
of this protein was very similar to that of rCNTI with the cDNA encoding a 659 
amino acid polypeptide with the unmodified relative molecular mass of 72 kDa and 
showing 64 % identity in amino acid sequence. Like rCNTI it has a number of 
potential N-linked glycosylation sites, consensus sites for protein kinase A and C 
phosphorylation in both termini, and an ATP/ GTP binding motif in the N-terminus. 
Considering the distribution it appears in relatively more tissues having been 
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demonstrated in the jejunum, spleen, heart and brain in addition to the liver [84,88]. 
Indeed, although both rCNT I and rCNT2 have been isolated from the same tissues it 
is obvious from evidence to date that the levels of expression of each are not 
equivalent and that their specificities differ. For example, comparative studies on 
hepatic nucleoside transport by Felipe et al. indicated that rCNT2 is greatly up- 
regulated in response to insulin in regenerating rat livers, while the amount of rCNTI 
remained relatively constant [89]. This provides evidence for the suggestion that 
rCNT2 was responsible for the uridine uptake observed in plasma membrane vesicles 
during regeneration of rat livers [45]. 
Having cloned the rat transporters rCNTI and rCNT2 the human homologues could 
be obtained with relative ease. Both hCNTl and hCNT2 were cloned by 
hybridization cloning and reverse transcriptase PCR amplification strategies. The 
former has been demonstrated to be 83 % identical in amino acid sequence to the rat 
isoform showing similar substrate specificities in that it was cit-type and transported 
AZT [83]. The cloning of this protein from the human kidney indicated that members 
of the CNT family existed in human tissues and provided evidence for their 
involvement in renal transport of physiological nucleosides and nucleoside drugs. 
Similarly the human homologue of rCNT2, hCNT2, showed 81 % identity to the rat 
isoform but differed markedly at the N-terminus in primary structure. Due to the 
specificities of the proteins being identical it is foreseeable that this difference may 
be a means of targeting the protein to a specific membrane surface and that in the two 
organisms this is achieved by different means. Alternatively, this may be a region of 
little functional importance which is consequently not conserved during evolution. 
Interestingly on comparison of the aligned sequences of rCNTI, rCNT2, hCNT1 and 
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hCNT2 in appendix 2, although the primary structure is variable there is the trait of 
the N-terminus being very hydrophilic with approximately 25 percent of the residues 
being either acidic or basic with a net charge of between plus 2 to plus 5. Therefore it 
is possible that relative conservation of these charged residues may play an important 
factor in protein activity or expression. Considering the remaining four transporters 
in the alignment with the extra N-terminal region, when compared to the facilitative 
hornologues, the pig kidney CNTI homologue, pCNTI, follows much the same 
pattern of charged residues in contrast to the hagfish transporter which is uniquely 
acidic (data not shown for hfCNT3 in alignment as this sequence was a personal 
communication from J. D. Young and has not yet been entered into Genbank or 
published). The final two clones come from C elegans coding for two nucleoside 
transporters with clone F27el 12 encoding an extra 79 amino acid residues at the N- 
terminus compared to clone F27el 1-1. Interestingly both clones conform to the net 
positive terminus similar to all the other fore-mentioned homologues, with the 
exception of the hagfish protein. 
Comparison of the shorter homologues with the concentrative nucleoside transporters 
suggested that the extra three helices located at the N-terminus of the concentrative 
transporters may be responsible for the co-transport of the sodium ion. Such localized 
sodium binding and transport activity has been shown previously with the E. coli 
melibiose transport protein which possesses four aspartate residues shared between 
helices one, two and four which when mutated decrease if not abolish sodium 
coupled transport [93]. However this does not appear to be the case with the active 
nucleoside transporters for two reasons. Firstly, on investigation for similar residues 
in the nucleoside transporter alignment only an aspartate residue within predicted 
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TMD 3 was conserved throughout the larger of the homologues. Secondly, bacterial 
transporters, lacking these helices, do nonetheless transport cations. Therefore 
sodium coupling must occur within the final eleven putative helices of this family of 
concentrative nucleoside transporters. Possible locations for the site(s) of sodium ion 
interaction could include regions containing either histidine or cysteine residues, 
which have been reported to participate in metal-protein interactions. A sodium- 
binding (SOB) motif, G-A-X-X-X-X-L-X-X-X-G-R where X is any amino acid, has 
been demonstrated to participate in sodium binding in glutamate, taurocholate and 
phosphate cotransporters [94]. However, examination of the concentrative transporter 
sequences indicated that this sequence was absent and therefore sodium-coupling 
cannot be via this motif 
Examination of the aligned sequences for potential residues involved in substrate 
binding indicated the presence of a number highly conserved single residues or 
motifs. These motifs were considered significant when nine or more of the fifteen 
sequences contained the same or similar residues. The first significant observation is 
the relatively high conservation of glycine residues throughout the sequences. 
Nineteen of these have been identified in the alignment suggesting that their presence 
is significantly important, these residues have been highlighted in appendix 2. 
P 
Moreover twelve out of the nineteen are located within predicted helices suggesting 
that their presence may be necessary to allow correct folding. Also of interest is the 
absolute conservation of a proline residue within putative TMD twelve, and the 
prevailing presence of other prolines within putative helix ten and towards the end of 
putative TMDs eight and ten. Unlike soluble proteins where prolines are rarely found 
in (x-helices a number of integral membrane proteins have been shown to possess this 
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residue within these secondary conformations. For example, bacteriorhodopsin has 
proline residues in the middle of three of its putative seven TMI)s while rhodopsin 
has prolines in five of its seven putative helices. Other studies have also indicated a 
bias toward prolines in the presumed membrane-spanning segments of membrane 
proteins, especially those involved in transport functions [95,96]. One suggestion is 
that proline residues may act as a hinge, thus allowing change of the protein from 
outward facing to inward facing or vice-versa, depending on the local conditions 
including substrate binding. However, this suggestion has tended to be discounted as 
a result of mutagenesis studies, exemplified by GLUTI [97], which have 
demonstrated such proline residues to be non-essential. 
The cluster of basic residues located at the C-terminal end of putative TMD four 
appears important. In all cases at least two basic residues are located within close 
proximity of each other, with at least one lysine residue always being present. These 
residues may therefore be important in either substrate binding or in signaling the 
end of this helix. Further conservation of either acidic or basic residues can be seen 
throughout the sequences although to a higher degree around TMD eight and in the 
hydrophilic loops between TMDs 8&9,10 & 11,12 & 13 and 13 & 14. These 
therefore may play a similar role in substrate recognition or structure determination. 
Apart from single residues being conserved a number of short sequences appear 
important. The first of these is located in putative helix six encoding the consensus 
G-X-S-F-V-F-G-X-A-L followed almost immediately by F-A-F-Q-V-L-P-1-1-V-F-F- 
S-X-V-M-S-V-L-Y-Y-L-G, where X can be any residue, suggesting that this region 
may be important as this is a very high level conservation and in those regions where 
X has been displayed it normally contains an amino acid of similar physio-chemical 
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properties throughout the aligned molecules. Inspection of further regions of the 
alignment indicated that areas C-terminal to this contained relatively high 
conservation, particularly within the predicted TMDs. Taking into consideration the 
more continuous of these indicated the G-X-A-T-1-A-G-S-L-L-G-A-Y sequence 
within putative helix nine; A-A-X-L-l-A-F-L-A-V-L-A-L-V-N in potential TMD 
eleven; the conservation of G-X-K-X-X-X-N-E-F-V-A-Y in the hydrophilic loop 
connecting TMI)s twelve and thirteen; and T-F-A-L-C-G-F-A-N-F-S-S-1-G-1-M-L-G 
in the thirteenth TMD. Although all of these sequences may play important roles in 
structure or substrate binding the absolute conservation of the N-E-F-V sequence is 
particularly interesting because it is found within a predicted hydrophilic loop. As a 
general concept of membrane proteins the hydrophilic regions tend to be very 
variable between homologues unless that region is of particular importance. This 
information in addition to the evidence discussed in chapter 5, indicating that this 
loop is provisionally extracellular, suggests that these residues may act in initial 
substrate recognition or form a predominant part in regulating access of the substrate 
to the substrate binding site. 
Although the majority of the discussion in this sub-section is purely speculative 
based on sequence similarity it provides suitable locations to start the mutagenic 
investigation of this group of proteins to determine features that are both important in 
confonnation and substrate recognition. 
1.4 Aims of the study 
The objectives of this study were two-fold in that distribution of the transporter 
rCNTI in rat tissues was to be investigated while performing parallel investigations 
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into the conformation of this protein in the lipid bilayer. A means that would allow 
the specific detection of rCNTI would be the production of polyclonal antibodies 
raised against this protein. To achieve this two strategies were adopted, 
principally this involved the generation of four synthetic site-directed peptides 
to predicted hydrophilic regions of the protein, which were be used for 
immunization following conjugation. Alternatively genetic manipulation of the 
rCNT I cDNA allowed the production of a glutathione S-transferase (GST)- 
fusion protein encoding a fragment from the N-terminus of this former protein, which 
was then be used in immunization. These anti-peptide antibodies enabled the 
detection of rCNTI expressed at the protein level in rat tissues to confinn and extend 
the original data published by Huang et al [81]. Furthermore, this was be taken a 
stage ftirther by the immunocytochernical investigation of these tissues to localize the 
protein at the subcellular level, and thus enhance the understanding of the 
physiological role of this protein in vivo. The second objective of this study was to 
investigate the basic topology of rCNTI. This was to be achieved by initially 
investigating the glycosylation state of the native protein, followed- by genetic 
manipulation of the cDNA to remove any accessible in vivo N-linked glycosylation 
sites to allow further analysis of the protein conformation by introduction of artificial 
glycosylation sites at defined locations within the peptide sequence. 
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Materials and methods 
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2.1 Materials and Suppliers 
Analytical grade chemicals were used throughout in this study with all solutions 
being prepared using deionised water. Materials were obtained from the following 
suppliers: 
General laboratory reagents and equipment 
Amersham International p1c, Amersham, Buckinghamshire 
Aldrich Chemical Company Ltd, Gillingham, Dorset 
BDH Laboratory Supplies Merck Ltd, Lutterworth, Leicestershire 
Bio-Rad Microscience Ltd, Hemel Hempstead, Hertfordshire 
Pierce and Warriner (UK) Ltd, Chester, Cheshire 
Pharmacia Biotech Ltd, St. Albans, Hertfordshire 
Sigma Chemicals Co., Poole, Dorset 
Peptide Synthesis 
Calbiochem-Novabiochern (UK) Ltd, Beeston, Nottingham 
Fisons Ltd., Loughborough, Liecestershire. 
Fluka Chemicals Ltd, Glossop, Derbyshire 
PerSeptive Biosystems (UK) Ltd, Hertford, Hertfordshire 
Immunological reagents 
Boehringer-Mannheim, Lewis, East Sussex 
Sigma Chemicals Co., Poole, Dorset 
Vector laboratories Inc., Burlingame, CA, USA 
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Molecular biology reagents 
Invitrogen, British Bio-technology Ltd, Abingdon, Oxon 
MBI Fermentas, Immunogen International Ltd, Sunderland, Tyne and Wear 
New England Biolabs (UK) Ltd, Hitchin, Hertfordshire 
Promega UK, Southhampton 
Qiagen, Hybaid Ltd, Teddington, Middlesex 
Stratagene Ltd, Cambridge 
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2.2 Synthetic peptide synthesis and analysis 
2.2.1 Peptide synthesis 
Site-directed peptides were synthesised on a Milligen/ Biosearch 9050 
PepSynthesiser according to the diisopropylcarbodiimide (DIPCDI) method 
described in the operator's manual. Syntheses were performed with Ig polyethylene 
glycol-polystyrene (PEG-PS) resin with a 4-fold excess of 
fluorenylmethyloxycarbonyl (FMOC) amino acid derivatives (PerSeptive 
Biosystems). Preformed FMOC amino acid-pentafluorophenol (Pfp) esters were used 
in all cases with the exceptions of Ser (t-butyl, tBu) and Thr (tBu) when 
dihydrohydroxyoxobenzotriazole (Dhbt) esters were utilised. Efficiency of coupling 
was monitored by the counterion distribution monitoring, CDMTM' system (section 
3.3.1). 
2.2.2 Peptide cleavage 
Resin-bound peptides were washed 5 times with dichloromethane (DCM), four times 
with HPLC-grade methanol and then Iyophilised. Cleavage of the peptide from the 
resin and removal of protecting groups was carried out using trifluoroacetic acid 
(TFA) containing a mixture of scavenger reagents (81.5 % (v/v) TFA, 5% (v/v) 
phenol, 5% (v/v) water, 2.5 % (v/v) 1,2-ethanedithiol (EDT), 5% (v/v) thioanisole, 
I% (v/v) triisopropylsilane (TIS); the latter three being obtained from Fluka 
chemicals) for 4h at room temperature (r. t. ) with shaking every 30 min. The 
cleavage mixture was separated from the resin by filtration and the resin then washed 
with 60 ml TFA, with the peptide/ TFA/ scavengers being collected in a round 
bottom flask. The TFA was removed by rotary evaporation using a dry ice/ ethanol 
cold finger trap. Scavengers were removed by ether precipitation following which the 
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peptides were dissolved in Milli-Q water or 2% (v/v) dimethylsulfoxide (DMSO), 
Iyophilised and finally stored at -70T. 
2.2.3 Peptide mass spectrometric analysis 
Peptide fractions for analysis were diluted to 20 pmol/ýtl in water or 2% (v/v) 
DMSO. I [d of a saturated solution of cc-cyano-4-hydroxy-cinnamic acid (Aldrich) in 
60 % (v/v) water / 40 % (v/v) acetonitrile and I ýtl of diluted peptide were mixed and 
air-dried (approx. 30 min) onto steel discs pre-washed with water and methanol. 
Measurements were performed by matrix-assisted laser desorption ionisation time- 
of-flight (TOF) mass spectrometry (MS) using a TOFspec mass spectrometer (VG 
Organics) by Dr J. N. Keene. Where necessary, the quantities of peptides used were 
adjusted to improve signal-to-noise ratio. 
2.2.4 Peptide high performance liquid chromatography 
Peptides were solubilised at 0.5 mg/ml by vortexing in either water or 2% DMSO in 
water. Debris was removed at 11600g for 2 min and the supernatant transferred to a 
fresh tube. Reverse-phase high performance liquid chromatography (rpHPLC) was 
performed using a Dynamax 3 OOA, 5 ýtrn, C 18 analytical column attached to a Gilson 
715 HPLC apparatus. Sample was applied using a 20 ýtl sample loop. Two reservoirs 
were used to create the elution gradient, reservoir A contained 0.1 % trifluoroacetic 
acid (TFA, from Fisons) in deionised water while reservoir B contained 0.1 % TFA 
in HPLC far UV grade acetonitrile (Fisons). Initial analysis was achieved by running 
a gradient from 0 to 40 % reservoir B solution against reservoir A. After each sample 
was analysed a control run was carried out using the solution in which the peptide 
was resuspended. This was subtracted from the sample profile to eliminate the 
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background signal. If required the gradient was altered to allow greater resolution 
over the region at which the peptide was eluted. 
2.3 Production and characterisation of anti-peptide antibodies 
2.3.1 Conjugation ofpeptides to ovalbumin 
Peptides were conjugated to ovalbumin with m-maleimidobenzoyl-sulfo-suceinimide 
ester using a method adapted from LaRochelle et al [98] with the exception that 
ovalburnin was used as the carrier protein in place of Keyhole limpet haemocyanin, 
which tends to come out of solution readily. Each conjugate (200ýtg at I mg/ml in 10 
mM sodium phosphate, 145 mM NaCl, pH 7.2; PBS) was mixed with 200ýtl 
complete Freund's adjuvant and subcutaneously injected into New Zealand white 
laboratory rabbits. The rabbits were given a second injection of 100 ýtg conjugate in 
incomplete Freund's adjuvant after 4 weeks and serum samples analysed 2 weeks 
later by enzyme-linked immunosorbent assays (ELISAs), section 2.3.3. Boosting 
continued for a further four months if necessary, at intervals of not less than I month, 
after which the rabbits were bled out under terminal anaesthesia. Cross-reactivity 
tests of each antiserum with each of the other three peptides was carried out by 
ELISA. Peptide-specific antibodies were then affinity purified from each antiserum 
using peptide columns as described in section 2.3.2. 
2.3.2 Affinity purification of anti-peptide antibodies using immobilised synthetic 
peptides 
Peptide affinity columns were prepared by dissolving 6 mg peptide in 500 ýd 50 mM 
Tris-HCI, 5 mM ethylenediaminetetraacetic acid (EDTA) pH8.5 plus a minimal 
amount of DMSO, if required, to solubilise the peptide. Any disulfide bonds in the 
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mixture were then reductively cleaved by addition of 25 gl IM dithiothreitol (DTT), 
flushing with nitrogen and incubating for Ih at r. t.. The reduced peptide was then 
separated from DTT by passage down aIx 20 cm Sephadex GIO column 
(Pharmacia) pre-equilibrated in Tris-HCI/ EDTA pH 8.5. The absorbance of fractions 
was measured at 230 nm, and the fractions corresponding to the peak eluting at the 
void volume were pooled (3-4 ml). Duplicate 50 ýtl samples of this pooled sample 
were taken to detennine coupling efficiency at a later stage by the 
dithiobisnitrobenzoic acid (DTNB) assay [99]. Meanwhile 6 ml Sulfb-link coupling 
gel (Pierce) was washed with 6 volumes Tris/EDTA buffer, composition as described 
above. The solution of reduced peptide was added to the Sulfo-link gel and incubated 
at r. t. for 25 min, rotating slowly in the dark, followed by incubation for 30 min 
without rotation. The mixture was centrifuged as briefly as possible in a clinical 
centrifuge and the supernatant removed, keeping duplicate 100 ýd samples of the 
latter to determine coupling efficiency by the DTNB assay. Unbound peptide was 
removed by resuspending the gel in Tris/EDTA buffer and centrifuging as 
previously. After this procedure had been repeated twice more, excess iodoacetyl 
groups on the coupling gel were blocked by the addition of 5 ml 50 mM cysteine in 
Tris/EDTA and then rotated slowly for 25 min at r. t. followed by incubation for 30 
min without rotation. After brief centrifugation as before, the supernatant was 
removed and the gel washed with 50 ml IM NaCl. The gel was equilibrated with 
PBS by washing with 50 ml of this buffer, centrifuged to remove most of the 
supernatant and loaded into a5 ml econo-column (Bio-Rad). PBS was then passed 
through the column at a flow rate of 15 ml/h for I h. For long term storage columns 
were equilibrated in PBS containing 0.02 % sodium azide. 
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Purification of antisera samples using the affinity columns involved the addition of 5- 
10 ml antiserum to the PBS pre-equilibrated column at a flow rate of 10 ml/h and 
measuring the absorbance of the eluate at 280nm (A280nm). After circulation of the 
serum through the column for 1-2 h non-specific and weakly-bound antibody was 
removed by elution with 10 mM sodium phosphate, 800 mM NaCl, pH 7.2 until the 
A280nm of the eluate fell to near zero, with 2 ml fractions being collected. Tightly- 
bound, peptide-specific antibodies were then eluted with 50 mM diethylamine pH 11. 
The peak fractions (4-6 ml) were pooled, rapidly neutralised by addition of a small 
volume of 0.5 M acetic acid, and then dialysed overnight (o/n) versus 41 PBS. 
Subsequent to alkaline elution, acid elution of the column with 0.2 M glycine-HCI 
pH 2.4 was also carried out and the peak fractions pooled and neutralized with 2M 
Tris prior to dialysis o/n as described for alkaline elution. Following dialysis 
bicinchoninic acid (BCA) protein determination was carried out on each fraction, in 
addition to ELISA to determine recovery efficiency. 
2.3.3 Enzyme-linked immunosorbent assay 
ELISAs were performed by placing 80 ýtl 0.5 ýtg/ml peptide, in 50 mM sodium 
carbonate pH 9.6, into each well of a 96-well microtitre plate and incubating o/n at 
4'C . The plate was washed 
5 times with phosphate-buffered saline Tween-20, PBS- 
T, (140 mM NaCl, 5 mM KCI, 3 mM Na2HP04,3 mM KH2PO4,6 mM NaN3,0.05 
% (v/v) Tween-20, pH 7.2) and then blocked for 2h at 37'C with blocking buffer (5 
% (w/v) milk powder in PBS-T). After washing the plates 5 times with PBS-T, 100 ýt 
I samples of primary antibody were added to the wells at successive 3-fold dilutions) 
starting with a 200-fold diluted stock in antibody buffer (I % milk powder in PBS- 
T), and incubated o/n at 37C . The plate was washed as 
before and 100 ýtl of goat 
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anti-rabbit IgG conjugated to alkaline phosphatase (Bio-Rad), diluted 3000-fold in 
antibody buffer, was added to each well for 2h at 37C. After washing the plate as 
before 100 ýd p-nitrophenol phosphate (PNPP) solution (5 mM p-nitrophenyl 
phosphate disodium salt in 10 mM diethanolarnine, 1 MM MgC'2, pH 9.8) was added 
and incubation continued for 2h at r. t.. Finally, the absorbance of each well at 405 
nm. was measured using a Titretex plate reader. 
2.4 General Protein techniques 
2.4.1 Membrane preparation 
Brain, heart, jejunum, kidney, liver, muscle, spleen and testis were obtained from 
male Wistar rats (200-250 g). Membranes were prepared by chopping the tissues to 
allow homogenization with a Kinematica CH-6010 polytron at setting 3 for 2-4 min 
in 4 volumes 250 mM sucrose, 100 mM sodium phosphate pH 7.5,1 mM EDTA, 2 
ýig/ml aprotonin, 1 mM benzamidine, 10 ýtM leupeptin, 0.1 mM 
phenylmethylsulfonyl fluoride, 10 ýtg/rnl pepstatin A. Homogenates were centrifuged 
at 4'C for 30 min at 7500g. The supernatants were passed through 150 ýtm nylon 
mesh prior to centrifuging at 100,000g for Ih at 4T. Supernatants were removed 
and the pellets were resuspended in phosphate buffered saline pH 7.2 (PBS), prior to 
homogenization by 10 strokes of a Teflon pestle. Samples were stored at -70'C until 
required. 
2.4.2 Protein determination 
Protein concentrations were determined with the BCA assay (Pierce) according to the 
manufacturer's instructions, using BSA as a standard. 
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2.4.3 SDS-polyacrylamide gel electrophoresis 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed according to Laemmli [1001.1.5 mm 10 % (w/v) resolving gels were run 
on vertical mini gel apparatus for Ih at 30 mA per gel. All samples were diluted 4: 1 
in SDS-sample buffer (0.2 M Tris-HCI pH 6.8,4 mM EDTA, 4% (w/v) SDS, 4% 
(v/v) glycerol, 40 mM DTT). The amount of protein present varied depending on the 
source of the sample, therefore the protein content will be stated in each case. Gels 
were stained with Coomassie blue (0.25 % (w/v) coomassie brilliant blue in 25 % 
methanol/ 10 % acetic acid) and destained with 10 % (v/v) acetic acid. 
2.4.4 Immunoblotting 
Transfer to nitrocellulose membranes was preformed as described by Towbin [101]. 
Membranes were washed in tris buffered saline (TBS, 20 mM Tris, 500 mM NaCl 
pH 7.5) for 10 min prior to blocking with 5% milk powder in TB S containing 0.2 % 
Tween-20 (TBS-T) for 2h at room temperature (r. t. ). Primary antibody (2 ýtg/ml) in 
antibody buffer, TBS-T containing I% milk powder, was added overnight at r. t.. 
Membranes were washed 3 times in TBS-T after which goat anti-rabbit peroxidase 
labelled secondary antibody, from Boehringer-Mannheim, in antibody buffer was 
added at 1: 10,000 for Ih at r. t.. The nitrocellulose was washed 3 times in TBS-T and 
peroxidase activity detected using Enhanced Chemical Luminescence (Amersham), 
according to the manufacturer's instructions. 
2.5 Molecular biology techniques 
The procedures used for DNA manipulations were essentially as described by 
Sambrook et al [102] with alterations mentioned where appropriate. Plasticware, 
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glassware and media were sterilised by autoclaving at 121'C for 15 min. Chemicals 
were made from molecular biology grade reagents and either autoclaved or filter 
sterilised prior to use. 
2.5.1 Small scale isolation ofplasmid DNA 
Plasmid DNA was prepared from the host strain based on a modified form of the 
alkali lysis method of Ish-Horowicz and Burke [103]. Single colonies were taken 
from Luria-Bertani (LB) agar (I % (w/v) NaCl, I% (w/v) tryptone, 0.5 % (w/v) 
yeast extract, 1.5 % (w/v) bacterial agar, pH 7) plates containing the appropriate 
antibiotics and used to inoculate 5 ml LB broth containing the correct antibiotics in 
50 ml Falcon tubes. These cultures were propagated overnight at 37'C with shaking 
at 200 rpm. The following day cultures were sedimented at I OOOg for 5 min and the 
pellets resuspended in 250 ýtl GET buffer (50 mM glucose, 10 mM EDTA, 25 mM 
Tris-HCI pH 8.0). The cells were lysed by addition of 250 ýtl lysis buffer (0.2 M 
NaOH, I% (w/v) SDS) with gentle inversion 15 times followed by neutralisation 
with 350 ýd neutralising buffer (3 M NaOAc pH 4.8) after which samples were left 
on ice for 5 min. Protein and chromosomal DNA precipitates were removed 
by transferring samples to 1.5 ml eppendorfs followed by sedimentation at 11600g for 
10 min in a bench-top microfuge. The supernatant was removed to a fresh eppendorf 
to which 750 ýtl 96 % ethanol was added to allow precipitation of plasmid DNA 
while standing on ice for 10 min. The DNA was sedimented at 11600g for 30 min 
and the pellet washed with 70 % (v/v) ethanol re-pelleted for 5 min and air-dried. 
The DNA was finally resuspended in 50 ýLl TE (10 mM Tris-HCI pH 8,1 mM 
ethylenediamine tetraacetic acid (EDTA)) containing 50 ýtg/ml RNase A incubated at 
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37'C for 30 min and stored at -20'C. Yields from 5 ml overnight cultures ranged 
from 0.5 to 5 [tg depending on the plasmid copy number. 
Production of ultra-pure plasmid DNA for automated DNA sequencing was 
performed by culturing the cells as described above followed by plasmid DNA 
extraction using the QIAGEN plasmid mini-prep kit which is also based on alkali 
lysis. 
2.5.2 Large scale isolation ofplasmid DNA 
A large scale culture was prepared using a 10 ml overnight culture in LB broth, 
containing the appropriate antibiotics, to inoculate IL of the same medium followed 
by o/n incubation at 37C with agitation at 220 rpm. Cells were harvested at 3500g 
for 10 min. The pellet was resuspended in 50 ml GET buffer and the cells lysed by 
the addition of 100 ml lysis buffer followed by inversion 10 times. The solution was 
neutralised by addition of 50 ml 3M potassium acetate, 5M acetic acid and inverted 
as before. Cell debris was removed at 3500g for 30 min at 4T with the supernatant 
being passed through a 0.45 ýtm sterile filter prior to DNA precipitation by mixing 
with 0.6 volumes isopropanol. DNA and RNA were pelleted at 3500g for 30 min at 
4'C, washed with 20 ml 70 % (v/v) ethanol and air-dried. The pellet was resuspended 
in 4.5 ml TE,, transferred to a 50ml Falcon tube to which 6 ml 5M LiCl was added 
and left on ice for 10 min. RNA was pelleted at 3500g for 10 min at 4'C and the 
supernatant transferred to a 50 ml Falcon tube containing 2.5 volumes 96 % ethanol 
and incubated on ice for 30 min. Plasmid DNA was pelleted at 3500g for 30 min at 
4'C,, washed with 5 ml 70 % ethanol and air-dried. The pellet was resuspended in 800 
ýtl TE containing 50 ýtg/ml RNase A, transferred to an eppendorf and incubated at 
37'C for 30 min. 400 ýtl 20 % (w/v) polyethylene glycol 6000,2.5 M NaCl was 
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added and incubated on ice for 15 min. Plasmid DNA was pelleted at 116009 for 15 
min at 4'C and resuspended in 500 [d TE. The DNA was further cleaned by phenol/ 
chloroform extraction as described in Sambrook et al [102] with the pellet being 
resuspended in 500 ýd TE following ethanol precipitation and stored at -20T. 
2.5.3 Restriction analysis and agarose gel electrophoresis ofplasmid DNA 
DNA (100 to 500 ng) was digested with 0.5-2 U of the appropriate restriction 
endonuclease in its corresponding buffer, as recommended by the supplier, with the 
addition of 100 ýtg/ml BSA for 3h in a final volume of 10 ýtl. 2 ýtl of 6x DNA 
sample buffer (40 % (w/v) sucrose in Milli-Q containing 0.1 % bromophenol blue) 
was then added and 6 ýtl of each samPle was subjected to 0.7 % agarose slab gel 
electrophoresis at 80 V using a lx TAE (40 mM Tris-acetate pH 8.3,1 mM EDTA) 
buffer system. For determining the molecular size of restriction products either 
Lambda/ BstEll or Phi X 147/ Haelll DNA markers were run along side the samples. 
Quantitation of plasmid DNA was carried out as for restriction analysis but with 
serial dilutions 1: 21,1: 4ý 1: 8 and 1: 16 of the DNA to allow visual comparison with 
250 ng of the fore-mentioned DNA markers. 
2.5.4 Preparation and transformation of competent bacterial cells with plasmid 
DNA 
Competent K coli were produced by a procedure based on the CaCl2method of 
Hanahan (1983) [104]. LB (5 ml) overnight cultures grown at 370C were used to 
inoculate 250 ml LB the following morning. This culture was incubated at 37C with 
agitation at 220 rpm until 
A600nm 
== 0.4-0.5 for RecA- strains. The cells were then 
incubated on ice for 10 min, and all subsequent stages performed at 4'C. Cells were 
sedimented at 2500g for 10 min followed by gentle resuspension in 125 ml sterile, 
Chapter 
42 
ice-cold 100 mM CaCl2 and incubated on ice for 10 min. The cells were re-pelleted 
as before, gently resuspended in 10 ml 100 mM CaCl2 and 400 ýtl aliquots prepared 
in eppendorfs. Aliquots were incubated at 4'C for 2h prior to use or snap-freezing in 
liquid nitrogen. 
Competent cells (100 ýtl) thawed on ice or freshly prepared cells were transformed by 
the addition of 40-200 ng plasmid DNA, including pBluescript control (Promega) to 
test competency. Following the addition of DNA the cells were incubated on ice for 
30 min in prechilled 15 ml Falcon tubes after which they were heat shocked at 42'C 
for 45 sec. Pre-wanned LB (0.9 ml, 37'C) was added to each tube which was 
incubated at 37C with agitation for 2 h. Cells were pelleted 2500g for 10 min, 900 ýtl 
removed and the pellet gently resuspended in the remaining 100 [tl LB which was 
spread onto an LB agar plate containing the appropriate antibiotics. Plates were 
incubated overnight at 370C and colonies counted the following day. Typically 
DH5a E coli gave 10' colony fonning units (cfu) per ýtg of pBluescript while 
recombinant DNA tended to produce ten-fold lower cfu/ [tg of DNA. 
2.5.5 Purification of DNA ftagments 
Digested DNA was mixed with 6x DNA sample buffer (section 2.5.3) and run on the 
appropriate percentage agarose gel to obtain sufficient separation of the desired 
fragment. This fragment was removed using a sterile scalpel and weighed. The DNA 
was purified using the QlAGEN gel extraction kit, with elution of the DNA in 50 ýtl 
Tris-HCI, pH 8.5. This eluted DNA was quantitated and if necessary concentrated by 
ethanol precipitation, followed by resuspension in 10 ýd Tris-HCI, pH 8.5. 
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2.5.6 Dephosphorylation of linearised plasmid DNA with Catf Intestine Alkaline 
Phosphatase (CIP) 
Prior to ligation of restriction digested vector DNA with insert the vector was 
routinely dephosphorylated with CIP when either both cohesive ends were 
complementary or blunt. DNA (5 ýtg) in 45 [tl Tris-HCI pH 8.5 was mixed with 5 ýtl 
I Ox CIP reaction buffer (supplied with CIP from NEB) to which IU CIP was added 
followed by incubation at 37C for 30 min for cohesive ends; or 37T for 15 min 
followed by 55'C for 45 min for blunt ends. The CIP was then inactivated by 
addition of EDTA, pH 8, to a final concentration of 5 mM and heated at 75T for 10 
min. Vector DNA was then cleaned by phenol / chloroform extraction as described 
by Sambrook et al [ 102]. 
2.5.7 Ligation ofDNAfragments 
To 100 ng vector DNA a 5-fold molar excess of insert DNA was added in addition to 
1.5 ýtl of both 5x KGB (500 mM potassium glutamate, 125 mM Tris-acetate pH 7.5, 
50 mM magnesium acetate, 0.25 mg/ml BSA, 2.5 mM 2-mercaptoethanol) and 5x 
PEG-6000 solution (50 % (w/v) polyethylene glycol 6000 in Milli-Q) with the 
volume being made up to 13 ýtl with sterile Milli-Q water. These components were 
heated at 45'C for 5 min to melt any complementation followed by cooling on ice for 
5 min. ATP was added to a final concentration of I mM and IU of T4 DNA ligase 
added. For cohesive end fragments the reaction was incubated at room temperature 
for 3 h; whereas blunt end fragments were incubated at 16T overnight in the 
presence of 50 ýtM ATP and I ýtM hexamine chloride. Controls were set up as 
described in Sambrook et al. [ 102]. 
Chapter 2 
44 
2.5.8 Automated DNA sequencing 
All DNA sequence analysis was carried out using an Applied Biosystems Inc. 373A 
system, a departmental facility. This was based on Taq dyedeoXYTM terminator cycle 
sequencing. Plasmid DNA (I ýtg) was mixed with 3.2 pmol primer and a reaction 
premix containing 80 mM Tris-HCI, 2MM MgC12,20 mM (NH4)2SO4 pH 9,4U 
AmpliTaqo DNA polymerase, deoxynucleotides (G, A, T and C) and DyedeoXYT" G, 
A, T and C terminators in 20 ýtl volume. The reaction mix was overlaid with 20 ýtl 
mineral oil and placed in a Hybaid thermal cycler. Tubes were subjected to 25 cycles 
of the following conditions; 
rapid thermal ramp to 96'C, 
96'C for 30 sec (denaturation), 
rapid thermal ramp to 50 T, 
50'C for 15 sec (annealing), 
rapid thermal ramp to 60'C, 
60T for 4 min (extension). 
Tubes were then allowed to come to room temperature prior to purification of 
extension products to remove unreacted dye terminator. This was carried out as for 
plasmid DNA phenol/ chloroform extraction except that it was necessary to use 
phenol/ chloroform without 8-hydroxyquinolone, since its fluorescence would 
interfere with detection of products. The samples were left in dry pellet form and 
submitted to Ms D. Ashworth for electrophoresis and data generation. 
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2.6 GST fusion protein expression 
2.6.1 Small scale In vivo expression offusion protein 
aliquots of 
From a5 MI LB overnight culture containing carbenicillin twoý 9 ml LB 
carbenicillin were inoculated with I ml each and incubated with shaking for 2h at 
37T. 10 ýtl of 0.2 M isopropyl-p-D-thiogalactoside (IPTG) was added to one of the 
cultures and incubated for a further 2h at 37C. Cells were harvested at I OOOg for 5 
min at 4'C. The pellets were resuspended in 200 VtI sonication buffer (50 mM Tris- 
HCI pH 8,150 mM NaCl, I mM EDTA, I mM phenylmethylsulfonylfluoride 
(PMSF)). 10 ýtl of 40 mg/ml lysozyme in TE buffer (10 mM Tris-HCI pH 8,1 mM 
EDTA) was added and incubated at 37T for 15 min. Samples were sonicated in an 
ice-water bath three times for I min at a time with I min on ice between each. Cell 
disruption was checked using oil immersion microscopy. Following confirmation of 
cell disruption 20 ýtl of 10 % Triton X-100 was added and the samples mixed at 4'C 
for 30 min. Cell debris was removed by centrifugation at 130OOg for 10 min at 40C. 
10 ýd of the uninduced and induced supernatants where analysed on an SDS-PAGE 
minigel. (DH5a strain of E. coli was used in all studies unless stated otherwise. ) 
2.6.2 Large scale In vivo expression offusion protein 
I ml of a 10 ml LB carbenicillin ovemight culture was used to seed 100 ml of LB 
carbenicillin which was incubated overnight at 37'C with shaking. This culture was 
used to inoculate 900 ml LB carbenicillin and grown at 370C until 
A600nm of 0.6-0.8 
was reached. The culture was induced by the addition of I ml 0.2M IPTG and 
incubated at 37'C for 3 h. The cells were harvested at 50OOg for 5 min at 4'C and the 
pellet resuspended in 10 ml sonication buffer prior to incubation with 250 Vtl 
lysozyme at 40 mg/ml in TE buffer for 30 min at room temperature. The cells were 
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sonicated three times for 20 sec each on ice, with I min interval on ice between each. 
The cells were checked with an oil immersion microscope for disruption and 
sonicated further if required. I ml 10 % Triton X-100 was added to the sonicated 
cells and mixed on a spiramix for 30 min at 4'C prior to pelleting the debris at 
I 1,600g for 10 min at 4'C. The resulting supernatant was frozen at -20'C until required. 
2.6.3 Affinity purification of GSTfusion protein 
The GST affinity column was prepared by placing 1.5 ml of the glutathione- 
sepharose (Pierce) suspension in a 10 ml column and washing with 50 ml sonication 
buffer containing I% Triton X-100 at 20 ml/h at 4'C. The solubilised cell extract 
was passed through a 0.45 ýtrn filter and applied to the column followed by 100 ml of 
sonication buffer containing Triton. The column was subsequently washed with 50 
ml 50 mM Tris-HCI pH 8.0 but on reaching the end of this wash the column was 
capped and brought to room temperature. 2.5 ml 10 mM glutathione in 50 mM Tris- 
HCl pH 8.0 was added to the column and 0.5 ml allowed to drip through before the 
column was capped and left for 10 min at room temperature. The eluate was 
collected and dialysed against thrombin cleavage buffer (10 mM Tris-HCI pH 8.0,20 
mM NaCl. 2.5 mM CaCl2). The column was regenerated by washing with 10 ml 0.1 
M Tris-HCI pH 8.5,0.5 M NaCl followed by 10 ml 0.1 MNa(CH3CO2)pH 4,0.5 M 
NaCl which was repeated prior to washing with 10 ml PB S and storage in 20 % (v/v) 
ethanol. 
2.6.4 Antibody production, purification and analysis 
Immunization with 200 ýtg of the fusion protein was carried out as described in 
section 2.3.1. The animals were boosted as described in this same section. Anti-GST 
antibodies were removed from the antisera (5 ml) raised against the fusion protein by 
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Miss E. Cox using aI ml immobilized GST column as directed by the manufacturers 
(Pierce), The resultant antiserum. was ftirther purified by passage through a column 
containing the GST fusion protein coupled to sepharose. The column was prepared 
by rehydrating I ml freeze-dried cyanogen bromide-activated sepharose (Sigma) in 
10 ml I mM HCI for 15 min at room temperature and washed with 200 ml I mM 
HCI in a sintered funnel. The gel was washed quickly with coupling buffer (100 mM 
NaHC03 pH 8.3,500mM NaCl) and added to 10 mg fusion protein, previously 
dialysed three times against 21 coupling buffer over 48 h, in a universal and mixed 
on a Spiramixer for 2h at room temperature. Unbound protein was removed by 
washing with coupling buffer through a sintered funnel followed by resuspending 
and incubating the gel in 10 ml blocking buffer (200 mM glycine- pH 8.0) on a 
spiramixer for 2h at room temperature. The gel was subsequently washed in a 
sintered funnel with 10 ml coupling buffer and 10 ml acetate buffer (100 mM 
Na(CH3CO2)pH4,500 mM NaCI) alternately five times each prior to packing in 5 ml 
column. The antiserurn from the immobilized GST column was purified by Mrs J. 
Ingram by passage through this immobilized fusion protein column as described for 
the purification of site-specific antibodies using a peptide affinity column (section 
2.3.2). 
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Chapter 3 
Generation of anti-peptide 
antibodies 
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3.1 Introduction 
Antibodies are some of the most useful tools available to the biochemist due to the 
specificity which they show towards a defined epitopic region. Owing to this 
property they have been used to study many aspects of the structure and function of 
membrane proteins. For example, they have been employed in the investigation of 
the human erythrocyte glucose transporter, GLUTI [20], and to probe the substrate 
binding/ translocation sites of transporters and channels, such as the P-type calcium 
channel of human small-cell lung carcinoma cells [105]. They have also been 
extensively used to identify the tissue and subcellular locations of transporters, such 
as the sodium-dependent glucose transporter SGLT2 in human kidney [106] and to 
immuno-affinity purify a number of membrane proteins, including the human 
erythrocyte nucleoside transporter [ 107]. 
Conventional procedures for production of antibodies have typically involved 
utilizing purified proteins as immunogens. For instance, following the isolation of the 
angiotensin 2 receptor from a murine neuroblastoma cell line it was used in the 
generation of polyclonal antibodies [108]. The advantage of this method is that it 
frequently yields antibodies capable of recognizing the native protein. However, 
because some epitopes are more immunogenic than others, the majority of the 
antibodies produced tend to be directed against only a few regions of the intact 
protein. Moreover, a major disadvantage of this methodology so far as the membrane 
proteins are concerned is that it is usually difficult to purify sufficient amounts of the 
proteins to the homogeneity required for the production of highly specific antisera. 
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Many of the difficulties associated with raising antibodies against intact membrane 
proteins can be overcome by instead using as immunogens either protein fragments 
generated by recombinant DNA techniques or chemical ly- synthesized peptides. 
Knowing the amino acid sequence allows the identification of potential antigenic 
regions (section 3.2). Synthetic peptides corresponding to these regions can then be 
used to generate either monoclonal or polyclonal antibodies (reviewed by Bailyes et 
al., [109]). Alternatively, genetic manipulation of the protein can be perfon-ned to 
excise the desired region and fuse it to a carrier protein in a bacterial expression 
vector, thus allowing over-production of the desired antigen. For example, Craig and 
Kumar [I 10] expressed and purified milligram quantities of the ligand binding 
domain of the human 1,25-dihydroxyvitamin D-3 receptor using a glutathione S- 
transferase (GST) fusion protein expression system. Unfortunately, in some instances 
the recombinant protein has proven toxic to the host strain, as demonstrated by Otto 
et al. [I I I]. In the latter study the turnour necrosis factor (TNF) gene was fused to 
the pFLAG-I E. coli expression vector, and expression resulted in arrest of cell 
growth. Occasionally this toxicity may be overcome by changing host strain. 
Having decided on the antigenic region and how it is to be presented to the humoral 
system the type of antibodies required now becomes a factor. Monoclonal antibodies 
are generated in vitro by immortalizing the antibody production of B lymphocytes 
through fusing the antibody producing cells with myeloma cells. Subsequently, 
clonal selection provides an infinite supply of antibodies to a defined epitope. 
Unfortunately, whilst monoclonals are specific for one epitope they sometimes have 
a low affinity [112]. Furthermore, their specificity for a single epitope may prevent 
their recognition of even closely related proteins, for example from different animal 
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species, if the epitope concerned lies in a region of sequence variation. In contrast, 
polyclonal antisera will contain a population of antibodies with differing specificities 
and affinities and so may exhibit greater cross-reactivity with related but non- 
identical antigens. However, a disadvantage of polyclonal antisera is that unless the 
immunogen used is pure the antisera may contain antibodies to contaminants as well 
as to the protein of interest. Even if the conditions for their generation have been 
favorable it is unlikely that more than 5% of the total serum immunoglobulin 
content will be specific. However, if the pure antigen is available in sufficient 
quantity this can be used in affinity purification of the specific antibodies. Therefore, 
in general polyclonal antibodies tend to be more useful as biochemical tools than 
monoclonal antibodies, with the exception of immuno-affinity purification where the 
specificity of monoclonals can be advantageous. 
3.2 Criteria for the design of antigenic peptides 
Considering the importance of antibodies in research the factors which define an 
efficient immunogen have remained elusive. Only recently have we begun to 
understand how to predict a suitable sequence or domain within the target protein 
that will yield avid antibodies. Scheidtmann [113] in reviewing the topic suggested 
that several factors have to be carefully considered when designing an immunogenic 
peptide. The fore-most aspect is that the antigenic site must be accessible to the 
immunoglobulin on the surface of the protein, i. e. the more polar and hydrophilic a 
region is the more likely it is that the antibody can gain access. Conversely, the more 
hydrophobic a region is the more likely it is to be buried within the protein thus 
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restricting access. Therefore when considering proteins associated with the lipid 
bilayer this factor takes precedence. For example, when the protein has several 
transmembrane regions the most suitable sites for pepticle design will lie outside of 
the bilayer in the surrounding inner and outer hydrophilic environments. For these 
reasons the N- and C- ten-nini in the majority of cases represent the best candidates 
for epitopes from which to generate immunogenic peptides, since they are frequently 
not only hydrophilic but are predicted to lie at some distance from the bilayer surface 
and may be conformationally less restrained than, for example, the shorter loops 
connecting transmembrane helices. 
Atassi [114] classified epitopes into two types: either continuous, consisting of a 
single, peptide bond-linked, region of primary structure; or discontinuous, formed by 
the juxtaposition in the secondary or tertiary structure of non-contiguous residues 
within the primary structure. Either type tend to be limited in size, typically covering 
6-7 amino acid residues at the protein surface, although they are not necessarily the 
most hydrophilic areas. Within synthetic peptides epitopes tend to be continuous, 
with short peptide sequences often only possessing a single epitope, whereas longer 
peptides may contain a series of overlapping epitopes. In consequence, the 
probability of successfully generating polyclonal antisera is greater for longer 
pepticles [115]. Furthermore, in longer pepticles one or more of the epitopes may 
adopt the native confonnation of that sequence within the native protein and 
therefore be of more use in techniques where the native protein is being investigated, 
for example immunocytochernistry. For this reason peptides encoding complete 
domains are good candidates for successful immunogens. However, it has been 
demonstrated that peptides as small as 13 residues can possess all the structural 
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information required to attain the correct native-like conforination in free solution 
and elicit a sufficient immunogenic response [116]. 
The immunogenic response appears to favor specific amino acid residues as 
perceived by Scheidtmann [113]. Here antigenic epitopes were observed to contain 
several amino acids residues with relatively high incidence. Apparently the order of 
antigenicity of these residues is His > Lys > Ala > Leu > Asp > Arg. Consequently, it 
may be advantageous to design peptides including at least one of these residues. 
However, this must not detract from the importance of the conformation of the 
peptide which also plays a major factor in antigenicity. Therefore it may also be 
beneficial to include amino acid residues which constrain the neighbouring 
conformation, such as proline. 
The final consideration is how the peptide is to be introduced to the immune system. 
The general consensus is to couple synthetic peptides to a carrier protein, such as 
keyhole limpet haernocyanin, with the hope that the proximity of the carrier molecule 
may induce a conformation in the peptide which is close to that present in the parent 
protein. However cases have been reported where free peptides of 14-25 residues 
have led to moderate antibody response using the method described by Muller et al 
[117]. More surprisingly reports of immunization with free peptides consisting of 
only 6-8 residues have indicated satisfactory results [118]. However, in general the 
larger the immunogen the better the humoral response resulting in a population of 
antibodies which recognize more epitopes on the desired protein. 
Based on the criteria in this and the previous section two strategies for antibody 
production were used. The first approach involved the generation of site-directed 
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peptides against four regions of rCNTI. The second involved the production of a 
GST-ArCNTI fusion protein. Each of these strategies will be considered 
independently with a final summarizing section. 
3.3 The synthetic peptide approach 
3.3.1 An introduction to peptide synthesis 
Historically the peptide hormone oxytocin was the first peptide to be synthetically 
produced, by Du Vigneaud et aL [119], with the synthesis of insulin being reported 
nine years later by Meienhoffer et aL [ 120]. In both cases synthesis was performed in 
solution, which required purification and characterization of each intermediate at 
every step. Hence the chemical synthesis of peptides was very time-consuming and 
complicated until the introduction by Merrifield [121] of the revolutionary approach 
of solid-phase peptide synthesis. In this approach the generating peptide chain is 
bound covalently through its C-terminus to an insoluble solid support. Synthesis is 
then carried out by the successive addition of N-terminal protected amino acids to 
give the desired sequence. The fonnation of a peptide bond, known as coupling, 
between the C-terminal of the newly added amino acid and the deprotected N- 
terminal of the preceding amino acid is achieved by use of a reactive C-terminal 
group such as an ester or anhydride. The advantages of solid-phase peptide synthesis 
came from the peptide remaining attached to the resin throughout the synthesis, 
making the loss of the intermediate products minimal. Moreover, by using excess 
soluble reagents the efficiency of each step could be increased dramatically. Over the 
years this process of Peptide synthesis has become more automated with the result 
that today reagents only have to be added to a pre-programmed synthesizer to obtain 
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the required peptide, which then has only to be cleaved from the support resin and 
purified from the side-chain protecting groups. 
Several criteria have to be fulfilled when considering which solid-phase technique to 
use. The system should allow flexibility of synthesis, maximal coupling efficiency 
under relatively mild conditions and a means to monitor the processes of 
deprotection and coupling to ensure efficient incorporation of amino acids into the 
growing peptide chain. For these reasons fluorenylmethoxycarbonyl (FMOC) solid- 
phase synthesis has become one of the most popular approaches. The favored solid 
supports for FMOC chemistry are polyethylene-polystyrene resins, which have 
replaced the more traditional inert Kieselguhr polyacrylamide matrix. Attached to 
these are linkers which extend the peptide out from the matrix to allow access for the 
reagents. Such linkers can vary in length and in terminal reactive group, some may 
even have the initial amino acid pre-coupled. The synthesis occurs in an envirom-nent 
of a dipolar solvent, such as dimethylformamide, which is ideally suited to the 
requirements of both the solid support and the peptide with its protecting side chains. 
Selection of the amino acid derivative is also an important factor, affecting both 
purity and yield of the final peptide. A great number of different amino acid 
derivatives are available, but those used in the present study are listed in Table 3.1. 
The importance of side-chain protecting groups is that they prevent chemical 
modification of the amino acid side-chains during peptide synthesis. The FMOC 
moiety at the cc-amino position of each residue is removed by the secondary base 
piperidine, which provides mild alkaline conditions but does not interfere with the 
side chain protecting groups. The C-terminal activation of the amino acid is achieved 
by formation of pentafluorophenol (Pfp) esters, or in the case of Ser and Thr, 3,4- 
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dihydroxy-3-oxobenzotriazole (Dhbt) esters. This reduces the local electron density 
of the C-terminal carbon and increases the susceptibility of the residue to (x-amino 
group attack. The efficiency of this process is increased by the presence of 
hydroxybenzotriazole (HOBt) which acts as a catalyst in the presence of 
carbodiimide. 
Throughout the synthesis, deprotection and coupling have traditionally been 
monitored by following the distribution of the FMOC moiety with pre- and post- 
column UV detectors. More recently, the counterion distribution monitoring system 
CDMTM (PerSeptive Biosystems) has been adopted. This measures the distribution of 
the acidic dye quinoline yellow between the free amine groups of the growing 
peptide on the resin and the base in solution. As the activated amino acid reacts with 
the deprotected amine group on the resin or peptide, the dye is displaced from the 
solid phase thus indicating coupling efficiency. 
Prior to using the synthetic peptide it has to be cleaved, deprotected, purified and 
analyzed. Cleavage and deprotection for FMOC chemistry involves the use of TFA 
in the presence of scavengers such as 1,2-ethanedithiol, triisopropylsilane, H20 and 
thioanisole which prevent undesirable modification of the amino acids by the reactive 
cleavage products. Purification of the peptide is by filtration, rotary evaporation and 
precipitation to remove the resin, TFA and scavengers respectively. The resultant 
product can then be analyzed by rpHPLC and/ or MS. 
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Table 3.1 Side chain protecting groups for FMOC chemistry 
RESIDUE SIDE CHAIN PROTECTING GROUP 
Ala None 
Arg Pmc 
Asn Tmob 
Asp OtBu 
Cys Trt 
Gln Tmob 
Glu OtBu 
Gly None 
Ile None 
Leu None 
Lys t-Boc 
Met None 
Phe None 
Ser tBu 
Thr tBu 
Trp, None 
Tyr tBu 
Val None 
Abbreviations used are: Pmcý pentamethylcbromansulfonyl; Tmob, 
trimethoxycarbonyl; Trt, triphenylmethyl; OtBu, t-butyl ester; tBu, t-butyl; t-Boc, t- 
butoxycarbonyl. 
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3.3.2 Results and discussion 
3.3.2.1 Peptide synthesis, cleavage andpurification 
Based on the criteria discussed in section 3.2 the four rCNTI peptides illustrated 
below, and in Figure 3.12, were synthesized on a Milligen/ Biosearch 9050 
Pepsynthesizer by solid phase peptide synthesis using FMOC chemistry, as described 
in section 2.2.1, with the side chain protecting groups indicated in Table 3.1. The 
resultant peptides were cleaved from the resin and purified to remove the side-chain 
protection groups giving a peptide which was Iyophilized and stored at -70 
0 C, as 
described in section 2.2.2. Yields of peptide synthesis can be seen in Table 3.2. 
Peptide A Residues 1-15, mol. wt: 1853 
MADNTQRQRESISLTC 
Peptide B Residues 389-406, mol. wt: 2161 
VEESKFRSENGVKLTYGDC 
Peptide C Residues 505-524, mol. wt: 2495 
CS Q YKQ RRLA GAEEWL GDKKQ 
Peptide D Residues 618-637, mol. wt: 2146 
CRQVFQSTSSEFSQVALDN 
In the sequences shown above C represents the incorporation of an additional 
cysteine residue to allow the conjugation of the peptide to the carrier. Molecular 
weights are given for each peptide. Yields for the synthetic production of the 
peptides indicated in Table 3.2 show that percentage yields varied between 
47 and 
74 percent. This variance was attributed to practical experience of the techniques 
used as with more experience the yields were observed to increase. 
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3.3.2.2 Peptide analysis 
Pepticles B and C were dissolved in Milli-Q H20whereas peptides A and D were 
dissolved in 2% DMSO prior to rpHPLC and MS analysis. Each peptide was then 
analyzed by MS and rpHPLC as described in sections 2.2.3 and 2.2.4, respectively. 
Mass spectrometric analysis of the peptides indicated that in each case a molecule of 
molecular mass essentially identical (within the limits of accuracy of the 
spectrometer) to that of the desired peptide was obtained (Figures 3. la-3.4a). 
However, in addition other molecules were present with molecular masses either 
larger or smaller than the required product. Comparison of the molecular masses of 
these species with those of the desired peptide in most cases led to their putative 
identification as peptide products into which either an extra amino acid had been 
incorporated, or from which an amino acid residue was lacking, or from which 
removal of the side-chain protection groups was incomplete. A summary of these 
putative identifications can be seen in Table 3.3. An explanation for the first of these 
side-product types is that the incorporation of an additional residue probably 
occurred when there was originally inefficient coupling during synthesis resulting in 
that residue being recoupled, thus allowing for duplication of the same residue in a 
small proportion of cases. The lack of a residue also derives from inefficient coupling 
where even on recoupling of that residue a second time a small proportion of 
synthesizing peptides do not conjugate the residue. Finally, the remainder with 
residual protecting groups attached are indicative of inefficient deprotection 
suggesting that a longer period of peptide treatment with TFA would have been 
beneficial. 
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While the peak height in the MS traces shown in Figures 3.1a-3.4a might suggest 
that the undesirable side-products were relatively abundant for some of the syntheses, 
in fact there is no simple relationship between peak height and abundance in such 
MS analyses. Indeed, further analysis by rpHPLC to determine the relative quantities 
of the desired product and side-products indicated that in each case only one major 
product was obtained (Figures 3. lb-3.4b). Considering this and the information in 
Table 3.3 it was concluded that in each case the correct molecules had been 
synthesized with only minor contamination by the side-products. Therefore, based on 
both MS and rpHPLC analysis it was considered that these four peptides synthesized 
were of satisfactory quality to proceed with conjugation to ovalburnin and 
subsequent antibody generation. 
3.3.2.3 Antibody production 
Each peptide was conjugated to ovalbumin as described in section 2.3.1. This 
involved blocking the endogenous thiol sites in ovalburnin with N-ethylmaleimide 
followed by its incubation with the linker m-maleimidobenzoyl-N-hydroxsulfo- 
succinimide ester (sulfo-MBS). Once derivatised in this fashion, the ovalbumin was 
mixed with the peptide (previously reduced by DTT treatment) in order to allow 
conjugation. 
Each peptide was used to immunize two New Zealand white laboratory rabbits by 
injection of 200 ýtg conjugate as described in section 2.3-1. Following boosting test 
bleeds were removed and tested by ELISA to determine the titre, as described in 
section 2.3.3. Titre is described as the dilution required to achieve 50 % maximal 
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immunogenic activity. During the immunization program several rabbits developed 
abscesses and therefore were destroyed. 
An example of the development of an immune response can be observed in Figure 
3.5 where the peptide B conjugate has been used for immunization. The initial bleed 
was obtained after two weeks while subsequent bleeds were obtained at four week 
intervals following this. Table 3.4 summarizes the development of the immune 
response in each of the rabbits immunized. This variance in immune response 
between different antigens and the same antigen in different animals is one of the 
disadvantages in producing antibodies from animal hosts. 
3.3.2.4 Affinity purification of anti-peptide antibodies 
In order to eliminate plasma proteins, including any non-specific IgG , the antibodies 
obtained were affinity purified by passing the antisera down the desired peptide 
affinity column. These affinity columns were synthesized by covalently coupling the 
Cys-containing peptides to SulfolinkTm by their terminal thiol groups, as described in 
section 2.3.2. Following DTT treatment, assay for free thiol groups indicated 70-90 
% of the peptide cysteine had become reduced, indicating that of the 5 mg of starting 
peptide 3.5 to 4.5 mg were capable of covalent attachment to the resin. The 
efficiencies of coupling were 59 %, 74 %, 51 % and 73 % for peptides A to D 
respectively. These columns were subsequently used in the affinity purification of 
anti-peptide specific antibodies from 5 ml of serum from each of the final bleeds. An 
example of such a purification can be seen in Figure 3.6. Following passage of the 
antiserum through the column, washing under high salt conditions elutes non- 
specifically bound IgG and other plasma proteins, leaving specific polyclonal 
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antibodies which can subsequently be eluted with alkali followed by acid to remove 
the more avid IgG. A summary of the purification of each peptide-directed antiserum 
can be seen in Table 3.5. This indicates that the extent of purification varies greatly 
from 2-fold to 200-fold when compared to the antisera. An explanation for this is that 
an avid antibody will bind strongly to the column, thus allowing washing to remove 
the majority of the non-specific IgG and plasma protein, while the specific antibody 
is retained for subsequent elution having been purified greatly. In comparison, an 
antibody with low avidity to the column will result in a proportion of this antibody 
being removed on washing, thus giving a lower degree of purification. 
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Table 3.2 Synthetic peptide production yields 
Synthetic Peptide Theoretical Observed Percentage 
Yield (mg) Yield (mg) Yield (%) 
A 324 153 47 
B 378 210 55 
c 359 260 74 
D 365 257 70 
Theoretical yields were obtained from the software supplied with the Milligen/ 
Biosearch 9050 Pepsynthesizer. Observed yields represent the actual amount of 
peptide obtained after cleavage, purification and Iyophilization. 
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Table 3.3 Side-products of peptide synthesis 
Peptide Mass Difference from desired product Identity 
A 1779 -76 ? 
1912 +57 + tBu 
2175 +320 + tBu + Pmc 
B 1811 -346 -2(Glu Lys) + Ser 
1941 -216 -(Glu Lys) + Ser 
2028 -129 - (Glu Lys) 
2287 +130 + (Glu Lys) 
2388 +231 +(Glu / Lys) + Val 
C 2552 +56 + tBu 
D-- 
MS analysis, Figures Ma to 3.4a, indicated that side-products of synthesis and 
cleavage were present in the final peptide samples. The MS peak values of these 
contaminants have been analyzed and their putative relationships to the desired 
peptide products summarized in the above table. Miscalibration of the instrument has 
resulted in minor differences of some contaminants. 
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Table 3.4 Immunogenic response to synthetic peptides 
Peptide Rabbit Titre 
Bleed I Bleed 2 Bleed 3 Bleed 4 
A 3795 T 
3895 1: 100 1: 500 1: 800 1: 2000 
B 3995 1: 900 1: 1050 1: 2000 1: 20000 
4095 1: 250 T 
c 4195 1: 9000 1: 10000 1: 40000 
4295 T 
D 4395 1: 9000 1: 10000 1: 10000 
4495 1: 26000 1: 40000 1: 30000 
For each peptide two rabbits were immunized with the peptide conjugate. Titre 
values were obtained by ELISA with the corresponding peptide. Final bleed titres are 
indicated (bold face) and T indicates where the rabbit developed side effects, 
necessitating its premature killing. Titre is defined as dilution for 50 % maximum 
activity. 
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Figure 3.1 MS and rpHPLC analysis of synthetic peptide A 
10 
%T 
1855 
A 
14.00 
12.00 
10.00 
8.00 
6.00 
4.00 
2.00 
0.00 
-2.00 
-4.00 
-6.00 
-8.00 
3.7E3 
2.3E3 
1.8E3 
IAE3 
9.9E2 
5.7E2 
M/Z 
0.00 10.00 20.00 30.00 40.00 50.00 60.00 
B Time (m±ýi) 
Peptide A dissolved in 2% DMSO was subjected to MS (A) and rpHPLC (B) as 
described in sections 2.2.3 and 2.2.4 respectively. The discrepancy between the 
theoretical and observed molecular masses, 1853 and 1855 respectively, may be due 
to miscalibration of the spectrometer. In the rpHPLC plot the grey line represents 
percentage of solvent B present during elution and washing of the column. 
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Figure 3.2 MS and rpHPLC analysis of synthetic peptide B 
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Peptide B dissolved in Milli-Q was subjected to MS (A) and rpHPLC (B) as 
described in sections 2.2.3 and 2.2.4 respectively. The discrepancy between the 
theoretical and observed molecular masses, 2161 and 2157 respectively, may be due 
to miscalibration of the spectrometer. In the rpHPLC plot the grey line represents 
percentage of solvent B present during elution and washing of the column. 
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Figure 3.3 MS and rpHPLC analysis of synthetic peptide C 
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Peptide C dissolved in Milli-Q was subjected to MS (A) and rpHPLC (B) as 
described in sections 2.2.3 and 2.2.4 respectively. The discrepancy between the 
theoretical and observed molecular masses, 2495 and 2496 respectively, may be due 
to miscalibration of the spectrometer. In the rpHPLC plot the grey line represents 
percentage of solvent B present during elution and washing of the column. 
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Figure 3.4 MS and rpHPLC analysis of synthetic peptide D 
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Peptide D dissolved in 2% DMSO was subjected to MS (A) and rpHPLC (B) as 
described in sections 2.2.3 and 2.2.4 respectively. The theoretical and observed 
molecular masses give the same value of 2146. In the rpHPLC plot the grey line 
represents percentage of solvent B present. 
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Figure 3.5 Development of immune response against peptide B conjugate 
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The antibody titre of rabbit 3995 following immunisation with an ovalbumin 
conjugate of peptide B was assessed by ELISA as described in section 2.3.3. 
Samples were taken 2 (o), 6 (o), 10 (. &) and 14 (*) weeks after the initial 
immunisation, and the rabbit was given booster immunisations one week after the 
removal of each of the first three samples. 
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Figure 3.6 Affinity purification of anti-peptide D antibodies 
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The elution profile of anti-peptide D antibodies from a peptide affinity column, as 
described in section 2.3.2, demonstrates the elution of non-specific IgG on addition 
of NaCI followed by the release of sPecific IgG under alkali and acid conditions 
successively. Comparison of the relative concentrations of alkali and acid eluted 
fractions of all four anti-peptide antibodies with their antisera is summarized Table 
3.5. 
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Table 3.5 Summarization of antibody purification 
Anti- Fraction Titre Approxi- Protein Ratio: Fold 
peptide mate conc. Titre/[Protein] purificatio 
IgG yields (mg/ml) n 
A Antiserum 1: 2000 67.8 30 
Alkali 1: 200 11.6 0.1 2000 67 
Acid 1: 600 39.0 0.1 6000 200 
B Antiserum 1: 20000 - 56.3 113 - 
Alkali 0 0 0.1 0 0 
Acid 1: 300 12.6 0.1 3000 27 
C Antiserum 1: 40000 - 46.5 860 
Alkali 1: 4500 14.0 0.1 45000 52 
Acid 1: 5500 12.4 0.2 27500 32 
D Antiserum 1: 30000 - 59.7 503 - 
Alkali 1: 700 2.0 0.7 1000 2 
Acid 1: 3000 5.0 0.1 30000 60 
Fractions referred to as alkali or acid apply to samples eluted under alkaline or acidic 
conditions respectively. Approximate yields were calculated by comparison of the 
(titre*volume) value of the purified samples with that of the antiserum from which 
they were purified. The values obtained for the purified antibodies can be compared 
with those of the antisera to give the fold purification (boldface). Titres of antisera 
were established by ELISA while protein concentration was determined by the BCA 
protein assay, as described in section 2.4.2. 
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3.4 The fusion protein approach 
3.4.1 An introduction tofusion proteins 
Fusion proteins have been widely used in the investigation of biological systems. For 
example, they have been used for the over-expression and purification of proteins as 
in the case of the soluble ligand binding domain of the human vitamin D3 receptor 
[I 10], for investigation of protein/ protein interactions such as those involved in the 
secretion of bacterial proteins [122] or the association of Ran GTPase with nuclear- 
pore proteins [123], and in the study of cellular signaling mechanisms including the 
role of tyrosine kinase in cell surface expression of the facilitative glucose 
transporters GLUTI and GLUT4 [124,125]. They have also been extensively used in 
vaccination against diseases such as parasitism by tape worm in sheep [126] and 
lyme disease in mice [127], and in the generation of antibodies for investigative 
procedures, for example the immunocytochemical analysis of Na+/Cl-dependent 
RXTI transporter of the rat central nervous system [128] and immuno-detection of 
the human herpes virus 7 glycoprotein B [1291. 
The expression of foreign genes in E coli presents a number of potential problems. 
For example, the foreign polypeptide may be toxic to the host cell, it may be 
degraded in vivo or incorrectly folded, and it may be difficult to purify. Toxicity can 
often be avoided by placing the gene under the control of a strong promoter which is 
normally repressed but that can be induced during the terminal stages of cell growth, 
thus allowing the polypeptide synthesis. Degradation can be overcome by fusing the 
foreign polypeptide to a native protein which acts as a vector in order to stabilize the 
introduced protein. Such fusion to a vector protein can also facilitate the purification 
of the polypeptide if the vector keeps its activity in the hybrid and allows for easy 
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purification, for example, by affinity chromatography. Alternatively the fusion 
protein can be selectively exported from the cytoplasm by the fusion to a signal 
peptide as a means of avoiding toxicity, although this in itself may prove toxic to the 
host cell. 
Several vector proteins have been used with varying success. For example, P- 
galactosidase has been fused to both the N- and C-tennini [130,131] of foreign 
proteins, the phosphate binding protein, PhoS, has been fused to the human growth- 
hormone-releasing factor [132], and the S. aureus protein A to alkaline phosphatase 
allowing a single-step purification by IgG affinity chromatography [133]. 
Additionally, a polyarginine tail has been fused to the C-terminus of human 
urgastrone to allow simple ion exchange purification [134] while the maltose binding 
protein has permitted an inexpensive means of purification of fusion proteins on an 
amylose affinity column [135,136]. Purification of the fusion protein products from 
each of the fore-mentioned systems varies greatly, as exemplified by the protein A 
fusion proteins requiring acidic elution which can be expected to alter the 
antigenicity and functional activity of the purified product whereas the maltose 
binding protein only requires competition with free maltose and is therefore 
relatively mild. 
A widely used fusion partner for protein expression in K coli is the enzyme 
glutathione S-transferase (GST), a 26 kDa protein from the parasitic helminth 
Schistosoma japonicum. Use of GST fusions have in particular been promoted by 
Pharmacia through its range of pGEX vectors, which are designed for inducible, 
high-level intracellular expression of the hybrid proteins. These vectors offer high 
level expression under the control of the strong tac promoter, which is lPTG- 
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inducible. In the absence of IPTG potent inhibition of expression is ensured by the 
presence of an internal lac Iqgene, and so problems of toxicity of the fusion protein 
are minimised. Following induction of their expression by IPTG, fusion proteins can 
be purified under mild conditions by adsorption to a column of immobilised 
glutathione, and then elution with free glutathione. Many vectors also encode 
proteolytic cleavage sites to facilitate subsequent release of the foreign polypeptide 
from the GST. Such a system has been used successfully in many applications 
including the production of vaccines [126,127], molecular immunology [137], and 
studies involving protein-protein [ 13 8] and DNA-protein [ 13 9] interactions. 
3.4.2 PCR amplification 
The polymerase chain reaction (PCR) allows the selective amplification of a chosen 
region of a DNA molecule using two oligonucleotide primers that flank the DNA 
fragment to be amplified. The process involves repeated cycles of heat denaturation 
of the template DNA, annealing of the primers to their complementary sequences and 
extension in the presence of a thermostable DNA polymerase [140]. The 
amplification takes place by extension between the two 3'-termini of the primer pair 
in such a way that after the initial cycle the first generation PCR product becomes the 
template for successive rounds of amplification and hence only the specific fragment 
is amplified. 
Successful PCR results in the generation of a specific fragment of DNA. Frequently 
non-specific products are produced which can interfere with subsequent 
manipulations. If these by-products occur early on in the amplification then they will 
be amplified similarly to the target DNA. Thus, in order to maximize the specificity 
of a PCR, it is necessary to ensure correct annealing of the primers to their desired 
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positions on the DNA template. Numerous factors influence the extent to which PCR 
is successful, including optimization of the magnesium ion concentration, primer 
concentration, template concentration, optimization of the annealing temperature and 
the design of the primers. The factor often given the strongest weighting is in the 
design of the primers in which the following simple rules allow the design of 
efficient primers. The 3' regions of the primers should comprise 15-25 nucleotides of 
sequence complementary to the target site, to allow high-temperature annealing; 
incorporation of restriction sites should occur at the 5' end, thus allowing efficient 
priming at the 3' end; restriction sites located adjacent to the ends of PCR products 
are normally inefficiently cleaved, so it is recommended to add 3-4 extra bases 
outside of the site; the incorporation of complementary regions which may lead to 
formation of 'primer-dimers' should be avoided; the melting temperatures (T .. ) of 
both primers should be similar; and their (G+C) content should be around 50 
These rules are incorporated in the Apple-Mac program Amplify vl. 2 which can be 
used to perform a theoretical PCR reaction indicating if the primers are suitable. If 
during the practical PCR false-priming occurs then the set annealing temperature can 
be increased to ensure more specific annealing, failing this the magnesium 
concentration is modified. 
3.4.3 Strategyfor production of ArCNTI-GSTfusion protein 
The aim of the work described in this section was to produce a GST fusion protein 
encoding a relatively large fragment of the rCNTI N-terminus for immunization 
purposes. The vector used was pGEX-KT [141], which was derived from the pGEX 
series vector pGEX- I (see above). pGEX-KT contains a glycine-rich kinker region, 
containing the sequence S-G-G-G-G-G, to increase the efficiency of cleavage at a 
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thrombin cleavage site. The latter is located C-terminal to the kinker, such that the 
foreign protein bears only an additional glycine and serine residue at its N-terminus 
following cleavage of the fusion protein. 
The template for amplification of the rCNTI N-terminal fragment was the plasmid 
pSRHI. This plasmid was derived from pQQH [81], obtained as a gift from 
Professor J. D. Young (University of Alberta, Edmonton, Canada). Plasmid pQQH 
contains the complete sequence of rCNTI cDNA inserted as a 2.4 kb fragment 
between the EcoRl and Xbal restriction sites of pGEM-3Z. To facilitate excision of 
the coding region of rCNTI for other purposes, an internal EcoRl restriction site at 
position 245 in pQQH was eliminated by PCR mutagenesis, through conversion of 
the sequence GAATTC to GAGTTC, thus creating pSRHI (results not shown). The 
mutation was silent, the glutamate residue at position 27 of rCNT I being retained. 
For the present purposes, PCR primers were designed for amplification of the region 
of pSRHI encoding residues 21 to 78 of rCNTI, the location of this peptide fragment 
in rCNTI is illustrated in Figure 3.12. This peptide fragment was designated 
ArCNTI. The choice of primer locations was made not only because this region of 
the protein was predicted to be immunogenic, but also because the nucleotide 
sequences of the primers were conserved in the cDNA sequence encoding the 
homologous transporter hCNTl (see Figure 3.7). Hence the primers could if 
necessary also be used for amplification of the corresponding region of the latter 
cDNA. 
The locations of the 5' and 3' primers chosen for the amplification are shown in 
Figure 3.7. The 5' primer sequence was designed to incorporate a 5' BamHl 
Chapter 3 
78 
restriction site, yielding the primer CNTl-2lBamHl, whose sequence is shown 
below (restriction site is italicized). The 3' primer sequence was designed to include 
a 5' EcoRl restriction site, producing the primer CNTI_78EcoRl, whose sequence is 
shown below (restriction site is italicized). In addition, the 3' primer was further 
modified to incorporate a stop codon (ATG, as indicated by the arrows in the primer 
sequence below). The resultant primer sequences were checked using the Mac 
program Amplify vl. 2. 
CNT1-2lBamHl =: > 
5' gccggatccCTGGAGAACATGGGG 31 Tm -800C 
<ý=CNT1-78EcoRl 
3' AAGACGTCCCTCGTGactcttaagccg 5' Tm -840C 
TTT 
Amplification of rCNTI using these primers, followed by restriction digestion with 
BamHI and EcoRl, was predicted to yield a cDNA fragment encoding residues 21 to 
78,, that could be ligated in frame to BamHll EcoRl digested pGEX-KT. The resultant 
nucleotide and protein sequences of the construct and fusion protein in the region of 
the fusion junction are illustrated below. 
rCNT1/ hCNT1 
TGGGATCTGTCTGGTGGTGGTGGTGGTCTGGTTCCGCGTGGATCCCTGGAGAACATGGGGGCA 
ACCCTAGACAGACCACCACCACCACCAGACCAAGGCGCACCTAGGGACCTCTTGTACCCCCGT 
SD L SC CC GG LV PR GSLE NM GA 
Kinker T Thrombin cleavage site 
The overall strategy for production of the fusion protein construct is illustrated in 
Figure 3.8. 
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Figure 3.7 Alignment of 5' regions of rCNT1 and hCNTI cDNAs 
rCNT1 166 ATGGCAGACAACACACAGAGGCAAAGAGAGTCCATTTCCCTCACGCCTATGGCCCACGGC 225 
hCNT1 5 ATGGAGAACGACCCCTCGAGACGAAGAGAGTCCATCTCTCTCACACCTGTGGCCAAGGGT 244 
a1MADNTQRQRESISLTPMAHG 20 
b1MENDPSRRRESISLTPVAKG 20 
CNT1-21 => 
CTGGAGAACATGGGG 
226 CTGGAGAACATGGGGGCAGAGTTCCTGGAAAGCATGGAGCAAGGCCGACTCCCTCACAGT 285 
245 CTGGAGAACATGGGGGCTGATTTCTTGGAAAGCCTGGAGGGAGGCCAGCTCCCTAGGAGT 304 
a 21 LENMGAEFLESMEEGRLPHS 40 
b 21 LENMGADFLESLEGGQLPRS 40 
286 CACTCAAGCCTGCCGGAGGGTGAAGGTGGCCTGAACAAAGCAGAGCGGAAGGCCTTCTCC 345 
205 GACTTGAGCCCCGCAGAGATCAGGAGCAGCTGGAGCGAGGCGGCGCCGAAGCCCTTCTCC 364 
a 41 HSSLPEGEGGLNKAERKAFS 60 
b 41 DLSPAEIRSSWSEAAPKPFS 60 
346 CGATGGAGGAGTCTGCAGCCGACTGTGCAAGCGAGAAGCTTCTGCAGGGAGCACCGGCAG 405 
365 AGATGGAGGAACCTGCAGCCAGCCCTGAGAGCCAGAAGCTTCTGCAGGGAGCACATGCAG 424 
AAGACGTCCCTCGTG 
<-- CNT 1- -7 8 
a 61 RWRSLQPTVQARSFCREHRQ 80 
b 61RWRNLQ PAL RARS FC REHMQ 80 
406 CTGTTTGGA 414 
425 CTGTTTCGA 433 
a 81 LFG 83 
b 81 LFR 83 
Locations of primers used for amplification of a region encoding a portion of the 
hydrophilic N-tenninus of rCNT I are shown. 
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Figure 3.8 Strategy for ArCNTI-GST fusion protein construction 
Amp ýeslstance 
9) 
p7AC 
Eco NT (269) 
GS7 
BamH 1 (952) 
EcoR 1 (962) 
-CN'ri laclq 
r (1929) 
I Ij 
M1 
# 
PCR amplification of bases 
226-399 Digestion with BarnHI and 
E co RI I 
Digestion with BarnHI and 
ECORI CIP treatment 
I I 
Purification of 183bp Purification of 4959bp 
fragment fragment 
N if 
Ligation 
oTAC 
N7 (269) 
G S, r 
BamH 1 (952) 
lac Iq Eco NT (1030) 
SRH2 , CN71 residues 21-78 
51p42b EcoR I (113 5) 
ORI 00, -Amp resistance 
lp '"Stalce 
Residues 226 to 399 of pSRHI are amplified with the oligonucleotides 
CNTI-20BamHI and CNTI-78EcoRI, represented by A* and B* respectively. This 
amplified fragment possesses 5' BamHI and 3' EcoRl restriction sites in addition to 
a stop codon 5' to the EcoRl site. Parallel digestion of pGEX-KT and the PCR 
product with these enzymes provides two fragments of 4959 and 183 base pairs 
respectively which after ligation produce the construct pSRH2, containing the gene 
for the fusion protein ArCNTI-GST under the control of the tac promoter and 
inducible by IPTG. 
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3.4.4 Results and discussion 
3.4.4.1 Production of ArCNTI-GSTfusion protein construct 
Amplification of a DNA sequence coding for residues 21 to 78 of WNTI, and 
incorporating flanking restriction sites, was achieved using the strategy outlined in 
section 3.4.3. The overall strategy for production of a construct encoding an N- 
terminal fragment of rCNTI fused to GST is illustrated in Figure 3.8. The conditions 
used for rCNT I fragment amplification are indicated below. 
Reaction mix: 
I Ox Amplification buffer 
1()mmmgs04 
2 mM dNTPs 
Forward primer 
Reverse primer 
Template DNA 
10 [tl 
I ýtl 
10 [11 
100 pmol 
100 pmol 
20 ng 
Made up to 100 ýfl with sterile Milli-Q water 
VentTm DNA polymerase 
(overlaid with 100 ýtl light mineral oil) 
I [tl 
The pSRHI template was used in conjunction with CNTI-2OBamHl and 
CNTI-78EcoRl primers. VentTm DNA polymerase (NEB) is a high-fidelity 
thennophilic polymerase with fidelity 5-15 fold higher than that observed with Taq 
DNA polymerase. This fidelity is derived in part from an integral 3'->5' proof- 
reading exonuclease activity. 
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Protocol: 
1.96 0C4 min I cycle 
2.96 0C 30 sec 25 cycles 
55 0C 45 sec 
72 0C 30 sec 
3.72 0C2 min I cycle 
Amplification using these conditions yielded a PCR product of the desired size of 
195 bp. The fact that no other fragments were produced (results not shown) indicated 
that the conditions chosen for the reaction were suitable and that the primers had 
been designed efficiently. 
Restriction digestion of pGEX-KT with BamHl and EcoRl excised a 10 bp fragment 
from the parent plasmid producing a 4959 bp linearised DNA fragment. This 
fragment was subsequently dephosphorylated by CIP treatment (section 2.5.6) and 
the resultant 4959 bp product purified by gel extraction (section 2.5.5). The PCR 
product was restriction digested in the presence of the same two enzymes and the 
resulting 183 bp fragment was purified from the terminal two small fragments using 
Qiagen PCR columns as indicated by the manufacturers. Ligation of the two 
resulting DNA fragments was performed as described in section 2.5.7.10 [d of this 
ligation mixture was used the following day to transform 100 ýtl of competent E. coli 
DH5cc cells, prepared and transfonned as described in section 2.5.4. This 
transformation resulted in no colonies on the either water transformed or vector 
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minus insert control plates but several hundred were obtained on each of the sample 
plates. (The 761 bp fragment has been visualized when sufficient loading occurred. ) 
30 colonies from one sample plate were screened for the presence of an insert 
encoding the rCNTI fragment by PCR using the reaction conditions described 
previously in this section but scaled down to a final volume of 20 ýtl. For this 
screening procedure, one colony was lifted from the agar plate with a sterile P 10 tip 
and swirled in the reaction mix for 5 sec. The colony was subsequently cultured by 
placing the tip placed in 1.5 ml of LB broth, containing carbenicillin, and incubating 
overnight at 37 0C with agitation. Meanwhile the reaction mix was overlaid with 20 ýt 
I of mineral oil and subjected to the same amplification program as used in the 
original fragment amplification described above. The results of this screening are 
illustrated in Figure 3.9a. Five of the 30 colonies tested (colonies 9,13,22,23 and 
30 in Figure 3.9a) yielded PCR products of the desired size of 195 bp, indicating the 
presence of an insert encoding the N-terminal fragment of rCNT I. 
To confirm the reliability of the PCR screening the positive colonies were further 
analyzed by restriction enzyme digestion singly with BamHl, EcoRI, or EcoNl and 
doubly with BamHl and EcoRl digestion. Digestion with EcoNl was chosen since 
the presence of a successful construct would result in elimination of a 761 bp 
fragment due to double digestion. However, the lack of an insert would result in 
single digestion with no resultant change in size of the plasmid. Figure 3.9 b shows 
the results for colony 9 but similar results were obtained for the other 4 PCR positive 
colonies. Lanes 3 and 4 show the linearised construct produced a band of 5142 bp as 
predicted; lane 5 indicates that digestion with EcoNI produced a fragment of 4381 bp 
and another of 761 bp is produced but is not visible in the figure due to under loading 
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of the sample; lane 6 demonstrates the elimination of the insert with the double 
digestion of EcoRl and BamHl gave the 4959 bp fragment of the parent pGEX-KT 
vector. These findings confirmed that ligation of the PCR fragment into pGEX-KT 
had been successful. Finally, the construct from colony 9 was sequenced as described 
in section 2.5.7 confirming that the TCR-amplified sequence was the desired product 
and that no errors had been introduced. This construct was designated pSRH2 and 
was used for the subsequent in vivo expression of the encoded fusion protein in the E 
coli strain DH5cc. 
3.4.4.2 In vivo expression offusion protein 
Expression of the fusion protein within the E. coli strain DH5a is under the control 
of the tac promoter. This is a hybrid promoter engineered from the lac promoter and 
the trp promoter in order to provide strong ribosomal binding for efficient translation 
while keeping transcription tightly regulated by the lac I' repressor, also encoded in 
the vector. During the initial stages of culture growth the expression of the fusion 
protein is repressed. However, once the culture has reached the log phase on the 
growth curve, IPTG is added to release the promoter from the inhibitory effect of the 
lac F gene product and thus allow induction of the fusion protein expression. After 
an incubation period of several hours the culture is processed and tested for fusion 
protein expression. 
Prior to carrying out a large scale preparation of the fusion protein a small scale pilot 
preparation of the fusion protein was carried out as described in section 2.6.1. 
Following growth and induction with IPTG, or culture under identical conditions in 
the absence of IPTG, the cell lysates were analysed by SDS-PAGE. Figure 3.10 
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shows an additional band with an apparent M, of 33 000 was present in the induced 
sample but not present in the uninduced, lanes 2 and 3 respectively. However, in 
addition to the desired product with an apparent M, of 33 000, a protein with an 
apparent M, of 26 000 was also expressed in the induced sample, an equivalent size 
to the GST carrier protein. This finding appeared to reflect the proteolytic 
degradation of the fusion protein to produce GST, because the addition of a higher 
concentration (1.5 mM) of the protease inhibitor cell lysis resulted in elimination of 
this band (results not shown). This now demonstrated that the complete fusion 
protein was being expressed successfully in DH5oc. Therefore indicating that large 
scale expression was viable. Subsequently, large scale expression of the ArCNTI- 
GST fusion protein was performed as described in section 2.6.2 with the resulting 
cell lysate being affinity purified using an immobilized-GST column. Following 
washing of the column free glutathione was used to elute the fusion protein, resulting 
in a yield of 17.5 mg from an initial II overnight culture. This provided sufficient 
amounts of the 33 kDa fusion protein (Figure 3.10, lane 5) to allow further studies, 
namely immunization. 
3.4.4.3 Antibody production, purification and analysis 
The use of fusion proteins in the development of antisera is a common technique 
with the GST system being one of the most frequently used, as applied in this case. 
Having successfully produced the fusion protein, immunization and antibody 
generation can be undertaken. At this stage a number of options were available for 
the generation of anti-rCNTI N-terminal antibodies. Firstly, the complete fusion 
protein could have been used but this would open up the opportunity for the 
generation of anti-GST antibodies in addition to anti-rCNTI antibodies. Secondly, 
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the N-terminal fragment could have been used for immunization by cleavage from 
the fusion protein to produce a 60 residue peptide of which 58 residues were from 
rCNTI and 2 from the C-terminal region of the RGS thrombin cleavage site. Finally, 
the cleaved rCNT I fragment could have been coupled to another carrier protein such 
as ovalburnin, as was the case for the synthetic peptides. This approach would 
certainly generate antibodies against the carrier protein as was suggested in the first 
option. Considering each alternative the former method was adopted based upon 
GST being reported by Pharmacia to have a low immunogenic response. 
The intact ArCNT I -GST fusion protein containing 58 residues of rCNT I fused to the 
soluble GST protein was used to perform immunization as described in section 2.3.1 
where 200 ýtg of the fusion protein was used in the initial iMMunization followed by 
boosting regularly using 100 ýtg. After a period of 2 months a sample bleed from 
rabbit A060 was used in an ELISA which resulted in a titre of 1: 1,000,000 against the 
fusion protein. Further boosting was carried out monthly, the terminal bleed 
occurring 4 months after the initial immunization. ELISA showed that the titre of this 
final sample had decreased to 1: 400,000. Such a decrease in titre is observed 
occasionally and its cause is unknown. 
Western blot analysis against the fusion protein and GST with the polyclonal 
antiserum. unfortunately demonstrated a significant cross-reactivity with GST was 
present (data not shown). Therefore it was necessary to affinity purify the anti- 
rCNTI N-terminal antibodies. This was perfonned in two stages, firstly the 
antiserum. was passed down an immobilized GST column, as described in section 
2.6.4, to remove any anti-GST antibodies. Secondly, anti-rCNTI antibodies were 
purified from the anti-GST antibody-depleted serum by passage down an 
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immobilized ArCNTI-GST fusion protein column and eluted with alkali, as 
described in section 2.3.2. Western blotting of this affinity-purified antibody (Figure 
3.11) indicated that although the majority of the non-specific antibodies had been 
removed, as demonstrated in lane 2, there was still cross-reactivity of the affinity 
purified antibody with GST, lane 3. However, the amount of GST protein added to 
the gel was I O-fold more than fusion protein, and considering that the signal obtained 
was significantly lower than that against the fusion protein, indicated that the 
antibody had been significantly purified. With the aim of totally eliminating the anti- 
GST antibodies that remained the affinity purified antibody was passed through the 
immobilized GST column a second time but on Western blot analysis showed no 
significant improvement over the first round purification. Therefore having produced 
an antibody that cross-reacts with two different proteins an anti-GST control will 
have to be carried out in parallel whenever this antibody is used. Interestingly, the 
affinity-purified antibody also cross-reacted with the uninduced sample, lane 1, 
giving a signal at an equivalent position to the fusion protein. This result suggests 
that there has been some slippage of the promoter, allowing some expression of the 
fusion protein prior to induction with IPTG. 
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Figure 3.9 Screening and confirmation of the ArCNT1-GST construct 
A 
B 
(A) PCR screening of ArCNTI-GST transformed colonies. ýX174 DNA/ Haelll 
markers are present in lanes marked A Their mobilities are represented by the bars 
located at the side of the image, which correspond to sizes of 1353,1078,872,603, 
310ý 281ý 234 and 194 base pairs, from the top down. (B) Restriction digestion 
analysis of colony 9. Lane 2 undigested control, lane 3 EcoRI digest, lane 4 BamHl 
digest, lane 5 EcoNl digest, lane 6 EcoFJI BamHl digest. The mobilities of X DNA/ 
BstEll markers, lane I, are represented at the side of the image by bars corresponding 
to 8454,7242ý 6369,5686,4822,4324 and 3675 base pairs respectively. 
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Figure 3.10 SDS-PAGE analysis of ArCNTI-GST expression in E. coli 
1 
66 ý 
45 - 
36 - 
29 - 24 ý 
20 ý, 
IIPTG +-++ 
Lanes 2 and 3 contain lysates from small scale expression of induced and uninduced 
ArCNTI-GST in Dtl5cc, respectively. Lane 4 contains lysate containing GST from a 
culture harbouring pGEX-KT, while lanes 5 and 6 contain purified protein samples 
from large scale expression under induced and uninduced conditions. 9 Vtg of sample 
protein is present in lanes 2 to 6. Molecular weight markers are present in lane I with 
their relative molecular mass in kDa indicated. 
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Figure 3.11 Immunoblot analysis with anti-ArCNTI purified antibodies 
1 
66 ý 
45 - 
36 - 
29 - 24 ý 
20 ý 
Affinity purified antibody (4 ýtg/ml) used to probe uninduced and induced ArCNT I- 
GST in E coli, lanes I and 2 respectively. Lane 3 represents the signal obtained with 
the GST vector protein. Lanes I and 2 contained 0.1 ýtg while lane 3 contained I Vtg 
total protein. Molecular weight markers are represented at the side of the image with 
their relative molecular mass in kDa indicated. 
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Figure 3.12 Location of antibodies raised within rCNT1 
Image on opposite page 
Regions within rCNTI to which site-directed antibodies have been generated by the 
synthetic peptide approach are indicated by a yellow background box while that 
generated with the fusion protein approach is illustrated by a lime background box. 
For further information on components of the diagram refer to Figure 1.2. 
Chapter 3 
2) 
u 
iJ 
- 
S 
8 
I 
0000 
0601 
1) 1) 
CD 
000 
4-. 1 
1. ) 
000 
7t 4 
0 
00 
'00, 00%, sltlý. 00-11. " -'-'O, -zýýI*a 
93 
3.5 Summary 
Four antibodies have been raised against synthetic peptides corresponding to residues 
1-15ý 389-406ý 505-524 and 618-637 of rCNTI, designated peptides A-D 
respectively. These have been affinity purified with the resulting antibodies showing 
varying levels of reactivity with rCNTI peptides. Additionally, a fifth antibody 
towards residues 21-78 of rCNTI (ArCNTI) was generated by the production of a 
GST fusion protein. However, affinity purification of this antibody was unable to 
totally remove antibodies raised towards the GST component of the fusion protein. 
Therefore an anti-GST control should be carried out in parallel when using this 
antibody. The locations of these five antibodies within the putative model of rCNTI 
are illustrated in Figure 3.12. The generation of these antibodies now provides a tool 
which will facilitate the characterization of expressed rCNTI (see Chapters 4 and 
5). 
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Chapter 4 
Distribution of rCNT] in 
rat tissues 
Chapter 4 
95 
4.1 Introduction 
Nucleosides Play a variety of physiological roles in many mammalian tissues, as 
described in detail in section 1.2.1. Briefly, they are involved in neurotransmitter 
release, cardiac contractility, vasodilation, lipolysis and platelet aggregation [23]. 
Additionally, in cell types that lack the pathways for de novo nucleotide synthesis, 
such as haernatopoietic stem cells, nucleoside salvage is essential for the production 
of nucleotides in the quantities required for intermediary metabolism and specialized 
cellular functions [33]. For example, inosine is an in vivo energy source for adult pig 
erythrocytes, cells that are unable to transport and hence metabolize glucose [24]. 
Therefore, due to the importance of these molecules it is expected that most if not all 
mammalian cells possess at least one type of nucleoside transporter. For example, in 
the rat cif, cit and cib transporters have been shown to be present in the kidney 
[63,72,75]; in hepatocytes and macrophages cif transport has been demonstrated 
[61,142]; and in the rabbit concentrative transport has been displayed in the choroid 
plexus, small intestine and the kidney [52,64,74]. These are to name but a few, 
however for a more in-depth discussion see the review by Cass [49]. 
An individual cell is unlikely to express all members of the facilitative and active 
nucleoside transporter families, and those expressed may reflect the particular 
metabolic requirements of the cell. Moreover, where two or more transporters are 
simultaneously present, these may occupy different regions of the cell surface, in 
particular in polarized cells. A comparable situation in the better understood field of 
glucose transport is presented by the epithelial cells of the small intestine. The 
polarization of these cells provides two contrasting environments, namely that of the 
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intestina lumen and that of the interstitial fluid. Considering the facilitative glucose 
transporters, GLUT's 1-7, and the active transporter SGLTI, only GLUT2 and 
SGLTI have been demonstrated to be present, located at the basolateral for the 
fon-ner and brush border membranes for the latter [143,144]. Additionally GLUT5 
has been demonstrated to be inducibly present at the brush border, although it is 
primarily concerned with fructose uptake [145]. Therefore it can be assumed that not 
every cell will possess all the nucleoside transporters although if they do the 
distribution within the cell may vary depending on the local environment present. 
Furthermore, the expression of these proteins may not be permanent but may be 
regulated depending on the stage of cellular development or by the receiving of 
stimulatory or inhibitory signals. One such case showed that hypothyroidism reduces 
the adenosine transport in rat brain stem synaptosomes by decreasing the number of 
both the es transporters and A, -receptors present [146], the latter of which may 
regulate some, if not all, nucleoside transporter activity. However, factors regulating 
the expression of such transporters have not been investigated to date extensively. 
The expression of rCNT I in the small intestine and kidney has been demonstrated by 
Northern blotting [81]. Here it is thought to be involved in the intestinal absorption 
of nucleosides from the diet and in renal salvage of nucleosides from the renal 
filtrate. Although the brain, heart, liver, lung, skeletal muscle, spleen and testis were 
also tested no signal on Northern blotting was observed. This however is not 
definitive proof that rCNTI is not expressed in these or other tissues. Since Northern 
blotting is the detection of mRNA, which is very unstable and thus its existence may 
be short lived prior to being degraded, protein may exist depending on both the initial 
levels of expression and the turnover rate of that protein within the cell. Therefore it 
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is possible that if the protein is not constitutively expressed it may be regulated, with 
the protein being expressed either due to developmental changes or environmental 
conditions, as mentioned above, in which case rCNTI may be present without the 
existence of its mRNA. Therefore, based on this information the aim of the work 
described in this chapter was to screen for the expression of rCNTI in adult Wistar 
rats using antibodies as a means of detecting the presence of the protein. Detection 
was two-fold with initial screening by Western blotting to indicate in which tissues 
the protein was present, followed subsequently by immunocytochemical detection to 
confirm these results and further identify the subcellular localization of the protein. 
For the purposes of understanding the approaches used and results obtained this 
technique of immunocytochemistry is described in the following section. 
4.2 Immunocytochemistry: an introduction 
The technique of immunocytochemistry was developed by Coons et al.. who first 
labeled an antibody with a fluorescent probe and used this to identify an antigen in 
tissue sections [147,148]. This method of directly labeling the antigen-specific 
antibody was further improved by Coons et al. by the introduction of a second layer 
[149]. The primary antibody in this procedure is unmodified and is specific for the 
desired epitope while a secondary antibody is directed against the Fc fragment of an 
IgG raised in the same host as the primary antibody. Thus conjugation of a 
fluorophore to this secondary antibody allows indirect labeling of the desired epitope. 
The advantages of this system are three-fold; firstly, the anti-IgG serum used as a 
second layer usually has a very high avidity and is hyper-immune; secondly, at 
least 
two secondary layer antibodies can bind to each primary antibody thus amplifying 
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the signal; and thirdly, by only labeling one general secondary antibody and not each 
specific primary antibody the process is made more economical. Furthermore, 
developments in indirect labeling have resulted in tertiary level systems, such as the 
peroxidase-anti-peroxidase (PAP) system [150] or the avidin-biotin methods [151], 
but these require more time due to the incorporation of an extra layer and thus may 
be more expensive so will not be discussed but are reviewed by S. J. Carlton [ 152]. 
Successful immuno-staining requires a number of conditions to be met. The tissue 
antigens must be made insoluble and yet their antigenic sites must be available to 
allow antibody binding. Concurrently the tissue architecture must be preserved so 
that the immuno-reactive target may be identified in context. Originally fixation of 
tissue to maintain its structure was thought to reduce antigen availability, due to the 
strong cross-linking of tissue proteins by the conventional aldehyde fixatives. 
However advances in the antibody production, more rigorously controlled techniques 
and the correct pretreatment of samples have all allowed for such fixatives to be used 
in some cases, but not in all. 
Several types of fixative are available but it is best to start by following published 
methods with fixatives which have worked for similar tissues or molecules and if 
necessary adapt these to the antigen in question. Fixatives available include, cross- 
linking agents which react with reactive end-groups of adjacent protein regions, such 
as formaldehyde which reacts primarily with amine groups of lysine; or precipitant 
fixatives which denature proteins by destroying the hydrophobic bonds which hold 
together the tertiary structure, such reagents are acetone or alcohols. Generally cross- 
linkers work better with smaller soluble proteins while precipitants work better with 
larger molecules. Therefore it may be beneficial to use a cocktail of both. 
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Alternatively, fresh samples may be frozen or freeze-dried in order to maintain the 
antigen. Furthen-nore, fixed or unfixed specimens can be embedded to maintain tissue 
structure while sectioning by providing support to reduce distortion due to the 
abrasion and pressure of the microtome blade. However, embedding in certain 
substances, such as paraffin wax, can itself reduce reactivity of the antibody with the 
antigen. 
Recent advances have been made in the recovery of epitopes in tissues fixed with 
aldehyde fixatives. In this form of fixation the formation of hydroxy-methylene 
bridges between amino acid chains of proteins may mask the antigenic site. In the 
quest to overcome this problem a number of pretreatment processes have been 
developed and collectively termed antigen retrieval techniques. One such technique 
involves simply washing the tissue to reverse the effects of fixation, while a second 
method involves incubating the sections in a solution of protease to break down the 
cross-linking bonds between the fixative and the protein [153]. For the latter of these 
methods the concentration of the enzyme, the incubation time, thickness of section 
and temperature are all important and must be controlled tightly. The most common 
enzymes used are trypsin and pronase, although the latter is more harsh on the tissue 
integrity. Another method involves the use of heat and is therefore termed heat- 
mediated antigen retrieval. Within this category there are a number of methods which 
have been reviewed by Taylor et aL [154]. Briefly, these include heating sections 
either in an oven, microwave or pressure cooker in the presence of a heavy metal 
0 
solution or chelating solution such as citrate or EDTA. An explanation on how these 
procedures might work was put forward by Morgan et al. [155]. These workers 
suggested that not only did heating provide energy to rupture the hydroxyl bonds 
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formed by aldehyde fixation but it also released tissue-bound calcium ions which 
contribute to tighter bonds with the fixative, thus exposing some antigenic sites 
previously masked. Considering these three pre-processing techniques for antigen 
retrieval it is possible that epitopes previously hidden may now be recovered, 
although even these techniques have not proven universally successful. 
Another important consideration is how the antigen is to be visualized. For this there 
are a number of methods available with the label conjugated at either the primary, 
secondary or tertiary levels. Fluorescent labels are the most commonly used due to 
their immediate reporting when excited at the correct wavelength. Numerous such 
labels are available with the most common being fluorescein isothiocyanate (FITC) 
and tetrarhodamine isothiocyanate (TRITC) which fluoresce green and red 
respectively. Alternatively, enzyme labels can be used which produce a permanent 
result, as opposed to the unstable fluorophores, by conversion of soluble substrates to 
insoluble residues which can be observed with a standard microscope. An example of 
this method is the use of horseradish peroxidase, which in the presence of hydrogen 
peroxidase and a chromogen, such as diaminobenzidine, produces a brown resin at 
the site of the antigen. A further method of labeling is with colloidal gold particles 
conjugated to the secondary or tertiary antibody which allows detection using an 
electron microscope. For a more detailed description of these labeling techniques and 
others refer to the review by Polak and Van Noorden [ 15 6]. 
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4.3 Methods for tissue localization 
4.3.1 Membrane preparation and Western blotting 
Total cell membranes from the brain, heart, jejunum, kidney, liver, skeletal thigh 
muscle, spleen and testis were prepared as described in section 2.4.1 from a packed 
tissue volume of 20 ml. It was noted, particularly with the jejunum, that it was 
necessary to keep the samples on ice throughout the processing in addition to using 
protease inhibitors to minimize degradation of the membrane proteins. Prior to snap 
freezing and storage of the samples at -700C an aliquot was removed for protein 
determination by the BCA method described in section 2.4.2. 
Western blot analysis was performed by the electrophoresis of 70 ýtg of each 
membrane preparation by SDS-PAGE analysis on a 10 % polyacrylamide gel 
followed by transfer to a nitrocellulose membrane and treatment as described in 
sections 2.4.3 and 2.4.4. Affinity purified antibodies raised against synthetic peptides 
were used at 2 ýtg/ml, unless stated otherwise, while antisera raised against the 
ArCNTI-GST fusion protein was applied at a 1: 1000 dilution or at 2 Vtg/ml when 
affinity purified. The Enhanced Chemical Luminescence (ECL) kit from Amersham 
was used in detection in conjunction with blue sensitive autoradiography film. 
4.3.2 Tissue extraction andprocessingfor immunocytochemistry 
Tissues required were obtained from male Wistar rats (200-250g) by cervical 
dislocation and subsequent dissection. This was perfonned as rapidly as possible to 
reduce any tissue degradation. Once removed each tissue sample was washed with 
PBS and then embedded in OCT compound, frozen in isopentane and stored at 
-70'C. Alternatively, samples were incubated 16 h in 4% paraformaldehyde at 
4'C 
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subsequently followed by incubation for 16 h in 0.5 M sucrose in PBS at 4'C. Such 
fixed tissue samples could either be embedded in OCT compound and frozen as 
before or paraffin-wax embedded. Additionally, whole kidneys were perfused by 
Miss J. Smith with PBS prior to perfusing with 4% paraformaldehyde in PBS until 
the tissue surface was evenly blanched. The kidney was subsequently removed for 
o/n incubation in 0.5 M sucrose at 4'C prior to freezing in isopentane and storage at - 
70T. 
Sectioning of unfixed and paraformaldehyde-fixed OCT-embedded tissues to yield 
sections of thickness 8 microns was performed using a Leitz Wetzlar Kryostat 1720 
pre-chilled to A 8'C. Cut sections were lifted onto Vectabond TM-coated slides. These 
were subsequently stored at -20T until required although immediate usage was 
preferred. Paraffin-wax embedded tissues were sectioned at r. t. to a thickness of 4 
microns and lifted onto untreated glass slides. Prior to use these sections were 
dewaxed by washing twice in xylene for 3 min each followed by subsequent 
rehydration by sequential washing twice in 100 % ethanol, once in 90 %, once in 80 
%, once in 70 % and twice in PBS for 3 min each. 
4.3.3 Antigen retrieval pretreatment offormaldehydefixed tissue 
Four methods of antigen retrieval were used independently. Tryptic digestion was 
performed using 0.1 % w/v trypsin in PBS for Ih at 37C [153]; wet autoclave in 
0.01 M sodium citrate, pH 6, for 5 min [157]; conventional oven heating at 700C in 
0.01 M sodium citrate, pH 6, overnight [158]; and microwave oven heating in 0.1 M 
sodium citrate, pH 6, for 10 min [ 15 9]. 
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4.3.4 Immunocytochemistry of unfixedfrozen tissue 
Sections were allowed to air-dry for Ih and fixed with acetone for 3 min at r. t.. 
Subsequently sections were washed twice for 10 min with PBS and blocked for Ih 
with 100 ýd blocking buffer (5 % w/v bovine serum albumin (BSA) in PBS 
containing 0.1 % Tween-20 (PBST)) in a humidified chamber at r. t.. The blocking 
buffer was then replaced by addition of 100 ýtl blocking buffer containing immune or 
pre-immune antisera at a dilution of 1: 100; or either affinity-purified antibody or 
non-specific rabbit IgG at 10 ýtg/ml. Following overnight incubation in a humidified 
chamber at 4'C, sections were washed 3 times for 10 min each with PBST. Anti- 
rabbit IgG FITC-conjugate (Sigma) was then added at a dilution of 1: 100 in blocking 
buffer and incubated for Ih at r. t.. Following washing 3 times for 10 min each in 
PBST the sections were mounted with VectashieldTm anti-fade mountant and sealed 
with DPX. Confocal microscopy was performed using an inverted Nikon Diaphot 
adapted for confocal laser scanning microscopy. 
4.3.5 Immunocytochemistryofparaformaldehyde-fLxed tissue 
Fixed OCT- or rehydrated wax-embedded sections were washed twice for 5 min each 
in PBS followed by washing twice for 5 min each with I mg/ml sodium tetra- 
borohydride to reduce auto-fluorescence. Subsequently, sections were either treated 
as for unfixed tissue, as described above, or blocked using an avidin/ biotin blocking 
kit (Vector Laboratories Inc. ). With the exception that the antiserum raised against 
the ArCNTI-GST fusion protein was used at a dilution of 1: 400. Subsequent steps 
were carried out as for frozen sections until addition of second antibody where 
biotin-conjugated IgG was used in combination with FITC-conjugated Extravidin TM 
(Sigma) to amplify the signal, according to the manufacturer's instructions. 
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4.4 Results and discussion 
4.4.1 Antibody usage 
Immuno-blotting using antibodies raised against pepticles A and B gave no signal in 
any tissue. Similarly, neither antibody yielded specific staining of any tissue when 
used in immunocytochemistry. Therefore these two antibodies will not be discussed 
in the following sections. 
Since anti-peptide C and D antibodies did recognize rCNTI, as described in section 
4.4.3. the former of these antibodies was used, either as antiserum or affinity purified 
antibody, in initial investigations aimed at optimizing methods of tissue preparation 
and immuno-staining. However, for subsequent tissue screening both anti-peptide C 
and D antibodies were used. 
Antibodies raised against the ArCNTI-GST fusion protein were developed towards 
the end of this study and thus their use has been more limited, only being used on 
paraformaldehyde fixed kidney. The advantage that has occurred using these 
antibodies was that they had the ability to recognize tissues which had undergone 
mild paraformaldehyde fixation and thus provided sections with better integrity. The 
reason why these antibodies raised against the fusion protein proved more successful 
than the anti-peptide antibodies in recognizing the mildly fixed tissue containing 
rCNTI was that the synthetic peptides on average were approximately twenty 
residues in length compared to the rCNTI fragment of the fusion protein which was 
nearly three times this size. Therefore having raised the antiserum against a larger 
portion of rCNTI it contained antibodies against more epitopes and thus some of 
these antibodies have proven to recognize mildly fixed tissue. However this 
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development was not achieved until much work had already been carried out on 
tissue preparation techniques, as described in the following section. 
4.4.2 Fixation vs. ftesh tissue 
Initial immuno-staining of unfixed frozen rat jejunal sections indicated disintegration 
of the villi, predominantly at the villi tips (Figure 4.1). Therefore, suggesting that 
fixation of the tissue was necessary. Table 4.1 summarizes the comparison of both 
unfixed and paraformaldehyde-fixed intestine after each stage of the immuno- 
staining process as observed by phase contrast microscopy. The results demonstrated 
that unfixed tissue was relatively fragile with significant disruption occurring during 
both sectioning and washing while paraformaldehyde-fixed tissue was much more 
stable, showing negligible tissue disruption. However on comparison of the end 
results of immuno-staining the sections fixed with paraformaldehyde demonstrated 
no staining above background levels in comparison to unfixed tissue which indicated 
specific staining at the enterocyte brush border. As mentioned in section 4.2 
paraformaldehyde cross-links adjacent amino acid residues in the same or 
neighboring peptides thus in some situations blocking the antigenic site. It was 
therefore reasoned that a lower degree of cross-linking might leave more epitopes 
available to react with the antibody. Therefore the period of time during which the 
tissue was exposed to the fixative was modified in order to test times of fixation 
ranging from 20 min to 16 h. Unfortunately, decreasing the time of fixation yielded a 
negligible increase in the intensity of staining while decreasing the tissue stability. In 
all cases no significant differences were seen between paraffin wax- and OCT- 
embedded paraformaldehyde-fixed samples. 
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As mentioned in section 4.2 a number of techniques have been developed to improve 
the immuno-reactivity of paraformaldehyde-fixed tissue. In the present studies four 
such techniques were used, involving the methods detailed in section 4.3.3. The 
results are summarized in Table 4.2. In each case the integrity of the tissue remained 
good but very little improvement was observed in the specific signal obtained. Where 
there was an improvement in signal, as for both wet autoclave and conventional oven 
heating, this was very weak when compared to unfixed tissue. In order to increase 
this signal streptavidin-biotin amplification was perforined but in addition to 
increasing the signal at the brush border the background signal was also 
correspondingly increased. Later attempts to reduce this background staining with 
differing blocking techniques and reducing the primary antibody concentration failed 
to eliminate this non-specific staining. 
Although antigen retrieval has proved a useful technique with some antigens it is not 
always successful. Trypsin treatment by Huang et al. was found to decrease the 
nonspecific background fluorescence through the digestion of the tissue while 
possibly unmasking a number of epitopes [153]. Here it has been shown that the 
epitopic regions of rCNTI investigated with such pretreatment proved unsuccessful 
in producing a specific signal with either paraffin wax- or OCT-embedded tissue. 
Similar results with the other attempts at antigen retrieval showed that rCNTI 
appears to be resistant to such techniques. Comparable results have been found in 
other investigations with numerous other proteins. Tanimoto et al. tested 27 anti- 
lymphocyte antibodies with porcine sections using antigen retrieval to improve 
results but this only resulted in 5 samples being successful [160]. Similarly, Piffko et 
al. screened 22 fixed carcinomas with four antibodies using both wet autoclave and 
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microwave oven pre-treatment showing that recovery of the epitopic site was 
unpredictable, with at maximum only forty percent recovery in the best case [157]. 
They also concluded that wet autoclave gave better recovery. On the whole antigen 
retrieval does appear to be a useful technique by increasing the number of epitopic 
sites made available following paraformaldehyde fixation but does not always prove 
successful. However, a rapid assessment technique by Shi et al., termed the 'test 
battery' approach, provides a strategy for testing a number of factors involved with 
antigen retrieval [ 161 ], including the use of buffered solutions at pH 1,6, and 10 with 
three different heating conditions (temperatures 120T, I OOT and 90T) and would 
therefore prove to be a good starting point for further antigen retrieval studies. 
Having shown that no significant recovery of antigenic sites could be obtained from 
parafonnaldehyde-fixed tissue for the rCNTI antigenic sites investigated, post- 
sectioning fixation of tissue was next tested on the reasoning that if disruption caused 
by sectioning could not be prevented then at least further disruption due to washing 
could. Therefore, following sectioning sections were exposed to PBS, methanol, 
ethanol,, acetone, 4% paraformaldehyde (in PBS) and calcium formol (4 % 
paraformaldehyde in PBS containing I% w/v calcium chloride) for 10 min at r. t. and 
subsequently air dried for 30 min prior to processing as described in section 4.3.4. 
Results from this investigation are summarized in Table 4.3. Although no post- 
fixation gave perfect integrity paraformaldehyde fixation was taken as the standard 
due to this giving the best fixation. Considering these results it is obvious that no 
treatment gives optimal fixation while allowing efficient staining so a compromise 
between both had to be reached. Considering this post-sectioning fixation with 
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acetone was adopted as a standard method for further studies, unless mentioned 
otherwise. 
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Figure 4.1 Integrity of unfixed tissue 
Immunocytochernical analysis of an unfixed frozen rat jejunal section probed with 
antiserum raised against peptide D at a dilution of 1: 100. rCN. T I localization at the 
brush border is indicated by the arrow while disintegration of the villus tip is 
marked by an asterisk (*). The inset shows a comparable section stained with pre- 
immune serum at the same concentration, as a control. Bar = 40ýLrn- 
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Table 4.1 Comparison of unfixed and paraformaldehyde-fixed tissue processing 
Stage Unfixed Fixed 
Tissue integrity: 
Post-sectioning ++++ 
Washing +++ ++++ 
Blocking +++ ++++ 
Primary antibody +++ ++++ 
Washing ++ ++++ 
Secondary antibody ++ ++++ 
Washing ++ ++++ 
Mounting ++ ++++ 
Immuno-staining: 
Tissue integrity after each stage was assessed by phase-contrast microscopy setting 
parafon-naldehyde-fixed tissue as the standard (++++), due to its providing the best 
tissue integrity. Immuno-staining was achieved after complete immuno-staining, with 
'-' indicating no specific staining. 
Chapter 4 
ill 
Table 4.2 Comparison of antigen retrieval techniques 
Pretreatment Integrity Immuno-staining 
None (frozen tissue) ++ 
None (PF fixed tissue) 
Tryptic digestion 
Wet autoclave 
Conventional oven 
Microwave oven 
Paraformaldehyde (PF) fixed tissue was taken as standard (++++) for tissue integrity 
while unfixed tissue was taken as standard (++++) for immuno-staining. Where no 
signal was obtained '-' is used. Processing of tissue was perforined as described in 
sections 4.3.2-4.3.4. 
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Table 4.3 Comparison of post-sectioning fixation reagents 
Fixative Integrity Immuno-staining 
PBS ++ ++++ 
Methanol +++ ++ 
Ethanol +++ + 
Acetone +++ +++ 
Paraformaldehyde ++++ 
Calcium formol +++ 
Although tissue integrity was not perfect due to sectioning disruption 
paraformaldehyde post-fixation gave the best tissue integrity and was thus used as a 
standard (++++). Unfixed, PBS treated tissue gave the best immuno-staining signal 
and was thus assigned as standard (++++). Where no stain was observed '-' is used. 
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Figure 4.2 Western blot analysis of rat tissues with anti-peptide C antibodies 
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Analysis of rat brain (B), heart (H), intestine (1), kidney (K), liver (L), skeletal 
muscle (M), spleen (S) and testis (T) membranes containing 70 ýtg total protein using 
affinity purified antibodies (2 ýtg/ml) raised towards peptide C and non-specific 
rabbit IgG as a control, plates A and B respectively. Molecular mass markers on left 
are in kDa. 
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Figure 4.3 Western blot analysis of rat tissues with anti-peptide D antibodies 
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Analysis of rat brain (B), heart (H), intestine (1), kidney (K), liver (L), skeletal 
muscle (M), spleen (S) and testis (T) membranes containing 70 ýtg total protein using 
affinity purified antibodies (2 ýtg/ml) raised towards peptide D and non-specific 
rabbit IgG as a control, plates A and B respectively. Molecular mass markers on left 
are in kDa. 
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Figure 4.4 SubceUular distribution of rCNTI in the rat jej unum 
Immunocytochernical analysis of an acetone post-fixed rat jejunum section probed 
with antiserum raised towards peptide C, used at a dilution of 1: 100. rCNTI 
localization at the brush border is indicated by the arrow with the basolateral 
membrane being marked by an asterisk (*). The inset shows a comparable section 
stained with pre-immune serum at the same concentration, as a control. Bar = 25ýLrn. 
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Figure 4.5 SubceUular distribution of rCNTt in the rat kidney 
Immunocytochernical analysis of perfused paraformaldehyde-fixed rat kidney 
sections. Plate A probed with antiserum raised to the ArCNTI-GST fusion protein 
(1: 400 dilution); plate B probed with antiserum raised against GST (1: 400 dilution); 
, plate 
C probed with antiserum raised against GLUT 1 (1: 400 dilution) identifying the 
proximal tubule, with pre-immune GLUT I control, plate D. Arrows in plates A&B 
and C&D indicate brush border and basolateral membranes, respectively. Bar = 40 
ýLm. 
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Figure 4.6 SubceUular distribution of rCNTI in the rat liver 
Immunocytochernical analysis of an acetone post-fixed rat liver section probed with 
antiserum raised towards peptide C, used at a dilution of 1: 100. rC-.. NT I localization 
at the bile canalicular membrane of hepatic parenchymal cells is indicated by the 
large arrow while its absence from the sinusoidal membrane is indicated by the 
small arrow. The inset shows a comparable section stained with pre-immune serum 
at the same concentration, as a control. Bar = 80 ýLrn. 
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Figure 4.7 Cellular distribution of rCNTI in the rat brain 
Immunocytochernical analysis of acetone post-fixed rat brain section probed with 
antiserum raised towards peptide D, used at a dilution of 1: 100. rCNT I localization 
is within the hippocampal region. The inset shows a comparable section stained with 
pre-immune serum at the same concentration, as a control. Bar = 40 um. 
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Figure 4.8 SubceUular distribution of rCNTI in the rat heart 
Immunocytochernical analysis of an acetone post-fixed rat cardiac section probed 
with antiserum raised towards peptide D, used at a dilution of 1: 100. rCNITI 
localization at the plasma membrane is indicated by the arrow. The inset shows a 
comparable section stained with pre-immune serum at the same concentration, as a 
control. Bar = 40 ýLrn. 
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Figure 4.9 Subcellular distribution of rCNTI in the rat skeletal thigh muscle 
Immunocytochernical analysis of an acetone post-fixed rat skeletal thigh muscle 
section probed with antiserum raised towards peptide D, used at a dilution of 1: 100 - 
rCNTI localization at the plasma membrane is indicated by the arrow. The inset 
shows a comparable section stained with pre-immune serum at the same 
concentration, as a control. Bar = 40 ýLrn. 
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Figure 4.10 Subeellular distribution of rCNTI in the rat testis 
Immunocytoc hem ic al analysis of an acetone post-fixed rat testicular section probed 
with antiserum raised towards peptide C, used at a dilution of 1: 100. rCN-TI 
localization at the central region of the serniniferous tubule is indicated by the 
asterisk (*). The inset shows a comparable section stained with pre-immune serum 
at the same concentration, as a control. Bar = 40 ýirn. 
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'Data discussed in chapter 5 indicates that rCNT1 can exist in vivo in varying 
glycosylation states, with either one or both of the asparagines at positions 605 and/ 
or 643 glycosylated. This observation may explain the differences in the banding 
patterns observed between the intestine, kidney and liver. That is, in the intestine and 
kidney either one or both of these sites appear to be glycosylated resulting in the 
presence of two rCNT I isoforms. In contrast, in the liver it appears that either one or 
other of the glycosylation sites are occupied, resulting in a protein, or mixture of 
proteins, with a single apparent M, of 60 000. Furthermore, in the intestinal sample 
proteins were detected with apparent M, of 100 000 and 50 000. These appeared to be 
degradation products of rCNT I with the latter representing truncated protein while 
the former may represent aggregation of this truncated form. C_ 
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4.4.3 Tissue distribution of rCNT] 
Immunoblot analysis of eight rat tissues indicated that antibodies raised against 
rCNTI peptide C reacted with a protein which migrated with an apparent M, of 
between 60 000 and 63 000 in jejunum, kidney and liver (Figure 4.2a)t Interestingly, 
although the rabbit non-specific IgG blot indicated that these bands were specific it 
also demonstrated that these control antibodies cross-reacted with several other 
proteins present (Figure 4.2b). The observation that the rCNTI antibodies 
specifically labelled proteins of apparent M, of between 60 000 and 63 000 was 
unexpected because according to the amino acid sequence rCNTI is predicted to 
have an unmodified M, of 71 000. However such a discrepancy between predicted 
and observed M, is a known phenomenon when investigating membrane proteins by 
SDS-PAGE related techniques. The basis of this technique is that in the presence of 
excess SDS proteins bind this molecule in relation to their size, giving the protein a 
constant negative charge per unit mass. When such protein-SDS complexes are then 
added to a polyacrylamide gel the proteins present will move towards the anode 
during electrophoresis and separate owing to the molecular-sieving properties of the 
gel. However in the case of highly hydrophobic proteins, such as membrane proteins, 
SDS binds to the hydrophobic regions to a much higher extent thus giving the 
proteins a higher unit charge per unit mass than normal resulting in such proteins 
running faster on SDS-PAGE than expected. Alternatively, it may be that 
hydrophobic proteins fail to completely unfold and therefore will pass through the 
SDS gel faster due to their reduced size. An example where a decrease between 
predicted and observed apparent M, is observed is with the facilitative glucose 
transporter GLUTI, which has an apparent M, of 54 000 based on the unmodified 
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protein sequence [162] but routinely migrates with an apparent M, of 45 000 on 
deglycosylation. The question then arises, how confident are we that the protein 
observed is rCNTI? There are two pieces of evidence that confirm the band 
observed, in each of the three tissues, with an apparent M, of between 60 000 and 63 
000 is rCNT I. Firstly, when a parallel blot was carried out using pre-immune or non- 
specific rabbit IgG, as control, no bands were observed migrating at an equivalent 
size to those mentioned above (Figure 4.2b). Secondly, anti-peptide C antibodies 
specifically reacted with a protein of similar apparent M, when blotted against 
vr- 
Aunopus oocyte membranes expressing rCNTI but not water injected control 
membranes, see chapter 5. Additionally, this work indicated that this antibody did 
not cross-react with the homologue rCNT2, a purine specific active nucleoside 
transporter which has been shown to be present in the liver [84]. 
As mentioned previously, section 4.1, the detection by Northern blotting of mRNA 
for rCNTI had suggested that this protein was present in the jejunum and kidney 
[81]. However the present study was the first to reveal that rCNT I was also present 
in the liver until Felipe et aL (1998) demonstrated that both rCNT I and rCNT2 were 
present in liver parenchymal cells and that the subcellular distribution was different 
with only rCNT2 appearing in basolateral membrane preparations [89]. 
Screening with anti-peptide D antibodies did not produce a signal of the expected 
apparent M, in any tissue although two bands in the brain were observed with 
apparent M of 45 000 and 56 000 (Figure 4.3a). Furthermore, this latter band was r 
also observed in the spleen. Although the control blot demonstrated significant cross- 
reactivity of the non-specific rabbit IgG with other proteins present (Figure 4.3b), no 
bands were observed with an equivalent apparent M, similar to the fore-mentioned 
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bands demonstrated in the brain and spleen, thus indicating that these bands were 
specific. Considering information discussed in chapter 5, where the deglycosylated 
protein is shown to produce a signal with an apparent M, of 56 000, this suggests that 
in both the brain and spleen at least a small percentage of the rCNTI population is 
present in the unglycosylated state. Indeed, it may be that all the rCNTI present is 
unglycosylated as a means of intra-cellular targeting, although this has not been 
proven. Alternatively, it is possible that rCNTI is present in the glycosylated state 
but due to the relative proximity of the oligosaccharide moiety to the epitopic region 
the saccharide may cause steric-hindrance, thus preventing the antibodies raised 
against the rCNTI peptide D from gaining access to the antigenic site, therefore 
suggesting that it is a degradation product or immature form of rCNTI that is being 
observed. Furthermore, the second band observed in the brain, with an apparent Mr of 
45 000, is possibly a truncated version of rCNT1, which in conjunction with the fact 
that the antibodies react towards the C-terminus of the protein suggests that the 
truncation occurs at the N-terminus. Further evidence for this is provided by a private 
communication from Prof J. D. Young (University of Alberta, Canada), which 
reported that elimination of the three putative N-terminal helices did not affect 
transport activity of rCNT I, suggesting that the band observed with an apparent M, of 
45 000 in the brain is a truncated isoform of rCNTI that may still be functional. 
To investigate further the subcellular localization of rCNTI in rat tissues 
immunocytochernistry was carried out in the present study. These 
immunocytochemical studies were initially focused on the tissues which produced a 
signal on Western blotting but were later extended to the remaining tissues initially 
screened. 
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4.4.4 Subcellular distribution of rCNT] 
Immunocytochernical investigation of the rat jejunum indicated that rCNTI was 
present on the brush border membrane but absent from the basolateral membrane, 
Figure 4.4. This observation is consistent with the distribution of other transporters 
in the intestinal epithelium. In the case of the glucose transporters, the active sugar 
transport protein SGLTI is located at the brush border but is absent from the 
basolateral membrane. Complementary to this the facilitative transporter GLUT2 is 
present at the latter membrane but is absent from the former [163]. These 
distributions reflect the roles of the two transporters: SGLTI is required for the active 
uptake of glucose from the intestinal lumen, where glucose is present at lower 
concentrations than in the cell, whereas GLUT2 allows the equilibrative transport of 
the cellular glucose down the concentration gradient into the interstitial fluid and 
hence blood supply. It is therefore possible that a similar situation is true for 
nucleoside uptake from the intestinal cavity and release into the blood supply, i. e. 
rCNTI present at the brush border is responsible for the active uptake of pyrimidine 
nucleosides from the lumen while another transporter may be responsible for the 
release of modified or intact nucleosides from the epithelial cells into the blood. One 
case where facilitative nucleoside transport has been demonstrated to be present at 
the basolateral membrane was that of the human es-type transporter in T84 intestinal 
epithelial cells [164]. Therefore, this suggests that a facilitative nucleoside 
transporter may also be present in the rat BLM. The observation that rCNTI is 
present at the brush border is consistent with previous work carried out on intestinal 
epithelial cells. Terasaki et aL in 1993 isolated the mRNA from rabbit small 
intestinal cells and showed that on expression in Xenopus oocytes this gave similar 
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Turther evidence for the presence of a purine specific nucleoside transporter in the 
intestinal brush border was demonstrated by Bronk et al. [185]. Working with 
isolated loops of jejunum they demonstrated that purine in addition to pyrimidine 
nucleosides were transported into epithelial cells. 
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characteristics to a cit-type nucleoside transport protein previously reported in brush 
border vesicles [165], suggesting that they were the same transporter. Later it was 
suggested that rat intestinal brush border membrane vesicles contained both 
facilitative and concentrative nucleoside transport systems [ 166]. This information in 
conjunction with the evidence for the human intestine containing both cif- and cit- 
type activity, and the cloning of a rat intestinal cif-type transporter, suggests that if a 
pyrimidine transporter is present at the brush border then a complementary purine 
specific transporter would also be expected [167,168]ý 
Immunocytochernical analysis of the rat kidney, using antibodies raised against the 
ArCNTI-GST fusion protein, demonstrated not only the expression of rCNTI at the 
brush border but its absence from the basolateral membrane as distinguished by the 
use of a GLUTI control, Figure 4.5. Additionally, since GLUTI was restricted to the 
proximal tubules [ 169] and rCNT I was localized to these same tubules, this indicated 
that rCNTI expression was not throughout the kidney but was also restricted to the 
proximal tubules of the renal cortex. Active nucleoside transport has previously been 
demonstrated in the rat and rabbit renal brush borders [64,75] but this is the first case 
where an active cit-type transport protein has been visualized to be present only at 
the brush border membrane of the renal cortical proximal tubule. The location of 
rCNTI at this membrane and its absence elsewhere in the kidney is due to its 
predicted physiological role of nucleoside salvage from the renal filtrate. A similar 
situation is also observed with the active glucose transporter SGLTI which is present 
at the renal proximal tubule brush border but absent from the basolateral membrane. 
Subcellular investigation of the rat liver indicated that the presence of rCNTI was 
restricted to the bile canalicular membrane of parenchymal cells and thus it was 
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absent from the sinusoidal membrane, Figure 4.6. Once again this localization of 
rCNTI suggests that its physiological role here in the liver is one of salvaging 
nucleosides from the bile following hepatic excretion. The recent cloning of the cif- 
type nucleoside transporter rCNT2 from the rat liver suggests that a complementary 
pyrimidine transporter is also required. More recently this has been proven by Felipe 
et al. who demonstrated that both rCNTI and rCNT2 are present in the rat liver [89], 
as mentioned in section 4.4.3. 
Although the presence of glycosylated rCNTI was not detected by Western blotting 
in the brain using antibodies raised against peptide Ca signal was obtained using 
antibodies raised against peptide D. However, the protein appeared to be either 
unglycosylated, or unglycosylated and truncated, as described in section 4.4.3. This 
previously observed Western blot signal, as described in section 4.4.3, was 
confirmed by the recognition of rCNTI in what appeared to be the cell membrane of 
hippocampal pyramidal cells, as demonstrated in Figure 4.7. Unfortunately, at the 
time of carrying out the initial immunocytochemistry on various tissues the ArCNT I- 
GST fusion protein antibody was not available so frozen sections were used. Due to 
this and the inability to prefix the tissue this meant that the specific cell type in which 
the signal was observed could not be identified due to partial tissue disruption. 
However this will be possible in future studies now that a method for detection with 
the ArCNTI-GST fusion protein antibody has been established. Other evidence for 
the presence of rCNT I in the brain comes from recent work carried out by Anderson 
et al. who demonstrated that both rCNTI and rCNT2 mRNA were present in the 
brain [881. 
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Surprisingly, immuno-localization of rCNTI was demonstrated in both cardiac and 
skeletal thigh muscle, as illustrated in Figures 4.8 and 4.9 respectively. Wherein the 
presence of the transporter was localized to the plasma membrane in each case, 
although this was very weak when compared to the levels of detection mentioned in 
the other tissues to date, however it did appear specific. These results were obtained 
using antibodies raised against peptide D with the signal being much weaker with 
those raised towards pepticle C. A possible explanation for this is that glycosylation 
confers structural constrains on the rCNTI peptide backbone when present and that 
when this glycosylation is removed the protein alters to a conformation to which the 
antibodies raised against pepticle D are avid. Therefore if rCNTI is present mostly as 
an aglyco-protein in these two tissues then anti-peptide D antibodies will Produce a 
stronger signal. Also, since the antibodies raised against peptide D produce a signal 
in the intestine, it may be that a proportion of rCNTI in the intestine is also 
unglycosylated. Returning to the heart, the presence of active nucleoside transport 
has not been reported to as great an extent as the existence of facilitative transport, 
which has been widely investigated [146,170]. The only existence to date of active 
transport in cardiac muscle is in human myocytes where the presence of one active 
transporter has been demonstrated in addition to two facilitative transporters by 
physiological techniques [171]. Skeletal muscle has also had very little work carried 
out on it in relation to nucleoside transport, in so far that no reported cases could be 
found for skeletal muscle nucleoside transport although facilitative transport has been 
demonstrated in the smooth muscle cell line DDTI MF-2 [172]. 
On immunocytochernical analysis of the testis a signal, indicating the presence of 
rCNTI, was observed at the center of the seminiferous tubule (Figure 4.10) in the 
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region where late development of the gametes occurs. On closer inspection it would 
appear that it was the central body region of the gametes where the signal was 
produced. Interestingly the mitochondrial fraction from rat testis has been 
demonstrated to possess facilitative nucleoside transport [173]. Coincidentally, the 
body region of the gamete is rich in mitochondria. Therefore it may be true that 
active nucleoside transporters are present on the gamete plasma membrane which 
transport nucleosides into the cell so that they are available for uptake from the 
cytoplasm by the mitochondria. Also of interest is that rat Sertoli cell-conditioned 
medium inhibited the uptake of thymidine by cells in culture [174]. This therefore 
may be a method of controlling gamete activity. 
Finally, although a signal was produced in the spleen with antibodies raised against 
peptide D on Western blotting indicating the presence of rCNTI, no signal was 
observed on immunocytochemical. analysis. Thus it may be that the antibodies only 
recognize the spleen isoform of rCNTI when denatured and unglycosylated. 
4.5 Summary 
Immunoblot analysis has confinned the presence of rCNTI in the rat brain, jejunum, 
kidney, liver and spleen. Further investigation by immunocytochemistry localized 
this protein to the brush border of both the jejunum and kidney, although in the latter 
case distribution was restricted to the brush border of the proximal tubules of the 
renal cortex while being absent from other tubules present. Within the liver, rCNTI 
was found at the bile canalicular membranes of hepatic parenchymal cells but was 
absent from the sinusoidal membranes. These results coincide with the predicted 
physiological roles of this protein in the absorption of nucleosides from the intestinal 
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lumen and in the salvage of nucleosides from both the renal filtrate and hepatic bile 
fluid. In the brain preliminary studies suggested that rCNTI was present in the 
plasma membrane of hippocampal pyramidal cells, although this remains to be 
confirmed using fixed tissue and antibodies raised against the ArCNTI-GST fusion 
protein. However a possible role for the transporter in this tissue is in the uptake of 
the neurotransmitter adenosine. Interestingly, having demonstrated rCNTI is present 
in the spleen by Western blotting this could not be confirmed by 
immunocytochemical analysis. However, rCNTI was also demonstrated by 
immuncytochernistry to be present in the heart, skeletal thigh muscle and testis, 
although these were not confirmed by Western blotting, in addition to its presence in 
the fore mentioned tissues. Possible reasons for the differences in Western blot and 
immunocytochernical analyses have been discussed in detail in the previous section 
but briefly, they appear to have been due to differences in the levels of expression of 
the glycosylated and unglycosylated fonns of rCNTI, and the preference of the 
different antibodies for one or other. Stemming from the observations made in this 
chapter, it is clear that further work is required to conclusively elucidate the reasons 
for the differences observed between the two techniques employed in this study. 
Therefore, presenting incitement for future investigation into the distribution of 
rCNTI within these tissues. 
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Chapter 5 
Topological analysis of rCNTJ 
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5.1 Introduction 
Information on the topology of rCNTI is very limited, with the majority of it based 
on predictive computer algorithms as discussed in section 1.3.2. This has led to the 
development of the putative model represented in Figure 1.2, where both the N- and 
C-termini were predicted to be cytoplasmic with fourteen hydrophobic 
transmembrane domains located between them. As a first step towards understanding 
how this protein functions it is essential that this tentative model be directly tested by 
experimental procedures. Techniques which can be used include circular dichroism, 
FTIR spectroscopy, proteolytic digestion, site-specific antibodies, biotinylation or 
glycosylation scanning mutagenesis. All of these techniques have been used 
previously in topological investigation of membrane proteins as discussed in section 
1.1. where the development of methods to elucidate the conformation of GLUT1 was 
considered. 
One of the most powerful methods for determination of membrane protein topology 
is glycosylation scanning mutagenesis, which exploits the fact that many membrane 
proteins bear oligosaccharide chains on their extracellular domains. The attachment 
of such chains occurs as the result of post-translational glycosylation reactions as the 
proteins are transported through the secretory pathway. There are two basic forms of 
glycosylation, either N- or 0-linked where an oligosaccharide is conjugated to an 
asparagine residue or to either serine or threonine respectively. N-linked 
glycosylation involves the transfer of a high mannose oligosaccharide structure en 
bloc from a dolichol donor to the nascent peptide in the endoplasmic reticulum [175]. 
The oligosaccharide chains are attached to an asparagine residue within the 
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consensus sequence Asn-Xaa-Ser/ Thr, where Xaa is any amino acid other than 
proline. However, a consensus sequence followed by a proline residue is unlikely to 
be glycosylated [176]. Following addition of the carbohydrate moiety the 
glycoprotein is translocated to the Golgi complex where the sugar component is 
modified by a number of different enzymes. Furthennore, it is in the Golgi where 0- 
linked glycosylation of serine and threonine residues takes place. The specificities of 
the acetylgalactosarninyltransferase enzymes involved in O-linked glycosylation are 
relatively poorly understood. Although, the specificity appears to be modulated by 
sequence context, secondary structure and surface accessibility. 
The majority of membrane proteins, such as receptors, channels or transporters, are 
N-linked glycosylated suggesting that this post-translational modification plays an 
important role in processing or expression of the protein. However there are 
exceptions such as the cc-subunits of cation-transpoirting ATPases and the cc, -subunit 
of the calcium channel which, although they themselves are unglycosylated, are 
tightly associated with other N-linked glycosylated subunits [ 177]. A number of roles 
have been proposed for this type of modification including directing protein folding, 
regulating cell-surface expression and increasing the half-life of proteins [178]. 
Interestingly, if more than one glycosylation site is present in a transmembrane 
protein then it appears that usually only the first is glycosylated, an exception being 
the (x, -subunit of the sodium channel which due to a duplication in structure contains 
two glycosylated sites [179]. The mechanisms that restrict glycosylation to a single 
loop in the majority of proteins is unclear. However, the size of the loop and the 
position of the site within this segment are important: it has been demonstrated that 
for an extracellular loop to be efficiently glycosylated it must be larger than 25 
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residues, with at least 12 residues N-terminal and 14 residues C-terminal to the 
asparagine that is to be modified [ 1801. 
Taking into account the features mentioned above glycosylation can be used as a 
means of probing the topology of integral membrane proteins. This can be achieved 
by a technique known as glycosylation scanning mutagenesis where an aglyco- 
protein is made by the mutagenic elimination of any endogenous N-linked 
glycosylation sites. This therefore provides a backbone for the incorporation of 
exogenous glycosylation sites at specific positions in predicted hydrophilic segments 
within the peptide. If such sites are incorporated into extracellular loops of the 
protein they are expected to become glycosylated, provided that the loops are 
sufficiently large to allow access of the glycosylation machinery. However, if the 
sites are incorporated into intracellular loops they will not be glycosylated. Thus, 
analysis of the glycosylation state of the mutant protein can be utilized to determine 
the orientation of each segment with respect to the plasma membrane. Such a 
strategy has been used to investigate a number of membrane proteins and thus 
provide data that has led to production of a two-dimensional model for these proteins 
in the membrane [22,180,181]. 
rCNTI has three potential N-linked glycosylation sites at Positions 543,605 and 643. 
The first of these is located in putative TMD thirteen and so is unlikely to be 
accessible to the glycosylating machinery of the endoplasmic reticulum. However, 
the sites at positions 605 and 643 lie in the hydrophilic C-terminal region of the 
protein, which was predicted by Huang et al. to be cytoplasmic [8 1 ], hence 
suggesting that these two sites are unglycosylated. Therefore, the initial aim of this 
investigation was to establish if rCNTI was glycosylated. This was achieved by 
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investigating the glycosylation state of wild-type rCNTI in Xenopus oocytes by 
comparing the protein in the presence and absence of the deglycosylating enzyme 
endoglycosiclase F. Having established if rCNTI was present as a glycoprotein the 
accessible consensus sequences were eliminated to produce an aglyco-rCNTI mutant 
that could be used as the basis for mutagenesis. This aglyco-protein allowed the 
generation of a number of mutants with either single residue mutations to introduce a 
glycosylation site or unique Kpnl restriction sites at which cDNA fragments 
encoding a potentially N-glycosylated hydrophilic loop region could be inserted. In 
the present study the extracellular glycosylated hydrophilic loop of human GLUT4, 
residues 46 to 78, was employed for the latter purpose, a suitable cDNA fragment 
bearing terminal Kpnl restriction sites being produced by PCR amplification of 
GLUT4 cDNA (Figure 5.1). 
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Figure 5.1 Amplification of human GLUT4 cDNA encoding a potential N- 
glycosylated loop 
GCTTGGCTCCCTGCAGTTTGGGTACAACATTGGGGTCATCAATGCCCCTCAGAAGGTGAT 
241 ------------------------------------------------------------ 300 
CGAACCGAGGGACGTCAAACCCATGTTGTAACCCCAGTAGTTACGGGGAGTCTTCCACTA 
hG4KpnIf >> cggGGTACCAATGCCCCTCAGAAGGTG 
LGSLQFGYNIGVTNAPQKV1 52 
a 
TGAACAGAGCTACAATGAGACGTGGCTGGGGAGGCAGGGGCCTGAGGGACCCAGCTCCAT 
301 ------------------------------------------------------------ 360 
ACTTGTCTCGATGTTACTCTGCACCGACCCCTCCGTCCCCGGACTCCCTGGGTCGAGGTA 
GRQGPEGPSS1 72 
gggaggtccgtgggagtggccatggccg << hG4KpnIr 
CCCTCCAGGCACCCTCACCACCCTCTGGGCCCTCTCCGTGGCCATCTTTTCCGTGGGCGG 
361 ------------------------------------------------------------ 420 
GGGAGGTCCGTGGGAGTGGTGGGAGACCCGGGAGAGGCACCGGTAGAAAAGGCACCCGCC 
92 
Primers designed to amplify the cDNA encoding the potential N-glycosylated 
hydrophilic loop of human GLUT4 are indicated above with 5' Kpnl restriction site 
tags (shown in italics). The translated protein is illustrated with the region amplified 
identified in bold. 
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5.2 Methods for topological analysis 
5.2.1 Endoglycosidase digestion to determine the glycosylation state of membrane 
proteins 
Xenopus oocyte membrane preparations expressing the nucleoside transporters 
rCNTI,, rCNT2, hCNTI and hCNT2, in addition to water injected control 
membranes, were obtained from Dr J. D. Young (University of Alberta, Canada). In 
each case oocytes were injected with 10 ng of cRNA encoding each of the 
transporters prior to incubation at I 80C for 3 days as described by Huang et aL [8 1 ]. 
Total protein membrane preparation (I Ogg) in 50 gl 100 mM sodium acetate, pH 7.2, 
50 mM EDTA, 0.2 % octyl- P-D-glucopyrano side, I% mercaptoethanol were 
digested with 0.125 U endoglycosidase F/ N-glycosidase F from Flavobacterium 
meningosepticum (Boehringer-Mannheim) overnight at 22'C. Controls were 
performed under identical conditions with water being substituted for the 
deglycosylating enzyme. Protein determination was performed with the BCA protein 
assay as described in section 2.4.2. SDS-PAGE and Western blot analyses were 
performed as described in sections 2.4.3 and 2.4.4 respectively. 
5.22 Mutagenic removal of rCNTI endogenous glycosylation sites 
Numerous strategies for mutagenesis are available but recently a non-PCR based 
mutagenesis technique has been developed by Stratagene, known as the 
QuikChange TM site-directed mutagenesis technique. This technique has a number of 
advantages over traditional PCR mutagenesis and will be used in the present study. 
The procedure starts with double-stranded DNA and two complementary primers 
containing the desired mutation. These are extended in the presence of the 
thermostable enzyme Pfu DNA polymerase. The incorporation of the primers 
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produces a mutated plasmid with staggered nicks. The mutated plasmid is then 
selected for by the digestion of the dam methylated parental DNA, which has been 
produced in E. coli by the methylation of adenine residues in the sequence GATC, 
leaving the nicked mutant plasmid containing the desired mutation which can then be 
transfonned into E. coli. An overview of this strategy can be seen in Figure 5.2. The 
main advantages of this procedure are that subcloning of the final product is 
eliminated, thus speeding the synthesis of mutants; Pfu DNA polymerase has a high 
fidelity, thus decreasing the number of mis-matches; the technique is reportedly 150 
times more efficient than standard PCR-based methods; and the complete procedure 
can be accomplished in one day. The efficiency of QuikChange TM site-directed 
mutagenesis is reported to produce greater than 80 % of the resulting colonies 
containing the desired mutation. This is due to the small amount of starting DNA 
template required for this technique, the high fidelity of Pfu DNA polymerase and 
the low number of thermal cycles. 
cDNA encoding rCNTI in the vector pGEM-3Z, designated pQQH by Huang et al 
[81], was mutated using the QuikChange TM site-directed mutagenesis kit 
(Stratagene). For mutagenesis of asparagine 605 to threonine the forward primer 
rCNTI_N605Tf was used in conjunction with the reverse primer rCNTI-N605Tr 
(see Table 5.1 for sequences of all primers used in this chapter). Asparagine 643 was 
mutated to threonine using the forward primer rCNTI-N643Tf in combination with 
the reverse primer rCNTI-N643Tr. The reactions were set up to a final volume of 
50 
ýtl according to the manufacturer's recommendations using 125 ng of each primer, a 
range of template DNA between 5 and 50 ng, 0.2 mM dNTPs, 
Ix amplification 
buffer (supplied with the kit), and 2.5 U Pfu DNA polymerase. Conditions used for 
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thermo-cycling were: stage 1, one cycle of 950C for 90 sec; stage 2, twelve cycles of 
950C for 30 sec, 550C for 60 sec and 680C for 12 min; and stage 3, one cycle of 680C 
for 10 min. Following mutagenesis the parental DNA was digested by addition of 20 
U Dpnl for Ih at 37C prior to transformation of competent XL I O-Gold E coli cells, 
as described in section 2.5.4, with 100 pg of the resulting mutated DNA. The N605T/ 
N643T double mutant was generated using the N605T mutant as template in 
conjunction with the N643T primers, using the same method used to obtain the 
single mutants. BamHI-Xbal cassettes of 477 bp, containing the mutated sequences, 
were subcloned into the original pQQH construct and then this region in each mutant 
was completely sequenced with the ABI 373A DNA sequencer using dye-deoxy 
terminator chemistry (Perkin Elmer) in order to confirm the presence of the desired 
mutation and the absence of any other mutations. The resultant constructs were 
designated pSRH3, pSRH4 and pSRH5 for the 605,643 and 605/ 643 mutants 
respectively. The locations of the mutated residues within rCNTI are illustrated in 
Figure 5.3, with the relative positions of restriction sites used in subcloning of the 
mutated cassettes, described above, indicated. 
5.23 Incorporation ofpotential glycosylation sites by single residue modification 
To generate potential N-linked glycosylation sites by the replacement of single amino 
acid residues, the construct pQQH was mutated by the QuikChange TM site-directed 
mutagenesis kit (Stratagene) as described in section 5.2.2. Three such mutations 
were attempted, at position 6 where glutamine was converted to threonine using the 
forward primer rCNTI_Q6Tf in conjunction with the reverse primer rCNTI_Q6Tr, 
at position 54 where alanine was mutated to threonine with the primers 
rCNTI-A54Tf and rCNTI-A54Tr,, and at residue 503 where glutamic acid was 
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replaced by asparagine using the complementary primers rCNTI_E503Nf and 
rCNTI_E503Nr. Following transformation into XLIO-Gold E. coli cells, colonies 
were screened by automated sequencing to confirm generation of the correct 
mutations. Subsequently the successful Q6T mutant was subdoned into pSRH5 by 
ligation of the 194 bp Ndel-EcoNI fragment from the Q6T mutant into pSRH5 
formerly digested with the two fore-mentioned enzymes. The resultant construct was 
designated pSRH22. The locations of the mutated residues within rCNTI are 
illustrated in Figure 5.3, with the relative positions of restriction sites used in 
subcloning of the mutated cassettes, described above, indicated. 
5.2.4 Amplification of cDNA encoding the glycosylated hydrophilic loop of 
GLUT4 
The region encoding residues 46 to 78 was PCR amplified from human GLUT4 
cDNA using primers hG4Kpnlf and hG4Kpnlr, which were designed to incorporate 
terminal Kpnl restriction sites. The 50 ýtl reaction was set up containing each primer 
at a concentration of I [tM, 20 ng of template DNA, 0.2 mM dNTPs, 0.5 U VentR 
DNA polymerase (NEB) and Ix amplification buffer (supplied with the polymerase). 
Conditions used for thermo-cycling were: stage 1, one cycle of 95 0Cr 90 sec; stage 
2, twelve cycles of 950C for 30 sec, 550C for 45 sec and 680C for 2.5 min; and stage 
3, one cycle of 680C for 7 min. The resulting product was blunt-end ligated into 
EcoRV pre-digested pBluescript 11 KS (+) as described in section 2.5.7 with 100 pg 
of the resulting DNA being used to transform competent XLI-blue E. coli cells as 
described in section 2.5.4. The resultant construct was sequenced over the complete 
region of the insert as described in section 2.5.8. This construct was designated 
pSRH6. 
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5. Z5 Incorporation of exogenous potential glycosylation sites 
The construct pQQH, containing the full-length coding region of rCNTI,, was 
mutated by the QuikChange TM site-directed mutagenesis kit (Stratagene) as described 
in section 5.2.2 in order to incorporate unique Kpnl restriction sites following 
residues 106,200 and 406 of the transporter, using the primers listed in Table 5.1. 
Following transformation into XLIO-Gold K coli cells, colonies were screened by 
automated sequencing to confirm generation of the correct mutations. Subsequently 
Ndell EcoNI, Apall Ncol and BamHll BspEl cassettes bearing the 106,200 and 406 
mutations respectively were subdoned into the aglyco-mutant, construct pSRH5, by 
replacement of the corresponding regions, as described in section 2.5.7. Finally each 
of these constructs was digested with KpnI to allow the insertion of the GLUT4 loop 
from the construct pSRU6, previously digested with Kpnl. The resultant GLUT4 106, 
200 and 406 constructs were designated pSRH17, pSRH19 and pSRH21 
respectively. The resultant constructs were sequenced over the complete regions of 
the inserts as described in section 2.5.8 to confinn that the inserted cDNA was in the 
correct orientation. The locations within rCNTI where the GLUT4 hydrophilic loops 
were inserted are illustrated in Figure 5.3, with the relative positions of restriction 
sites used in subcloning of the mutated cassettes, described above, indicated. 
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Figure 5.2 QuikChange'rm mutagenesis strategy 
Mix 
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resulting in nicked L'ircular strands 
Digestion qj'parental D., V4 template 
it, A DpnI 
Mutated plasmid 
Transjbrm the resulting annealed 
ds nicked DNA molecule 
After transformation E coli strain 
repairs nicb, in plasmid 
QuikChange T\4mutagenesis has been developed by Stratagene. This allows the non- 
PCR generation of site-directed mutants, thus making the procedure more efficient 
and eliminating the immediate need to subclone the mutants, as described in section 
5.1.1. 
F 
Gene in plasmid with 
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Figure 5.3 Summary of mutation sites located within the putative model for 
rCNT1 
Image on opposite page 
Mutations perfon-ned on rCNTI, described in chapter 5, are illustrated in the 
following diagram. Single mutations are indicated adjacent to the amino acid residue 
modified while locations where the GLUT4 hydrophilic loop was substituted are 
represented by arrows labeled AGLUT4. In addition, the relative locations of 
restriction enzyme sites used in subcloning of mutated cassettes are indicated by the 
name of the enzyme in italics. For ftirther information on components of the diagram 
refer to Figure 1.2. 
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Table 5.1 Mutagenic primers used in the topological analysis of rCNTI 
Primer name Sequence 5'->3' Comments 
rCNTI-N605Tf GCGTGTCCCTTCTGACCCAAACTG Asn 605 to Thr fp 
TCAGC 
rCNTI-N605Tr GCTGACAGTTTGGGTCAGAAGGGA Asn 605 to Thr rp 
CACGC 
rCNTI_N643Tf CTGCTGTCGATTTTACACCCACAC Asn 643 to Thr fp 
AGTCTGCAC 
rCNTI_N643Tr GTGCAGACTGTGTGGGTGTAAAAT Asn 643 to Thr rp 
CGACAGC AG 
rCNTI_Q6Tf 
rCNTI_Q6Tr 
rCNTI-A54Tf 
rCNTI-A54Tr 
CATGGCAGACAACACAACGAGGC Gln 6 to Thr fp 
AAAGAGAGTCC 
GGACTCTCTTTGCCTCGTTGTGTT(i Gln 6 to Thr rp 
TCTGCCATG 
GGTGGCCTGAACAAAACAGAGCG 
GAAGGCCTTCT 
AGAAGGCCTTCCGCTCTGTTTTGT 
TCAGGCCACC 
rCNTI-E503Nf GTTTGTGGCCTATCAAAACCTTTC 
CCAGTACAAG 
Ala 54 to Phe fp 
Ala 54 to Phe rp 
Glu 503 to Asn fp 
rCNTI_E503Nr CTTGTACTGGGAAAGGTTTTGATA Glu 503 to Asn rp 
GGCCACAAAC 
rCNTI-106Kf CTCCTGGACCTCGGTACCCAGAGG Introduction of KpnI site 
GCCCTAGCA after residue 106 fp 
rCNTI-106Kr TGCTAGGGCCCTCTGGGTACCGAG Introduction of KpnI site 
GTCCAGGAG after residue 106 rp 
rCNTI_20OKf CAAAGCATCACCGTGGTACCGCGG Introduction of KpnI site 
TGTCATGGCGAG after residue 200 fp 
rCNTI-20OKr CTCGCCATGACACCGCGGTACCAC Introduction of KpnI site 
GGTGATGCTTTG after residue 200 rp 
rCNTI_406Kf CAGAACCTCTTGGGTACCGAAGCA Introduction of KpnI site 
GCCAGTGCTG after residue 406 fp 
Chapter 5 
146 
Table 5.1 (cont. ) 
Primer name Sequence 5'->3' Comments 
rCNTI-406Kr CAGCACTGGCTGCTTCGGTACCCA Introduction of KpnI site 
AGAGGTTCTGAGC after residue 406 rp 
hG4KpnIf cggGGTACCAATGCCCCTCAGAAGG Generation of KpnI site 
TG in GLUT4 loop fp 
hG4Kpnlr gccGGTACCGGTGAGGGTGCCTGGA Generation of KpnI site 
GGGA in GLUT4 loop rp 
fp= forward primer, rp= reverse primer 
Mutated bases are represented by underlining while inserted bases incorporating 
restriction sites are italicized. Furthermore, additional bases that have been added to 
facilitate restriction digestion are represented in non-capitals. 
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Figure 5.4 Glycosylation state of wild-type rCNT1 and homologues 
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Western blot analysis of the Xenopus oocyte membranes untreated (-) and treated 
with endoglycosidase F/ N-glycosidase F, as described in section 5.2.1. Each lane 
contained 5 ýtg total membrane protein from oocytes injected with water (lanes A 
and B), or with 10 ng of cRNA encoding rCNT I (lanes C and D), hCNT I (lanes E 
and F), rCNT2 (lanes G and H) and hCNT2 (lanes I and J). Oocytes were incubated 
at 180C for 3 days following injection, as described in section 5.2.1. Detection 
employed affinity-purified antibodies (2 ýtg/ml) raised against peptide C as described 
in chapter 3. Molecular mass markers on left are in kDa. 
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Figure 5.5 Kinetic comparison of rCNT1 deglycosylation mutants 
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Oocytes were injected with 10 ng of cRNA encoding each of the transporters, 
including water injected control, prior to incubation at I 8'C for 3 days. Fluxes of 10 
ýM uridine for 5 min at 20'C were determined as described by Huang et aL [8 1 ]. The 
data illustrated above was obtained from Dr S. Y. M. Yao (University of Alberta, 
Canada). 
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Figure 5.6 Extent of wild-type rCNT1 glycosylation 
66 
43 
Western blot analysis of the Xenopus oocyte membranes untreated (-) and treated 
with endoglycosidase F/ N-glycosidase F, as described in section 5.2.1. Each lane 
contained 5 [tg total membrane protein from oocytes injected with 10 ng of cRNA 
encoding wild-type rCNTI (lanes A and B), N605T mutant (lanes C and D), N643T 
mutant (lanes E and F), N605T/ N643T mutant (lanes G and H), and water (lanes I 
and J). Oocytes were incubated at 18T for 3 days following injection, as described in 
section 5.2.1. Detection employed affinity-purified antibodies (2 Vtg/ml) raised 
against peptide C as described in chapter 3. Molecular mass markers on left are in 
kDa. 
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Figure 5.7 Kinetic comparison of rCNT1 topological mutants 
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Oocytes were injected with 10 ng of cRNA encoding each of the transporters, 
including water injected control, prior to incubation at 18T for 3 days. Fluxes of 10 
ýM uridine for 5 min at 20'C were determined as described by Huang et al. [8 1 ]. The 
data illustrated above was obtained from Dr S. Y. M. Yao (University of Alberta, 
Canada). 
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Figure 5.8 Glycosylation state of rCNT1 mutants 
-+-+-+ 
-+ -+-+ 
Western blot analysis of the Xenopus oocyte membranes untreated (-) and treated (+) 
with endoglycosidase F/ N-glycosidase F, as described in section 5.2.1. Each lane 
contained 5 [tg total membrane protein from oocytes injected with 10 ng of cRNA 
encoding the 106-rCNTI/ GLUT4 insert (lanes A and B), 200-rCNTI/ GLUT4 insert 
(lanes C and D), 406-rCNTI/ GLUT4 insert (lanes E and F), Q6T mutant (lanes G 
and H), wild-type rCNTI (lanes I and J), and water (lanes K and L). Oocytes were 
incubated at 18T for 3 days following injection, as described in section 5.2.1. 
Detection employed affinity-purified antibodies (2 [tg/ml) raised against peptide C as 
described in chapter 3. Molecular mass markers on left are in kDa. 
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5.3 Results and discussion 
5.3.1 Deglycosylation of wild-type rCNTI 
The immunoblot analyses of rCNT I in the rat intestine, kidney and liver described in 
chapter 4 indicated that this protein was present as a number of isoforms with 
differing apparent M, depending on the tissue under observation. Based on this 
finding it was postulated that these differences might be due to variations in the 
extent of rCNTI glycosylation. To test this theory rCNTI mRNA was expressed in 
Xenopus oocytes and the resulting membranes treated with the deglycosylating 
enzyme endoglycosidase F, as described in section 5.2.1, before examination of the 
mobility of the transporter on Western blots stained with antibody against rCNT I 
peptide C. Figure 5.4 demonstrates that rCNTI, which normally migrates with an 
apparent M, of 63 000, decreases in size to a protein with an apparent M, 56 000 upon 
enzyme treatment, thus indicating that this protein exists in a glycosylated form. In 
addition to testing rCNTI the three homologues hCNTI, rCNT2 and hCNT2 were 
treated with the same enzyme to observe if similar effects were achieved. The human 
homologue of rCNT I, hCNT I was detected on the blots as a band that migrated with 
an apparent M of 66 000 that decreased to 61 000 on enzyme treatment. This finding r 
indicated that like rCNTI, hCNTl bears one or more N-linked oligosaccharides. 
However, no cross-reactive bands were seen on the blots of membranes expressing 
rCNT2 and hCNT2, indicating that the anti-peptide C antibodies were specific for the 
CNTI homologues. This latter information confirmed that the observations made in 
chapter 4 using these antibodies reflected the presence of rCNTI and not the purine- 
specific homologue rCNT2. 
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5.3.2 Extent of wild-type rCNTI glycosylation 
As discussed in the previous section rCNTI has been demonstrated to bear at least 
one N-linked oligosaccharide. Although there are three N-linked glycosylation 
consensus sites present in the peptide sequence the predicted arrangement of rCNTI 
in the membrane [81] suggests that only those at positions 605 and 643 would be 
accessible to the glycosylating machinery of the endoplasmic reticulum. In order to 
determine which, if either, of these sites is in fact glycosylated, they were removed 
either independently or collectively by site-directed mutagenesis as described in 
section 5.2.2. The resultant mutants expressed in Xenopus oocytes showed no 
significant differences in transport activity from that of wild-type rCNTI (Figure 
5.5). Subsequently the glycosylation states of these mutants were assessed by 
endoglycosidase F treatment to deten-nine if N-linked glycosylation was present, as 
illustrated in Figure 5.6. The elimination by mutation of either asparagine, singly, 
resulted in a decrease in apparent M, from the wild-type-value of 63 000 to one of 60 
000. Furthermore, after treatment with endoglycosidase F the mutants both migrated 
with an apparent M, of 56 000, similar to that of the deglycosylated wild-type 
protein. In addition to the major band with an apparent M, of 56 000, a minor band of 
apparent M 50 000 was also evident on blots of the deglycosylated protein samples r 
(Figure 5.4). As can be seen from the comparison of Figures 5.4 and 5.6, this was 
not always present, and may correspond to either a degradation product of rCNTI or 
to a unique conformational state of the SDS-denatured protein, dependent upon the 
exact conditions for sample preparation. Elimination of both of the potential 
glycosylation sites collectively in the double mutant N605T/ N643T resulted in a 
protein which migrated with the same apparent M, as the deglycosylated wild-type 
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transporter and which was not affected by endoglycosidase F treatment. This lack of 
effect confirmed the hypothesis, mentioned earlier, that the potential glycosylation 
site at position 543 is not in fact glycosylated, presumably because of its location in a 
membrane-spanning portion of the transporter. As observed in chapter 4 wild-type 
rCNTI appears in vivo as two isoforms, with apparent Mr values of 60 000 and 63 
000 respectively. On comparison with the single mutants it would appear that in the 
natural state rCNTI is present as a heterogeneous population with glycosylation 
occurring at either or both of the asparagine residues at positions 605 and 643. 
The data described above indicated that in the wild-type rCNT I molecule one or both 
of the asparagine residues at positions 605 and 643 are glycosylated. This finding 
was interesting in two respects. Firstly, these residues lie within the hydrophilic C- 
terminal region of the rCNTI molecule, that in the published model of Huang et aL 
for the protein topology was predicted to be cytoplasmic [8 1 ]. Clearly, glycosylation 
of these sites indicates that the C-terminus is extracellular and that the model, at least 
in this respect, is incorrect. Such a finding exemplifies the caution with which 
models produced by use of predictive algorithms must be treated: while such models 
provide a useful starting point it is essential that their predictions are tested by direct 
experimen ion. 
A second interesting outcome of the glycosylation experiments was the finding that 
rCNTI can apparently be simultaneously glycosylated at two sites. It has been 
suggested that the majority of N-linked glycosylated proteins are only glycosylated at 
one extracellular consensus site, the only known exception to date being the a- 
subunit of the sodium channel [ 182]. This exception probably results from the fact 
that the channel structure has arisen from an internal gene duplication event, such 
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that two glycosylation sites are present in distant regions of the protein. In contrast 
the two accessible N-linked glycosylation sites of rCNTI, which the present study 
has demonstrated can be simultaneously glycosylated, are present within the same 
extracellular segment. While other membrane proteins that are known to possess 
more than one potential N-linked glycosylation site in the same region, usually only 
one of these is glycosylated. Such a situation can be exemplified by bovine rhodopsin 
which has two potential glycosylation sites in its N-teirminus, only one of which is 
glycosylated [183]. A possible explanation for this phenomenon may be that if two 
potential glycosylation sites occur in the same extracellular hydrophilic segment then 
they must be a defined distance apart in order for both to be glycosylated. In the case 
of rCNTI the two sites are 37 residues apart, whereas in bovine rhodopsin the two 
consensus sites are only thirteen residues apart, a distance that may be insufficient to 
allow access of the glycosylating machinery of the endoplasmic reticulurn to each. 
5.3.3 Topological analysis by glycosylation scanning mutagenesis 
The aglyco-mutant of rCNTI described in section 5.3.2, being functional and thus 
presumably arranged in the membrane in the same fashion as the wild-type rCNTI, 
provided a suitable template for further investigation of the transporter topology by 
glycosylation scanning mutagenesis. Two separate approaches were used to 
incorporate consensus N-linked glycosylation sites into the N605T/ N643T double 
mutant, either the modification of a single amino acid residue or the introduction of 
the glycosylated hydrophilic loop of human GLUT4. The regions of rCNTI selected 
on which to perforrn these mutations were within several of the predicted hydrophilic 
loops, based on the model of Huang et aL [8 1 ]. For the first approach, an attempt was 
made to construct three consensus glycosylation sites by making the mutations Q6T, 
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A54T and E503N as described in section 5.2.3. Unfortunately, sequence analysis of 
the constructs showed that only the Q6T mutant had in fact been successfully 
generated, but this did result in the incorporation of a consensus glycosylation site in 
the N-terminus of the aglyco-rCNTI mutant. Expression of the Q6T mutant in 
Xenopus oocytes indicated that this mutant retained approximately 40 % transport 
activity of that displayed by wild-type rCNTI (Figure 5.7). Subsequently, Xenopus 
oocyte membranes prepared from the Q6T mutant were treated with endoglycosidase 
F (Figure 5.8). The result of which indicated that there was no change in apparent M, 
of this mutant when treated with endoglycosidase F, demonstrating that the 
introduction of an N-linked glycosylation site into the N-terminus of the aglyco fonn 
of rCNT I did not change the glycosylation state of the aglyco-mutant. Deriving from 
this two interpretations could be reached. Either the N-terminus was extracellular but 
was not glycosylated or that it was cytoplasmic and hence could not be glycosylated. 
The fon-ner of these interpretations was possible but unlikely as this mutant contains 
a glycosylation site which is located 68 residues from where the peptide backbone is 
first predicted to enter the membrane and thus would be freely accessible to the 
glycosylating machinery of the endoplasmic reticulum. Furthermore, based on 
sequence analyses discussed in chapter 1, the N-tenninus of rCNTI lacks a signal 
sequence and is very hydrophilic. This hydrophilicity indicates that it would be very 
energetically expensive to translocate this region of rCNTI across the lipid bilayer. 
Therefore, together this infonnation suggested that the lack of glycosylation observed 
with the Q6T mutant was due to the N-terminus residing on the cytoplasmic face of 
the membrane. Based on this suggestion that the N-terminus is cytoplasmic and 
former data indicating that the C-terminus is extracellular this dictates that rCNTI 
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must have an odd number of TMDs and not fourteen as predicted by the original 
model by Huang et al. [81]. As previously discussed in chapter 1 rCNTI was 
predicted to have between 10 and 14 TMDs. Analysis of the rCNTl amino acid 
sequence using a number of hydrophobicity scales indicated that the prediction of 
helices 6,8 and 12 being TMI)s was weaker than for the remaining eleven helices. 
Thus the absence of any one of these helices would result in a predicted model with 
thirteen TMDs with both tennini in the correct orientation when considering the fore- 
mentioned evidence. Therefore, based on this information rCNTI has been proposed 
to exist in the lipid bilayer as one of the three new putative models illustrated in 
Figure 5.9. Of these models, the one which predicts that the "helix" 6 region resides 
outside of the lipid bilayer is the most likely since while the predictions that helices 8 
and 12 are TMDs were weaker than for the other regions of the protein, they were 
predicted to be membrane-spanning depending on whatever hydrophobicity scale 
was used in the analyses. In contrast, putative "helix" 6 was not identified as a TMD 
in any of the analyses performed. Further evidence to support any of these three 
models came from the insertion of the human GLUT4 hydrophilic loop between 
predicted TMDs 4 and 5. Normally the GLUT4 loop in vivo is glycosylated so by 
placing the cDNA encoding the GLUT4 hydrophilic loop in the cDNA of another 
protein, in the region of a predicted extracellular hydrophilic, loop, should result in 
that protein becoming glycosylated. Doing this with rCNTI at the fore-mentioned 
position did not produce a glycosylated mutant protein. Therefore it has been 
concluded that the hydrophilic loop between predicted TMDs 4 and 5 was 
cytoplasmic, as suggested by either of the two new putative models. 
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Two further mutants were attempted to be generated by single residue mutation. 
These involved the conversion of alanine 54 to threonine and glutamate 503 to 
asparagine. However following genetic manipulation of the rCNTI cDNA no such 
mutants could be detected on sequencing. Analysis of the primer sequences for these 
two mutations (Table 5.1) did not identify any problems with the exception of the 
primers having the ability to form primer-climers. However this is a standard event 
using this strategy of mutagenesis and has not proved to a problem in the generation 
of other mutants. This information suggested that the inability to generate these two 
mutants was a practical problem. Unfortunately time did not permit this to be 
rectified. Although altering both the primer concentrations and the annealing 
temperatures may prove suitable starting points. 
The second approach used to introduce N-linked glycosylation consensus sequences 
into the rCNTI aglyco-mutant involved mutagenesis to incorporate a foreign 
glycosylation site from another protein. This was achieved by the incorporation of 
the hydrophilic loop of human GLUT4 which possesses an N-linked glycosylation 
site, known to be glycosylated in vivo. Locations chosen for introduction of the 
exogenous GLUT4 hydrophilic loop were following leucine 106, arginine 200 and 
leucine 406 since these residues were predicted in the original model by Huang et al. 
to be located in the first, fourth and tenth predicted hydrophilic loops respectively 
[8 1 ]. A diagrammatic representation of these locations can be seen in Figure 5.3. 
Synthesis of the three mutants incorporating this exogenous loop following residues 
1061.200 and 406 (designated 106KAGLUT4,200KAGLUT4 and 406KAGLUT4 
respectively), resulted in successful generation of the former two mutants but a 
mutant containing a single insert of the loop could not be obtained for the 406 
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mutant, even after several attempts at subdoning with various amounts of insert 
present. Due to this repetitive failure to isolate the 406 mutant containing a single 
insert a 406 construct containing two tandem copies, in the same orientation, of the 
cDNA region encoding the GLUT4 loop was isolated and used in subsequent 
investigations. Incorporation of the loop succeeding the leucine at position 106 
resulted in a mutant that demonstrated approximately 12 % transport activity of the 
wild-type rCNTI (Figure 5.7), indicating that although this mutation resulted in the 
insertion of 58 residues into rCNTI, the protein was still partially functional. 
Western blotting of Xenopus oocyte membranes expressing this mutant indicated an 
apparent N-terminal truncation of the aglyco-rCNTI, as observed by the decrease in 
apparent M, from 56 000 to 50 000 (Figure 5.8). Such a decrease was equivalent to 
loss of the N-tenninus of rCNTI to the region of the inserted loop, although the exact 
location could not be determined without amino acid sequencing which was not 
performed. Alternatively, the mutation generated in the 106KAGLUT4 mutant may 
facilitate the protein in adopting the conformational isoform of rCNTI with an 
apparent M, of 50 000 which has previously been observed (Figure 5.6). More 
important than the 106KAGLUT4 protein migrating with a reduced apparent M, of 50 
000 was the observation that this protein was unaffected by endoglycosidase F 
treatment. This initially suggests that the hydrophilic loop connecting putative 
helices I and 2, in the original model by Huang et al. [8 1 ], is cytoplasmic, although 
it 
may be that the insertion of the GLUT4 loop into this very small 
loop between 
putative helices I and 2 has prevented the correct insertion of the protein 
into the 
membrane. Therefore a hydrophilic loop that is predicted to 
be extracellular5 in the 
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three new models, has not been translocated correctly, resulting in the protein being 
unglycosylated. 
Introduction of the exogenous GLUT4 loop into the aglyco-rCNTI after arginine 200 
resulted in a mutant that demonstrated approximately 65 % of the transport activity 
demonstrated by wild-type rCNTI (Figure 5.7), thus indicating that this protein was 
functional. However expression of this mutant in Xenopus oocytes resulted in a 
protein whose apparent M, did not change from 56 000 on treatment with 
endoglycosidase F (Figure 5.8). Considering both of these pieces of evidence it was 
assumed that the 200KAGLUT4 mutant had folded correctly and that it was not 
glycosylated. This confirmed the predicted changes in conformation discussed 
previously in this section. Briefly, if the N-terminus was cytoplasmic and the C- 
ten-ninus extracellular with either helix 6,, 8 or 12 not residing in the lipid bilayer then 
this would place the hydrophilic loop, between helices 4 and 5 into which the 
exogenous hydrophilic loop was placed, on the cytoplasmic side of the membrane 
resulting in this loop not being glycosylated as observed. 
The final mutant made by this strategy involved the insertion of the exogenous loop 
following leucine 406. Unfortunately, attempts at expressing this mutant in Xenopus 
oocytes were unsuccessful: no transport activity was measurable and no rCNTI 
protein was detectable on Western blots stained with antibody raised against rCNTI 
peptide C (Figures 5.7 and 5.8 respectively). An explanation for these observations 
may stem from the duplication of the GLUT4 hydrophilic loop within this mutant 
causing excessive distortion on the protein conformation which has subsequently 
resulted in the lack of any significant expression of functional rCNTI. Western blot 
analysis further confinned that the lack of transport activity was not due to incorrect 
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folding of rCNTI, since rCNTI would still have been detected. However this was not 
the case thus confirming that if rCNTI was expressed then the levels were 
insignificant. 
5.4 Summary 
Initial evidence for the topology of rCNTI came from the observation that rCNTI 
was present in rat tissues as a number of different isoforms, based on the variation 
observed in apparent M, from 60 000 to 63 000 (chapter 4). Assuming that it was N- 
linked glycosylation that was being observed then treatment of rCNTI with the 
cleglycosylating enzymes endoglycosidase F/ N-glycosidase F should result in a 
decrease in apparent M,. To achieve this rCNTI was expressed in Xenopus oocytes 
and the membranes subsequently treated with the fore-mentioned enzyme. The result 
of which was a shift in apparent M, from 63 000 to 56 000, thus indicating that 
rCNTI was indeed glycosylated. This result was very significant since the amino 
acid sequence of rCNTI only contained three potential glycosylation sites at 
asparagines 543,605 and 643. The former was predicted to reside within putative 
be 
TMD thirteen and therefore would not4accessible to the glycosylating machinery of 
the endoplasmic reticulum, consequently indicating that either or both of the 
asparagines at positions 605 and 643 were glycosylated. The significance of this 
observation was that both of these residues are located in the C-tenninus of rCNTI 
which has previously been predicted to be cytoplasmic [8 1 ], however contrary to this 
the present study has proven that the C-terminus is extracellular. Thus with the first 
piece of experimental evidence to the topology of rCNTI the original model, 
predicted by computer algorithmic analyses, has already been dramatically modified. 
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To further investigate the topology of rCNT I the technique of glycosylation scanning 
mutagenesis was adopted. The basis of this strategy is that an N-linked glycosylation 
site is introduced into the predicted hydrophilic loop of the protein backbone with 
subsequent enzymatic cleavage of any oligosaccharide moieties indicating if that 
hydrophilic loop is cytoplasmic or extracellular [22]. However prior to adopting this 
methodology, endogenous N-linked glycosylation sites had to be eliminated. This 
was achieved by mutagenic elimination of asparagines 605 and 643 either 
independently or collectively. Following expression in Xenopus oocytes 
deglycosylation of these mutants indicated that in wild type rCNT I either one or both 
of these residues were glycosylated. Furthermore, as discussed in the previous 
section, not only is the occurrence of two glycosylated asparagines in the same 
protein rare but for both of these to occur in the same hydrophilic region, as they do 
in rCNT I, is unique in that no reported cases of this glycosylation pattern could be 
located. Furthermore, the absence of glycosylation with the N605T/ N643T double 
mutant confirmed that asparagine 543 was not glycosylated. 
Having produced the aglyco-rCNTI mutant subsequent mutagenesis was performed 
to investigate its topology in the lipid bilayer. The first -such piece of evidence which 
aided in the deten-nination of rCNTI structure was produced by the introduction of a 
potential N-linked glycosylation site into the N-terminus of the protein at residue 6. 
Deglycosylation studies indicated that the Q6T mutant was not glycosylated, which 
in addition to sequence analyses indicating that this terminus is very hydrophilic and 
possesses no identifiable signal sequence. This suggests that the 
N-terminus of 
rCNTI is cytoplasmic and furtherinore indicates that it is an odd number of 
TMDs 
that reside in the lipid bilayer, and not fourteen as prediced in the original model 
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Considering information discussed in the previous section concerning 
transmembrane prediction algorithms, one of predicted helices 6,8 or 12 is not a 
TMD. Taking this into consideration in conjunction with the protein having an odd 
number of TMDs indicates that any one of these hydrophobic regions may not reside 
in the lipid bilayer. Collectively the information to date suggests the C-terminus is 
extracellular, the N-terminus is cytoplasmic and that one of the predicted helices 6,8 
or 12 does not reside in the membrane, thus allowing for three new models for 
rCNTI in the lipid bilayer to be proposed, as illustrated in Figure 5.9. Further 
evidence for the existence of rCNT I in one or other of these predicted conformations 
comes from the generation of the introduction of a glycosylation site following 
arginine 200 which was originally predicted to be extracellular [81] but in this study 
was demonstrated to be unglycosylated, thus suggesting that it is cytoplasmic as 
predicted by the three new putative models of rCNTI. Unfortunately, other mutations 
of rCNT I generated in this study did not produce any definitive information into the 
topology of rCNTI. 
In conclusion, this study has involved a number of preliminary studies into the 
topology of rCNTI in the lipid bilayer and has demonstrated that the putative model 
originally proposed [8 1] was incorrect. Furthermore, the evidence obtained in the 
present study has led to the proposal that rCNTI exists in the lipid bilayer as one of 
the three new putative models illustrated in Figure 5.9. These models now provide a 
basis for further investigation of rCNTI topology with the overall aim of elucidating 
the protein's 3-dimensional structure. In addition, this work illustrates that although 
computer predicted models provide a starting point for the investigation of 
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membrane protein topology, 
experimental evidence. 
such predictive models must be confirmed by 
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Figure 5.9 Three new putative models for the topology of rCNT1 in the lipid 
bilayer 
Image on opposite page 
Evidence discussed in chapter 5 has led to the adaptation of the original model 
proposed by Huang et al. [81] so that rCNTI is actually present as one of the three 
forms represented in plates A to C. Residues in the three models have been colour 
coded as described previously (Figure 1.2). 
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Chapter 6 
General discussion 
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6.1 Distribution of rCNTI in rat tissues 
Recent cloning of the active nucleoside transport protein rCNT I has allowed for a in- 
depth study of this protein [81 ]. In the investigation by Huang et al. it was suggested 
that this protein was present in both the jejunum and kidney. However this 
conclusion was based on the presence of rCNTI mRNA which was only evidence 
that the gene encoding this protein was transcribed and not conclusive proof that 
rCNT I was expressed. Therefore to confirm these earlier observations and to further 
localize the protein at the subcellular level, site-directed polyclonal antibodies were 
raised to identify rCNTI as described in chapter 3. Of the antibodies raised against 
the synthetic peptides, A to D, only those antibodies raised against peptides C and D 
produced significant signals against the protein in the native or denatured state. 
Additionally, the production of antibodies raised against a rCNTI N-terrninal/ GST 
fusion protein proved essential for investigation of fixed rat tissue. Overall the 
polyclonal antibodies raised against synthetic peptide C were considered the most 
reliable as these cross-reacted strongly with a protein in both the jejunum and kidney 
on Western blotting where rCNTI mRNA was previously observed by Northern 
blotting [8 1 ]. Additionally these antibodies cross-reacted with a protein in the liver of 
similar relative molecular mass. In these three tissues the relative molecular mass of 
rCNTI was demonstrated to be approximately 63 000 although this varied 
marginally depending on the tissue. This variation in size suggested that the protein 
could be present in a number of differing glycosylation states. Evidence shown in 
chapter 5, indicated that in the jejunum and kidney the protein was present with 
either one or both of its predicted accessible asparagines being glycosylated, residues 
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605 and 643. In comparison, in the liver only one or the other of these sites is 
glycosylated, as indicated by the presence of only one apparent isoform. 
To further identify the location of rCNTI expression within the fore-mentioned 
tissues immunocytochernical analysis of these tissues was perfonned. In the jejunum 
rCNTI was demonstrated to be present at the brush border and not at the basolateral 
membrane. This observation suggested that within this tissue rCNTI is involved in 
the active uptake of nucleosides from the intestinal lumen but is not involved the 
translocation of nucleosides out of these enterocytes at the basolateral membrane. As 
discussed in chapter 4 this distribution parallels that reported for other sodium 
symport systems that are present in the intestinal membranes. For example, the 
sodium-dependent glucose transporter SGLTI is located in the brush border 
membrane where it is involved in the active uptake of glucose from the intestinal 
lumen. Like rCNTI,, it is absent from the basolateral membrane,, where the 
complementary protein GLUT2 is present for the facilitative translocation of glucose 
down its concentration gradient into the nearby capillary network [163]. The 
restriction of active nucleoside transporter to the brush border suggests that if the 
nucleosides translocated into the enterocyte by rCNTI are not all metabolized, then 
there may be a facilitative nucleoside transporter in the basolateral membrane which 
allows the transport of nucleosides down the concentration gradient and into the 
nearby capillaries, paralleling the basolateral facilitative transport demonstrated in 
human intestine [ 164], previously discussed in section 4.4.4. 
Localization of rCNTI in the kidney proved to show similar distribution within the 
polarized cells as observed in the intestine. Once again this protein was confined to 
brush border membranes but only of proximal tubules and was absent from the 
basolateral membranes. Like the case of SGLTI with glucose, rCNTI is thought to 
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be involved in the active transport of nucleosides from the renal filtrate back into the 
proximal tubule cells from where they can return to the blood, thus conserving 
pyrimidine nucleosides. 
Within the liver rCNTI was demonstrated in the bile canalicular membrane of 
parenchymal cells but absent from the sinusoidal membrane suggesting that here too 
rCNTI is involved in the conservation of pyrimidine nucleosides. Recently, work 
carried out by Felipe et al. has verified that rCNTI is present in the liver in addition 
the purine specific nucleoside transport protein rCNT2 [89]. Here they suggest that in 
regenerating rat liver it is rCNT2 that is responsible for the increase in the uptake of 
uridine due increases in the amount of this protein present, while no such increase is 
observed with rCNTI. It must be noted however that this increase is observed at the 
basolateral membrane and not at the brush border suggesting that the uridine uptake 
is from the blood. 
Interestingly, although the antibodies raised against synthetic peptide D did not 
identify the presence of rCNTI in the jejunum, kidney or liver, they did identify two 
proteins in the rat brain with apparent M, of 45 000 and 56 000 with the latter of these 
also being present in the spleen. As discussed in chapter 5, rCNTI when 
unglycosylated has an apparent M, of 56 000. Therefore indicating that the anti- 
peptide D antibodies showed preference for unglycosylated rCNTI, which only 
occurred in the brain and spleen. Furthermore, a private communication from Dr J. 
D. Young has indicated that an N-terminal truncated isoform of rCNTI showed 
non-nal transport activity, suggesting that the protein observed in the brain with an 
apparent M of 45 000 may be a naturally occurring N-terminal truncated rCNTI r 
isoform. Cellular distribution within the brain indicated that rCNTI was present in 
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the hippocampus but unfortunately due to poor tissue integrity the subcellular 
distribution could only be suggested to have been on the cell membrane of pyramidal 
cells. Definitive subcellular distribution of rCNTI in the brain will shortly be known 
due to the establishment of a protocol which can detect the protein in mildly fixed 
tissue, using the antibodies raised against the rCNTI N-terminal/ GST fusion protein 
(chapter 4). Recently work carried out by Anderson et al. has demonstrated that the 
mRNAs for rCNTI and rCNT2 are both present in the brain [88]. Furthermore, this 
work confirmed that rCNTI was present in the hippocampus. Although Western 
blotting has demonstrated unglycosylated rCNTI to be present in the spleen, 
subcellular localization of this protein could not be identified. A possible explanation 
for this was that if the protein was present in all cells in this tissue the low levels of 
expression observed on blotting may have been too low to detect by the method of 
immunocytochemistry used. Although no cit-type transport has been demonstarted 
in the spleen, cif-type activity has been demonstrated in murine splenocytes [7 1 ]. 
In addition to the fore-mentioned tissues rCNTI was also suggested to be present in 
the heart, skeletal muscle and testis. Although due the absence of a signal on Western 
blotting of a protein of the expected apparent M, these results require further 
investigation, as suggested in chapter 4. Furthennore, reports by other researchers 
has only identified active nucleoside transport in human cardiac myocytes [171] but 
not in skeletal muscle or the testis. 
Summarizing, information obtained in this study has demonstrated conclusively that 
rCNTI is present in the rat jejunum, kidney and liver, where it is proposed to 
be 
involved in the active uptake and salvage of nucleosides from the intestinal lumen, 
renal filtrate and hepatic bile respectively. Furthermore, unglycosylated rCNTI 
has 
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been demonstrated to be present in the brain in addition to initial indications that 
rCNTI is also present in the spleen, heart, skeletal muscle and testis, although these 
latter observations remain to be confirmed by future studies. 
6.2 Elucidating the topology of rCNT1 
Cloning of rCNTI by Huang et al. allowed for the first time for the amino acid 
sequence of this protein to be deduced. Initial analysis of this protein indicated the 
absence of an N-terminal signal sequence, while hydrophobicity analysis suggested 
that the protein had fourteen potential transmembrane domains. In the light of this 
information Huang et aL proposed that both the N- and C-termini resided on the 
cytoplasmic side of the cell membrane while the fourteen potential TMI)s transverse 
the membrane between the two termini. Since this initial model was proposed in 
1994 no further information has been published relating to the structure of rCNTI. 
The present study therefore provides the first experimental evidence relating to the 
actual topological arrangement of rCNT I within the lipid bilayer. 
The first experimental clue to a topological feature of rCNTI was derived from the 
observation that rCNTI in the rat jejunum, kidney and liver was present as different 
isofonns, varying in their apParent M, (chapter 4). Based on this observation it was 
suggested that rCNTI was glycosylated. According to the protein sequence rCNTI 
possessed only three potential N-linked glycosylation sites at asparagines 543,605 
and 643. The former of these was predicted to be in the center of a predicted TMD 
while the remaining two were present in the C-ten-ninus, which was predicted to be 
cytoplasmic. To investigate if rCNTI was glycosylated its mRNA was injected into 
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Xenopus oocytes and the resultant membranes treated with an enzyme mixture 
containing the deglycosylating enzyme endoglycosidase F. The results confirmed the 
initial observation that rCNTI was glycosylated due to a decrease in apparent M, 
from 63 000 to 56 000. Furthermore, this information indicated that the C-terminus 
of rCNTI was extracellular and not cytoplasmic as originally predicted [81], since 
the only predicted accessible N-linked glycosylation sites were located in the C- 
terminus. 
Having deten-nined the location of the C-tenninus the most useful information that 
could be obtained next was the location of the N-terminus. This was achieved by the 
incorporation of an N-linked glycosylation site into the N-terminus by mutating the 
glutamine at position 6 to threonine after elimination of the two accessible 
endogenous glycosylation sites at positions 605 and 643 (chapter 5). Following 
Vý- 
Aunopus oocyte expression deglycosylation studies were perfonned indicating that 
this Q6T mutant was not glycosylated. It may have been that this terminus was 
extracellular but was not glycosylated. However, a study performed by Landolt- 
Marticorena and Reithmeier, involving the known glycosylation state of many 
membrane proteins, indicated that in all reported cases if an N-linked glycosylation 
site was present at the N-terminus of a protein it would be glycosylated [182]. 
Furthermore, sequence analysis indicated that the N-tenninus of rCNTI lacked a 
signal sequence and that it was very hydrophilic. This hydrophilicity indicated that it 
would be very energetically expensive to translocate this region of rCNTI across the 
lipid bilayer. Therefore it has been suggested that that N-terminus of rCNTI was 
located on the cytoplasmic face of the cell membrane, although conclusive 
experimental verification of the location of this terminus remains to be established. 
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The result of positioning the N-terminus on the cytoplasmic face of the membrane 
and the C-terminus extracellular, dictated that there must be an odd number of TMDs 
located within the bilayer. Analysis of the rCNTI amino acid sequence using a 
number of hydrophobicity scales indicated that the prediction of helices 6,8 and 12 
being TMDs was weaker than for the remaining eleven helices. Therefore, based on 
this infonnation rCNTI has been proposed to exist in the lipid bilayer as one of the 
three new putative models illustrated in Figure 5.9. Of these models, the one which 
predicts that the "helix" 6 region resides outside of the lipid bilayer is the most likely 
since while the predictions that helices 8 and 12 are TMI)s were weaker than for the 
other regions of the protein, they were predicted to be membrane-spanning 
depending on whatever hydrophobicity scale was used in the analyses. In contrast, 
putative "helix" 6 was not identified as a TMD in any of the analyses performed. 
Further evidence to support any of these three models came from the insertion of the 
human GLUT4 hydrophilic loop between predicted TMDs 4 and 5. Non-nally the 
GLUT4 loop in vivo is glycosylated so by placing the cDNA encoding the GLUT4 
hydrophilic loop in the cDNA of another protein, in the region of a predicted 
extracellular hydrophilic loop, should result in that protein becoming glycosylated. 
Doing this with rCNTI at the fore-mentioned position did not produce a glycosylated 
mutant protein. Therefore it has been concluded that the hydrophilic loop between 
predicted TMDs 4 and 5 was cytoplasmic, as suggested by either of the three new 
putative models. 
Interestingly, the present study has also demonstrated rCNTI to be unique in 
reference to its glycosylation state. This is the first protein to demonstrate 
simultaneous glycosylation Of two N-linked glYcosylation sites within the same 
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extracytosolic hydrophilic region of a membrane protein (chapter 5). Although 
previous work by other researchers has indicated that proteins may possess more than 
one accessible N-linked glycosylation site, generally only one of these sites is 
glycosylated. For example, bovine rhodopsin has two potential glycosylation sites in 
its N-terminus but only one site can be glycosylated [183]. The only reported case 
known to date of another protein which is simultaneously glycosylated more than 
once is the cc-subunit of the skeletal muscle sodium channel, although this arises 
from a duplication in structure with the two sites occurring on separate extracytosolic 
regions of the protein [ 182]. 
6.3 Epilogue 
In essence, the present study has not only demonstrated the existence of rCNT I in the 
rat jejunum and kidney, as previously suggested, but has also provided conclusive 
evidence for the expression of this Protein the liver and brain. In addition, 
preliminary data suggested that rCNTI was also be present in cardiac muscle, 
skeletal muscle,, testis and possibly spleen. Furthermore, the present study has 
established three novel putative models for the topology of rCNTI in the lipid 
bilayer, from which further investigations will be able to elucidate the complete 3- 
dimensional structure of this protein. There is no doubt that due to the close 
homology of this rat protein to its human counterpart there will be further extensive 
research on rCNT I. both at the physiological and structural levels. 
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Sequence accession numbers for rCNTI gene family 
Homologue Source Database Accession number 
rCNTI Rat gb U10279 
hCNTI Human gb U62968 
pCNTI Pig gb AF009673 
rCNT2 Rat gb U25055 
hCNT2 Human gb AF036109 
hfCNT3 Hagfish 
F27e 111 Caenorhabditis gb AFO 16413 
elegans 
F27e 112 C elegans gb AFO 16413 
YeiM-Haein Raemophilus sp P44742 
influenzae 
YeiJ-Ecoli Escherichia coli sp P3 3 021 
YeiM-Ecoli E. coli sp P33024 
Nupc-Bacsu Bacillus subtilis sp P39141 
Nupc_Ecoli E. coli sp P33031 
Nupc-Helpy Helicobacterpylori gb AE000623 
Nupc_Strep Streptococcus 
pyogenes 
Yxja_Bacsu B. subtilis sp P42312 
Database accession information for obtaining rCNTI and its homologues from 
Genbank (gb) or Swissprot (sp) database services. The sequence for hfCNTI was 
supplied by Dr J. D. Young (Canada) while Nupc_Strep was obtained as an open 
reading frame from contig 18 8 from the S. pyogenes sequence database at Oklahoma 
UniversitY. 
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